

Acknowledgements

This report is based upon data collected from 33 Health Care Organizations that were members of the Canadian Neonatal NetworkTM during the year 2021. In addition to all the investigators and the funding agency, we would like to recognize the invaluable support of the Neonatal Intensive Care Units (NICUs) that collected this information, the support of all of the participating sites and most importantly, the dedication and hard work of the Site Investigators, NICU Medical Directors and Data Abstractors.

Structure of the CNN

The Canadian Neonatal Network[™] (CNN) is a group of researchers who collaborate on research issues relating to neonatal care. The CNN was founded in 1995 by Dr. Shoo Lee. The CNN maintains a standardized neonatal database and provides unique opportunities for researchers to participate in collaborative projects on a national and international scale. Health care professionals, health services researchers, and health care administrators participate actively in clinical, epidemiologic, outcomes, health services, health policy and informatics research aimed at improving quality, effectiveness and efficiency of neonatal care. Research results are published in Network reports and in peer-reviewed journals.

Funding

The CNN infrastructure is funded by the Canadian Institutes of Health Research. Individual participating sites provided additional funding, support for data collection and other related resources. The coordinating center, Maternal-Infant Care Research Centre, is supported by Mount Sinai Hospital, Toronto, Ontario.

Coordinating Centre of the CNN, Year 2021

Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario

Chairman:	Dr. Shoo K. Lee, University of Toronto
Governing Board:	Dr. Khalid Aziz, University of Alberta Dr. Karen Beattie, University of McMaster Dr. Kimberly Dow, Queen's University Dr. Shoo K. Lee, University of Toronto (Chair) Dr. Douglas McMillan, Dalhousie University Dr. Eugene Ng, University of Toronto Dr. Anne Monique Nuyt, University of Montréal Dr. Bruno Piedboeuf, Université Laval (Vice-Chair) Dr. Molly Seshia, University of Manitoba Dr. Nalini Singhal, University of Calgary
Director:	Dr. Prakesh Shah, University of Toronto
CNN Associate Director	Dr. Marc Beltempo, McGill University

EPIQ Associate Director	Dr. Joseph Ting, University of Alberta
Executive Committee:	Dr. Marc Beltempo, McGill University Ms. Martine Claveau, McGill University Dr. Kyong-Soon Lee, University of Toronto Dr. Amit Mukerji, McMaster University Dr. Prakesh Shah, University of Toronto (Chair) Dr. Sandesh Shivananda, University of British Columbia Dr. Amuchou Soraisham, University of Calgary Dr. Joseph Ting, University of Alberta
CNN Coordinator: Report Analyst:	Ms. Priscilla Chan, Mount Sinai Hospital Mr. Eugene W. Yoon, Mount Sinai Hospital
Report Review Committee:	 Dr. Marc Beltempo, McGill University (Co-Chair) Dr. George Carson, University of Saskatchewan Dr. Orlando DaSilva, Western University Dr. Akhil Deshpandey, Memorial University Dr. Amit Mukerji, McMaster University Ms. Wendy Seidlitz, Hamilton Health Sciences Dr. Prakesh Shah, University of Toronto (Co-Chair) Dr. Joseph Ting, University of Alberta

Participating CNN Sites and Site Investigators, Year 2021:

Victoria General Hospital, Victoria, British Columbia BC Women's Hospital, Vancouver, British Columbia	Dr. Jaideep Kanungo Dr. Joseph Ting & Dr. Jonathan Wong
Royal Columbian Hospital, New Westminster,	Dr. Zenon Cieslak
British Columbia	
Surrey Memorial Hospital, Surrey, British Columbia	Dr. Rebecca Sherlock
Foothills Medical Centre, Calgary, Alberta	Dr. Ayman Abou Mehrem
Alberta Children's Hospital, Calgary, Alberta	Dr. Carlos Fajardo
Royal Alexandra Hospital, Edmonton, Alberta	Dr. Jennifer Toye &
& University of Alberta Hospital –	Dr. Joseph Ting
Stollery Children's, Edmonton, Alberta	
Jim Pattison Children's Hospital, Saskatoon, Saskatchewan	Dr. Lannae Strueby
(Formerly Royal University Hospital)	-
Regina General Hospital, Regina, Saskatchewan	Dr. Jaya Bodani
Winnipeg Health Sciences Centre, Winnipeg, Manitoba	Dr. Mary Seshia &
	Dr. Deepak Louis
St. Boniface General Hospital, Winnipeg, Manitoba	Dr. Ruben Alvaro
Windsor Regional Hospital, Windsor, Ontario	Dr. Sajit Augustine
London Health Sciences Centre, London, Ontario	Dr. Orlando DaSilva
Hamilton Health Sciences, Hamilton, Ontario	Dr. Amit Mukerji
Mount Sinai Hospital, Toronto, Ontario	Dr. Prakesh Shah
Hospital for Sick Children, Toronto, Ontario	Dr. Kyong-Soon Lee
Sunnybrook Health Sciences Centre, Toronto, Ontario	Dr. Eugene Ng

Kingston Health Sciences Centre, Kingston, Ontario	Dr. Faiza Khurshid
Children's Hospital of Eastern Ontario, Ottawa, Ontario	Dr. Thierry Daboval
The Ottawa Hospital, Ottawa, Ontario	Dr. Brigitte Lemyre
Jewish General Hospital, Montréal, Québec	Dr. Victoria Bizgu
Hôpital Sainte-Justine, Montréal, Québec	Dr. Keith Barrington,
	Dr. Anie Lapointe &
	Mr. Guillaume Ethier
Montreal Children's Hospital – McGill University Health	Dr. Marc Beltempo &
Centre, Montréal, Québec	Ms. Martine Claveau
Centre Hospitalier Universitaire de Québec, Sainte Foy,	Dr. Bruno Piedboeuf &
Québec	Dr. Christine Drolet
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke,	Dr. Valérie Bertelle &
Québec	Dr. Edith Massé
Hôpital Maisonneuve-Rosemont, Montréal, Québec	Dr. Marie St-Hilaire
Dr. Everett Chalmers Hospital, Fredericton, New Brunswick	Dr. Hala Makary
Saint John Regional Hospital, Saint John, New Brunswick	Dr. Cecil Ojah &
	Dr. Luis Monterrosa
Moncton Hospital, Moncton, New Brunswick	Dr. Rody Canning &
	Dr. H. Mehdizadeh-Hakak
IWK Health Centre, Halifax, Nova Scotia	Dr. Jehier Afifi
Cape Breton Regional Hospital, Sydney, Nova Scotia	Dr. Andrzej Kajetanowicz
Janeway Children's Health and Rehabilitation Centre,	Dr. Julie Emberley &
St. John's, Newfoundland	Dr. Jo-Anna Hudson
University of Utah Hospital, Salt Lake City, Utah	Dr. Bradley A. Yoder

Written & Prepared By:

Marc Beltempo, Prakesh Shah, Eugene W. Yoon, Priscilla Chan, Nevetha Balachandran and Members of the Annual Report Review Committee

Cover page adapted by Tasnim Gurey @ www.123rf.com/profile_hypnocreative

Table of contents

<u>nary</u>	1
acteristics	3
<u>stems</u>	5
<u>alyses</u>	6 7
d on number of eligible admissions to participating sites	
All admissions: Type of admissions: All sites	9
All admissions: Admission illness severity scores (SNAP-II and SNAP-IIPE): Sites with complete data	11
d on number of eligible neonates admitted to participating sites	
Gestational age distribution: All sites and all admitted neonates	14
Survival to discharge by GA: All admissions including delivery room deaths	16
Birth weight distribution: All sites and all admitted neonates	17
Survival to discharge by BW: All admissions including delivery room deaths	18
Survival to discharge by BW: BW < 1000g including delivery room deaths	19
Maternal and peripartum characteristics: All neonates	20
Timing of single course of Antenatal Corticosteroids: GA <33 weeks	22
Timing of deferred cord clamping: GA <33 weeks	23
<u>Resuscitation details: $GA < 31$ weeks</u>	24
<u>Resuscitation details: GA \geq 31 weeks</u>	25
Early onset sepsis: All GA	26
Late onset sepsis: All GA	27
Late onset sepsis: All BW	28
Other diagnoses / interventions / procedures: All GA	29
ed on number of very preterm (GA < 33 weeks) or VLBW (< 1500g) neonates	
Patent ductus arteriosus treatments: GA < 33 weeks	32
<u>Patent ductus arteriosus treatments: $BW < 1500g$</u>	33
Neuroimaging findings: $GA < 33$ weeks	34
Neuroimaging findings: BW < 1500g	36
Necrotizing enterocolitis treatments: $GA < 33$ weeks	38
<u>Necrotizing enterocolitis treatments: $BW < 1500g$</u>	39
Chronic lung disease at 36 weeks PMA or discharge: GA<33 weeks	40
Chronic lung disease at 36 weeks PMA or discharge: BW <1500g	41
Retinopathy of prematurity staging: GA < 33 weeks	42
Retinopathy of prematurity staging: BW < 1500g	43
Retinopathy of prematurity treatments: GA < 33 weeks	44
Retinopathy of prematurity treatments: BW < 1500g	45
Mortality or select morbidity: $GA < 33$ weeks	46
	acteristics tems tyses d on number of eligible admissions to participating sites All admissions: Type of admissions: All sites All admissions: Admission illness severity scores (SNAP-II and SNAP-IIPE): Sites with complete data d on number of eligible neonates admitted to participating sites Gestational age distribution: All sites and all admitted neonates Survival to discharge by GA: All admissions including delivery room deaths Birth weight distribution: All sites and all admitted neonates Survival to discharge by BW: All admissions including delivery room deaths Birth weight distribution: All sites and all admitted neonates Survival to discharge by BW: All admissions including delivery room deaths Survival to discharge by BW: All admissions including delivery room deaths Survival to discharge by BW: SIW < 1000g including delivery room deaths Maternal and peripartum characteristics: All neonates Timing of single course of Antenatal Corticosteroids: GA <33 weeks Resuscitation details: GA < 31 weeks Resuscitation details: GA < 31 weeks Early onset sepsis: All GA Late onset sepsis: All GA Late onset sepsis: All GA Late onset sepsis: All BW Other diagnoses / interventions / procedures: All GA Meuroimaging findings: GA < 33 weeks Neuroimaging findings: GA < 33 weeks Neuroimaging findings: GA < 33 weeks Neuroimaging findings: BW < 1500g Necrotizing enterocolitis treatments: GA < 33 weeks Necrotizing enterocolitis treatments: BA < 500g Chronic lung disease at 36 weeks PMA or discharge: GA < 33 weeks Chronic lung disease at 36 weeks PMA or discharge: BW < 1500g Retinopathy of prematurity staging: GA < 33 weeks Retinopathy of prematur

E. Site Comparisons

E.1. Site Comparisons – Care Practices

Presentation #26	Prenatal and delivery room care	practices: GA<29 weeks: Site specific crude rates	49

Page

(inborn only)

Presentation #27	Postnatal care practices: GA <29 weeks: Site specific crude rates (inborn only)	50
Presentation #28	Proportion of babies on Invasive Mechanical Ventilation (IMV) among babies ALIVE at the	51
riesentation #20	specified post-natal ages	51
	ons – Survival / Mortality	50
Presentation #29	Survival rates by site: All GA	53
Presentation #30	Survival rates by site: All BW	54
Presentation #31a	<u>Mortality: $GA < 33$ weeks: Adjusted standardized ratios by site</u>	55
Presentation #31b	Mortality: GA < 33 weeks: Adjusted standardized ratios by site: Funnel plot	56
Presentation #31c	Mortality: GA < 29 weeks: Adjusted standardized ratios by site	57
Presentation #31d	Mortality: GA < 29 weeks: Adjusted standardized ratios by site: Funnel plot	58
Presentation #31e	Mortality: All neonates: Adjusted standardized ratios by site	59
Presentation #31f	Mortality: All neonates: Adjusted standardized ratios by site: Funnel plot	60
E.3. Site Comparise	<u>ons – Mortality / Morbidities</u>	
Presentation #32	Martality / markidition $C \Lambda < 22$ market Site an arite and rates	()
Presentation #32 Presentation #33	Mortality / morbidities: GA < 33 weeks: Site specific crude rates Mortality / morbidities: GA < 29 weeks: Site specific crude rates	62 63
Presentation #35	Mortanty / morbidities: GA<29 weeks: Site specific crude rates	03
E.3.1. Site Compari	isons – Late Onset Sepsis and Antimicrobial Use	
Presentation #34	Late onset sepsis: GA < 33 weeks: Site specific crude rates	65
Presentation #35a	Late onset sepsis: GA < 33 weeks: Adjusted standardized ratios by site	66
Presentation #35b	Late onset sepsis: GA < 33 weeks: Adjusted standardized ratios by site: Funnel plot	66
Presentation #35c	Late onset sepsis: GA < 29 weeks: Adjusted standardized ratios by site	68
Presentation #35d	Late onset sepsis: $GA < 29$ weeks: Adjusted standardized ratios by site: Funnel plot	69
Presentation #36	Late onset sepsis per 1000 patient days: GA < 33 weeks: Site specific crude rates	70
Presentation #37a	<u>CLABSI per 1000 central line days: $GA < 33$ weeks: Site specific crude rates</u>	71
Presentation #37b	CLABSI per 1000 central line days: All neonates: Site specific crude rates	72
Presentation #38	Days of antimicrobial use per 1000 patient days: GA \leq 33 weeks	73
Presentation #39	Days of antimicrobial use per 1000 patient days: $GA < 29$ weeks	74
	Days of anamicrobial use per 1000 padelle days. Off <u>D</u> , weeks	
E.3.2. Site Compari	isons – Patent Ductus Arteriosus	
Presentation #40	Rate of treatment for PDA: GA < 33 weeks who had PDA: Site specific crude rates	75
Presentation #41	Surgical PDA ligation rates: GA < 33 weeks who had PDA: Site specific crude rates	76
-	isons – Severe Brain Injury	
Presentation #42	Severe brain injury rates: GA < 33 weeks: Site specific crude rates	77
Presentation #43	Periventricular leukomalacia (PVL) rates: GA<33 weeks: Site specific crude rates	79
Presentation #44a	IVH grade 3 or 4 or PVL: GA < 33 weeks: Adjusted standardized ratios by site	81
Presentation #44b	IVH grade 3 or 4 or PVL: GA < 33 weeks: Adjusted standardized ratios by site: Funnel plot	82
Presentation #44c	IVH grade 3 or 4 or PVL: $GA < 29$ weeks: Adjusted standardized ratios by site	83
Presentation #44d	IVH grade 3 or 4 or PVL: GA < 29 weeks: Adjusted standardized ratios by site: Funnel plot	84
F 3.4 Site Compar	isons – Necrotizing Enterocolitis	
Presentation #45	NEC treatment rates: GA < 33 weeks: Site specific crude rates	85
Presentation #46a	NEC: GA < 33 weeks: Adjusted standardized ratios by site	83 87
Presentation #46b	NEC: $GA < 33$ weeks: Adjusted standardized ratios by site: Funnel plot	88
Presentation #46c	NEC: $GA < 29$ weeks: Adjusted standardized ratios by site	89
Presentation #46d	NEC: $GA < 29$ weeks: Adjusted standardized ratios by site: Funnel plot	90

E.3.5. Site Comparisons – Chronic Lung Disease

Abbreviations

.	Isons – Chronic Lung Disease	
Presentation #47	<u>CLD: GA < 33 weeks: Site specific crude rates</u>	91
Presentation #48a	<u>CLD: GA \leq 33 weeks: Adjusted standardized ratios by site</u>	92
Presentation #48b	CLD: GA < 33 weeks: Adjusted standardized ratios by site: Funnel plot	93
Presentation #48c	CLD: $GA < 29$ weeks: Adjusted standardized ratios by site	94
Presentation #48d	CLD: GA < 29 weeks: Adjusted standardized ratios by site: Funnel plot	95
E 3.6 Site Compar	risons – Postnatal Use of Steroids	
Presentation #49a	Postnatal use of steroids for treatment of CLD: GA < 29 weeks: Site specific crude rates	96
Presentation #49b	Systemic steroids for hypotension: $GA < 33$ weeks: Site specific crude rates	97
i resentation // 195	Systemic steroids for hypotension. On (5.5) weeks, one specific crude faces	21
E.3.7. Site Compar	risons – Retinopathy of Prematurity	
Presentation #50a	<u>ROP > Stage 3: GA<33 weeks: Adjusted standardized ratios by site</u>	98
Presentation #50b	<u>ROP > Stage 3: GA<33 weeks: Adjusted standardized ratios by site: Funnel plot</u>	99
Presentation #50c	<u>ROP > Stage 3: GA<29 weeks: Adjusted standardized ratios by site</u>	100
Presentation #50d	ROP > Stage 3: GA<29 weeks: Adjusted standardized ratios by site: Funnel plot	101
E 3.8 Site Compar	risons – Mortality or Major Morbidity	
Presentation #51a	Mortality or major morbidity: GA < 33 weeks: Adjusted standardized ratios by site	102
	Mortality or major morbidity: GA < 33 weeks: Adjusted standardized ratios by site: Funnel	102
Presentation #51b	<u>plot</u>	103
Presentation #51c	$\overline{\text{Mortality or major morbidity: GA}} < 29$ weeks: Adjusted standardized ratios by site	104
Duranteting #E11	Mortality or major morbidity: GA < 29 weeks: Adjusted standardized ratios by site: Funnel	105
Presentation #51d	plot	105
F. Discharge Disp	osition & Status	
<u></u>		
Presentation #52a	Final Discharge destination: All GA: Crude rates	107
Presentation #52b	Final Discharge destination by site: GA <33	108
Presentation #53	Support at discharge: Neonates who were discharged directly home: Crude rates	110
G. Hypoxic Ischen	nic Encephalopathy	
~ ~		
Presentation #54	Hypoxic Ischemic Encephalopathy	112
H. Trend Analyses	s over the last 12 years	115
I. 2021 CNN publi	cations	134
I Appendices		
J. Appendices	Outcomes Definitions	137
	CNN Definitions and Major Anomalies	138

139

A. Executive Summary

Inclusion summary:

This report from the Canadian Neonatal NetworkTM (CNN) is based on data from 33 tertiary NICU sites that contributed data in the year 2021. Admissions between January 1, 2021 and December 31, 2021 who were discharged by March 31, 2022 were included. Seven (7) infants who were admitted in 2020 but discharged after March 31, 2021 were also included in the 2021 report. Delivery room deaths, moribund neonates, and readmissions from 2020 were excluded.

Total number of eligible admissions to participating sites (See section D.1 for analyses)	15 760
Total number of eligible individual neonates (See section D.2. for analyses)	14 651
Total number of eligible very preterm (GA <33 weeks) neonates Total number of eligible extremely preterm (GA <29 weeks) neonates (See section D.3. for analyses)	4 469 1 676
Total number of eligible very low birth weight (BW <1500 g) neonates (See section D.3. for analyses)	2 959

Important information for data interpretations:

- a. Neonates who were transferred to a "normal newborn care area" (level I nursery) or discharged home within 24 hours of their admission to the site were excluded.
- b. In 2021, ten (10) sites were only able to contribute data from a subset of eligible neonates admitted to their NICUs due to resource limitations. See <u>pages 3-4</u> for data collection criteria of all participating sites.
- c. Characteristics of participating sites were highlighted at the outset of the presentations.
- d. 'Missing' data on outcome variables varied for each presentation. Caution should be used when interpreting the information. When possible, both the total number of neonates and the number of neonates with available data were provided.
- e. The denominators for all percentages in this report included neonates whose data for that particular item were available.
- f. This report included data from neonates who were admitted to the NICUs, except for Presentations #4, #6a and #6b.
- g. Presentations #4, #6a and #6b included delivery room deaths.
- h. Neonates who were not admitted to participating NICUs were not included in this report.

Noteworthy findings:

- a. Out of 33 CNN sites, 31 had maternity units in their facilities; and of those, 30 collected data on delivery room deaths in 2021.
- b. Among infants born <33 weeks' GA and admitted to Level 3 NICUs, rate of outborn birth continues to decrease from 16.5% in 2010 to 14.4% in 2021.
- c. The proportion of infants receiving active care in the delivery room among hospital with a Level 3 NICU remained similar at lower GAs:
 - i. At 22 weeks' GA, 40% of all neonates received active care in the delivery room
 - ii. At 23 weeks' GA, 65% of all neonates received active care in the delivery room
- d. The survival rate has remained similar at lower GAs:
 - i. At 22 weeks' GA, 11% of all neonates and 27% of neonates who received intensive care survived.
 - ii. At 23 weeks' GA, 35% of all neonates and 54% of neonates who received intensive care survived.
- e. The survival rate also remained similar at lower BWs:
 - i. At 400-499g, 23% of all neonates and 46% of neonates who received intensive care survived.
 - ii. At 500-599g, 50% of all neonates and 65% of neonates who received intensive care survived.
- f. Among inborn neonates <29 weeks' GA at birth:
 - i. 40% received a complete course of antenatal steroids within the last week prior to birth
 - ii. 85% received MgSO4 for neuroprotection.
 - iii. 56% received deferred cord clamping \geq 30 sec
 - iv. 30% were hypothermic (temperature $<36.5^{\circ}$ C) on admission.
 - v. 83% received feeds within the first 2 days of admission
 - vi. 26% were never intubated during their stay.
 - vii. 43% were exclusively receiving mother's own milk at discharge
- g. Among neonates <33 weeks that received only a single course medical treatment for PDA, rate of acetaminophen use has increased from 20% in 2018 to 36% in 2021.
- h. Among infants <33 weeks with early onset sepsis, E. Coli was the most common etiology (46% of cases).
- i. Among neonates born >30 weeks' GA and >1250g, none were diagnosed with severe ROP.
- j. A total of 682 neonates were diagnosed with HIE and of whom 520 received hypothermia (compared to 460 in 2020).

Among neonates born <29 weeks' GA, rate of BPD increased from 55% in 2020 to 58% in 2021

SITE	CNN data collection criteria	Level II / Step- down nursery	Level II / Step-down data included in CNN	Delivery room deaths included in CNN	ROP treatment service?	PDA surgical service?	Therapeutic hypothermia treatment?	General pediatric surgical Services?
Victoria General Hospital, Victoria, BC	All eligible admissions	у	у	у	у	у	у	у
BC Women's Hospital, Vancouver, BC	All eligible admissions	у	n	У	у	у	у	У
Royal Columbian Hospital, New Westminster, BC	All eligible admissions	У	у	у	у	n	У	У
Surrey Memorial Hospital, Surrey, BC	All eligible admissions	У	у	у	у	n	У	n
Foothills Medical Centre, Calgary, AB	All eligible admissions	n	n/a	у	у	у	у	n
Alberta Children's Hospital, Calgary, AB	All eligible admissions	n	n/a	n/a	у	у	у	у
Royal Alexandra Hospital, Edmonton, AB*	< 33 weeks GA & HIE babies who were cooled	у	у	У	у	n	У	n
University of Alberta Hospital - Stollery, Edmonton, AB*	< 33 weeks GA, HIE, CDH & gastroschisis	n	n/a	n/a	n	у	у	у
Regina General Hospital, Regina, SK	All eligible admissions	у	у	у	у	n	у	у
Jim Pattison Children's Hospital, Saskatoon, SK (Formerly Royal University Hospital)	All eligible admissions	n	n/a	n	у	у	у	у
Health Sciences Centre Winnipeg, MB	≤33 weeks GA, HIE, CDH & gastroschisis and other selected admissions	у	у	у	у	у	у	у
St. Boniface General Hospital, Winnipeg, MB	All eligible admissions	n	n/a	Incomplete	у	у	у	у
Hamilton Health Sciences Centre, Hamilton, ON	All eligible admissions	У	n	у	у	у	у	У
London Health Sciences Centre, London, ON	< 33 weeks GA and other selected admissions	у	у	у	у	у	У	у
Windsor Regional Hospital, Windsor, ON	All eligible admissions	n	n/a	у	у	n	n	n
Hospital for Sick Children, Toronto, ON	All eligible admissions	n	n/a	n/a	у	у	у	у

B. CNN Site Characteristics

Mount Sinai Hospital, Toronto, ON	All eligible admissions	у	у	у	n	n	у	n
Sunnybrook Health Sciences Centre, Toronto, ON	All eligible admissions	n	n/a	у	у	n	у	n
Children's Hospital of Eastern Ontario, Ottawa, ON	< 36 weeks GA and HIE babies who were cooled	n	n	n	у	у	у	у
The Ottawa Hospital, Ottawa, ON	< 33 weeks GA	у	partial	у	у	n	n	n
Kingston General Hospital, Kingston, ON	All eligible admissions	У	у	у	у	n	у	у
Jewish General Hospital, Montreal, QC	All eligible admissions	У	у	у	у	n	n	n
Hôpital Sainte-Justine, Montreal, QC	All eligible admissions	у	n	у	у	у	у	у
Centre Hospitalier Universitaire de Quebec, Quebec city, QC	< 33 weeks GA, CDH & gastroschisis and other selected admissions	у	n	У	у	У	у	у
Montreal Children's Hospital – MUHC, Montreal, QC	All eligible admissions	n	n/a	у	у	у	у	у
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC	< 29 weeks GA	у	n	у	n	n	у	у
Hôpital Maisonneuve- Rosemont, Montreal , QC	< 33 weeks GA	n	n/a	у	n	n	n	n
The Moncton Hospital, Moncton, NB	All eligible admissions	n	n/a	У	у	n	у	n
Dr. Everett Chalmers Hospital, Federicton, NB	All eligible admissions	n	n/a	у	n	n	у	у
Saint John Regional Hospital, Saint John, NB	All eligible admissions	n	n	у	n	n	у	у
Janeway Children's Health & Rehab Centre, Saint John , NL	All eligible admissions	у	у	у	у	у	у	у
IWK Health Centre, Halifax, NS	< 34 weeks GA, HIE, CDH & gastroschisis	у	у	у	у	у	у	у
Cape Breton Regional Hospital, Sydney, NS	All eligible admissions	n	n/a	у	n	n	n	n
University of Utah Hospital, Utah, US	< 33 weeks GA	у	n	У	у	n	у	n
* Royal Alexandra H	lospital & University	of Alberta Hos	spital transmit d	ata as one site	1			

C. Information Systems

Neonates included in this report are those who were admitted to a CNN participating site between January 1, 2021 and December 31, 2021, and were discharged by March 31, 2022. The neonates must have had a length of stay at one of the CNN participating sites for greater than or equal to 24 hours, or died or were transferred to another level 2 or 3 facility within 24 hours. Seven (7) infants who were admitted in 2020 but discharged after March 31, 2021 were also included in the 2021 report. Delivery room deaths, moribund neonates, and readmissions from 2020 were excluded. A total of 14 651 patients accounted for 15 760 admissions as some neonates were admitted on more than one occasions.

Patient information was retrospectively abstracted from patient charts by trained personnel using standard definitions and protocols contained in a standard manual of operations. Data were usually entered into a laptop computer using a customized data entry program with built-in error checking and subsequently sent electronically to the Canadian Neonatal NetworkTM Coordinating Centre located at the Maternal-Infant Care Research Centre (MiCare) in Toronto, Ontario. Patient data at each participating site are available to the respective site investigator and data abstractor only. Patient identifiers were stripped prior to data transfer to the Coordinating Centre. Patient confidentiality was strictly observed. A unique identifier was generated for each entry of neonate into the system and that identifier was followed throughout one or more hospital stays. Individual-level data are used for analyses, but only aggregate data are reported. The results presented in this report will not identify participating sites by name; each site is anonymous using a randomly assigned number. Whenever a small cell size (1 to 4 individuals) was observed in the data output, the data were grouped to maintain anonymity.

At each participating site, data are stored in a secured database in the site or in an alternate secured site used by the site to store patient information (e.g. health records department, computer services department). At the Coordinating Centre, the central database is stored in a secured computer database located on a server and an off-site back up that is maintained and secured by the Mount Sinai Hospital Information Technology Department. At the Coordinating Centre, information was verified for completeness and was reviewed for accuracy by looking for "unusual" and missing values on individual data items and by comparison with other information that might be related (e.g. gestational age [GA] and birth weight [BW]). However, the principal accuracy rests upon the diligence and capabilities of the individual sites. Each site had one or occasionally two dedicated person(s) responsible for data acquisition and transmission.

At the Coordinating Centre, analyses were conducted using univariate, bivariate, and multivariate analyses for the total cohort, and for individual sites. Multivariable regression analysis was used to identify risk factors associated with mortality and major morbidities. Grouped data enabled development of outcome graphs by GA and BW for mortality and selected major morbidities. Similar systems have been used to assist in quality assurance and predict resource utilization.

D. Descriptive Analyses

This section is divided into three sub-sections.

Section D.1. Analyses based on number of eligible admissions to participating sites

These include data from 15 760 eligible admissions (including readmissions) to 33 sites. 23 of these sites submitted complete data (n=12 963) on all admissions and 10 sites submitted data on a selected admission cohort (n=2 797).


Section D.2. Analyses based on number of eligible neonates admitted to participating sites

These include data from 14 651 eligible neonates admitted to 33 sites. 23 of these sites submitted complete data (n=12 109) on all eligible admitted neonates and 10 sites submitted data on selected eligible admitted neonates (n=2 542).

Section D.3. Analyses based on number of eligible very preterm (GA <33 weeks) or very low birth weight (BW <1500g) neonates

These include data from 4 469 eligible very preterm neonates and 2 959 eligible very low birth weight (VLBW) neonates.


Canadian Neonatal NetworkTM Database: Admissions between January 1, 2021 and December 31, 2021 who were discharged by March 31, 2022. Seven (7) infants who were admitted in 2020 but discharged after March 31, 2021 were also included in the 2021 report. Delivery room deaths, moribund neonates, and readmissions from 2020 were excluded.



Section D.1

Analyses based on number of eligible admissions to participating sites

These include data from 15 760 eligible admissions (including readmissions) to 33 sites. 23 of these sites submitted complete data (n=12 963) on all admissions and 10 sites submitted data on a selected admission cohort (n=2 797).




Presentation #1 All admissions: Type of admissions: All Sites

[•] Data collected on selected cohort of eligible admissions only.

		Admission Status			Type of admissions: Al			Admission			
Sites		Inborn	Outborn	Readmission	Total	Total Sites		Inborn	Outborn	Readmission	Total
	Count	117	19	3	139	ф	Count	247	38	6	291
а	%	84.2	13.7	2.2	(100.0)	r¢	%	84.9	13.1	2.1	(100.0)
b∮	Count	0	108	5	113	0	Count	323	112	3	438
DΨ	%	0.0	95.6	4.4	(100.0)	S	%	73.7	25.6	0.7	(100.0)
c∳	Count	142	43	5	190	t	Count	143	2	2	147
Cr	%	74.7	22.6	2.6	(100.0)	t	%	97.3	1.4	1.4	(100.0)
d∮	Count	184	37	9	230		Count	1124	36	29	1189
۵ ⁴	%	80.0	16.1	3.9	(100.0)	u	%	94.5	3.0	2.4	(100.0)
e∳	Count	301	113	40	454		Count	330	55	5	390
er	%	66.3	24.9	8.8	(100.0)	v	%	84.6	14.1	1.3	(100.0)
f	Count	401	388	28	817		Count	0	835	51	886
L	%	49.1	47.5	3.4	(100.0)	W	%	0.0	94.2	5.8	(100.0)
۰đ	Count	146	13	5	164	T.	Count	363	274	14	651
g∮	%	89.0	7.9	3.1	(100.0)	х	%	55.8	42.1	2.2	(100.0)
1.	Count	272	67	2	341		Count	297	48	3	348
h	%	79.8	19.7	0.6	(100.0)	У	%	85.3	13.8	0.9	(100.0)
i	Count	0	219	8	227	z∳	Count	99	24	0	123
1	%	0.0	96.5	3.5	(100.0)	Zĭ	%	80.5	19.5	0.0	(100.0)
j	Count	878	111	6	995	0.0	Count	415	28	15	458
)	%	88.2	11.2	0.6	(100.0)	aa	%	90.6	6.1	3.3	(100.0)
k∮	Count	40	3	0	43	ab	Count	742	145	12	899
KΨ	%	93.0	7.0	0.0	(100.0)	aD	%	82.5	16.1	1.3	(100.0)
L	Count	261	24	6	291	ac∳	Count	773	200	17	990
L	%	89.7	8.3	2.1	(100.0)	act	%	78.1	20.2	1.7	(100.0)
\$	Count	95	5	8	108	ad	Count	440	151	8	599
m	%	88.0	4.6	7.4	(100.0)	au	%	73.5	25.2	1.3	(100.0)
n	Count	405	64	9	478	20	Count	877	305	57	1239
n	%	84.7	13.4	1.9	(100.0)	ae	%	70.8	24.6	4.6	(100.0)
0	Count	344	90	13	447	af	Count	645	219	8	872
0	%	77.0	20.1	2.9	(100.0)	ai	%	74.0	25.1	0.9	(100.0)
n	Count	520	77	20	617	ag∳	Count	165	18	16	199
р	%	84.3	12.5	3.2	(100.0)	ag	%	82.9	9.1	8.0	(100.0)
a	Count	331	52	4	387	Total	Count	11420	3923	417	15760
q	%	85.5	13.4	1.0	(100.0)		%	72.5	24.9	2.6	(100.0)

Presentation #1 (continued) All admissions: Type of admissions: All Sites

COMMENTS: These analyses include 15 760 admissions to participating sites across the CNN during the period of January 1, 2021 to December 31, 2021. After adjusting for readmission, 14 651 neonates are represented. Twenty-three sites collected data on all eligible admissions whereas ten sites (marked by Φ) collected data on selected cohort of eligible admissions only. See pages 3-4 for data collection criteria of all participating sites.



Data collection status	Number of sites	Score	Mean	Std Dev	Q1	Median	Q3
Complete	23	SNAPIIPE	10.1	0.1	0	0	18
		SNAPII	5.0	0.1	0	0	7
Restricted	10	SNAPIIPE	14.6	0.3	0	9	23
		SNAPII	6.5	0.2	0	0	9

Site		SNAP-IIPE	SNAP-II	Site		SNAP-IIPE	SNAP-II
•	Mean	7.7	3.5		Mean	7.8	2.8
Α	SEM	0.6	0.4	Q	SEM	0.6	0.3
\mathbf{B}^{ϕ}	Mean	22.6	11.1	ъ	Mean	13.0	6.2
\mathbf{D}^{Ψ}	SEM	1.0	0.6	R	SEM	0.6	0.4
C∳	Mean	19.3	7.0	s	Mean	12.2	6.4
CΨ	SEM	1.4	0.6	3	SEM	1.2	0.8
D	Mean	12.9	7.4	Т	Mean	6.9	4.1
D	SEM	0.5	0.3		SEM	0.7	0.4
Е	Mean	14.9	9.4	U	Mean	5.3	2.5
E	SEM	1.3	0.9		SEM	0.5	0.3
F	Mean	11.1	7.6	V	Mean	14.7	7.8
Г	SEM	0.8	0.5	VΨ	SEM	1.3	0.9
C	Mean	8.6	4.6	WZA	Mean	14.6	6.5
G	SEM	0.5	0.3	\mathbf{W}^{Φ}	SEM	1.3	0.9
T T Å	Mean	12.1	4.8	▼ ZÅ	Mean	21.8	7.7
\mathbf{H}_{ϕ}	SEM	1.3	0.8	\mathbf{X}^{ϕ}	SEM	1.9	1.2
T	Mean	10.3	3.2	N 7	Mean	13.1	5.9
Ι	SEM	0.5	0.2	Y	SEM	0.6	0.3
ті	Mean	13.0	6.2	7	Mean	10.1	5.6
\mathbf{J}^{ϕ}	SEM	0.9	0.5	Z	SEM	0.5	0.3
V	Mean	7.0	2.9		Mean	7.0	3.4
K	SEM	0.7	0.4	AA	SEM	0.5	0.3
т	Mean	9.2	5.3		Mean	13.6	7.4
L	SEM	0.4	0.3	AB	SEM	0.6	0.4
м	Mean	12.8	6.3		Mean	5.6	2.1
Μ	SEM	0.7	0.4	AC	SEM	0.9	0.5
NT	Mean	8.5	3.0	4.0	Mean	10.0	5.0
Ν	SEM	0.6	0.3	AD	SEM	0.7	0.4
0	Mean	3.7	0.2	4174	Mean	15.8	7.2
0	SEM	0.8	0.1	AE∳	SEM	1.5	0.8
ъ	Mean	7.8	3.1	A T I	Mean	8.8	3.7
Р	SEM	0.7	0.4	AF∳	SEM	0.5	0.3
					Mean	30.5	13.6
				AG∳	SEM	3.4	2.0

Presentation #2 (continued)


All admissions: Admission illness severity scores (SNAP-II & SNAP-IIPE): All sites

COMMENTS: These analyses include 15 760 admissions (499 missing data on SNAP scores) to participating all sites during the year 2021. Adjusting for readmission, these analyses represent 14 651 Neonates. Twenty-three sites collected data on all eligible admissions whereas ten sites (marked by [§]) collected data on a selected cohort of eligible admissions only. These ten sites were not included in the Presentation #2 bar graph but were included in the Presentation #2 Table. [§] Please note that the criteria for entering neonates in the CNN dataset are not the same for these ten sites and thus, the scores are not comparable with each other or with centers contributing complete data. These ten sites may have included neonates at lower GAs and/or lower BWs; thus, their severity of illness scores may be different.

Section D.2

Analyses based on number of eligible neonates admitted to participating sites

These include data from 14 651 eligible neonates admitted to 33 sites. 23 of these sites submitted complete data (n=12 109) on all eligible admitted neonates and 10 sites submitted data on a selected cohort of eligible admitted neonates (n=2 542).




Presentation #3 Gestational age distribution: All sites and all admitted neonates

GA in completed weeks at birth	Frequency	Percent	Cumulative percent
22	32	0.2	0.2
23	99	0.7	0.9
24	214	1.5	2.4
25	254	1.7	4.1
26	298	2.0	6.1
27	331	2.3	8.4
28	448	3.1	11.4
29	514	3.5	15.0
30	577	3.9	18.9
31	761	5.2	24.1
32	941	6.4	30.5
33	812	5.5	36.1
34	1119	7.6	43.7
35	1072	7.3	51.0
36	1307	8.9	59.9
37	1373	9.4	69.3
38	1507	10.3	79.6
39	1440	9.8	89.4
40	1023	7.0	96.4
41	511	3.5	99.9
≥42	18	0.1	100.0
Total included	14 651	100.0	
Total # of missing GA	0		
Total # of neonates	14 651		

Presentation #3 (continued) Gestational age distribution: All sites and all admitted neonates

COMMENTS: The GA distribution of neonates is shown here. Term babies (\geq 37 weeks) represent 40.1% of the total number of neonates. Twenty-three sites collected data on all eligible admissions whereas ten sites collected data on a selected cohort of eligible admissions.


Presentation #4 Survival to discharge by GA: All admissions, including delivery room (DR) deaths



CNN admis	ssions, exclu	ding deliver	y room deaths		Delivery deaths*		Total CNN admissions including delivery room deaths*					
GA (completed weeks)	#of neonates	#of survivors	Percent survival among CNN admissions, excluding DR deaths	#of neonates who received comfort care	Palliat ive care	Active care **	Total	#of neonates who received comfort care	# of neonates who received active care**	Percent survival among those who received active care	Percent survival among all neonates (CNN admissions + DR deaths)	
	а	b	b/ a	С	d	е	a+d+e	c+d	(a-c) +e	b/ (a-c)+e	b/(a+d+e)	
22	32	10	31	0	54	5	91	54	37	27	11	
23	99	55	56	1	53	3	155	54	101	54	35	
24	214	154	72	0	10	2	226	10	216	71	68	
25	254	205	81	0	9	3	266	9	257	80	77	
26	298	274	92	0	4	2	304	4	300	91	90	
27	331	305	92	0	2	1	334	2	332	92	91	
28	448	430	96	0	2	0	450	2	448	96	96	
29	514	504	98	0	3	0	517	3	514	98	97	
≥30	12 461	12 289	99	4	26	19	12 506	30	12 476	99	98	
Total included	14 651	14 226	97	5	163	35	14 849	168	14 681	97	96	
Missing GA	0				3	0	3	3	0			
Total	14 651				166	35	14 852	171	14 681			

*Please note that delivery room deaths are *only included in Presentations #4, #6a, and #6b* in this report. **Active care refers to infants who received cardiopulmonary resuscitation at birth.


Note: The results should be used cautiously for antenatal counseling. The survival rates are based upon the final discharge from the participating neonatal site. <u>Note that these rates include only neonates admitted to the sites or dying in the delivery rooms of participating sites and thus are not reflective of the entire Canadian population.</u> Only one CNN site did not contribute delivery room death data.



Presentation #5 Birth weight distribution: All sites and all admitted neonates

BW (grams)	Frequency	Percent from total number of neonates	Cumulative percent
<500	43	0.3	0.3
500-749	479	3.3	3.6
750-999	673	4.6	8.2
1000-1249	831	5.7	13.8
1250-1499	933	6.4	20.2
1500-2499	4 704	32.1	52.3
2500-4499	6 781	46.3	98.6
>4499	207	1.4	100.0
Total included	14 651	100.0	
Missing BW	0		
Total # of neonates	14 651		

COMMENTS: The BW distribution of neonates admitted to the CNN sites. Eighty percent weighed more than 1 500g at birth and 47.7% weighed more than 2 500g. Twenty-three sites collected data on all admissions whereas ten sites collected data on a selected cohort of eligible admissions only.




Presentation #6a
Survival to discharge by BW: All admissions, including delivery room (DR) deaths

CNN Admi	ssions, exclu	iding delive	ry room death	S	Delivery deaths*		Total CNN admissions + Delivery room deaths*					
BW (grams)	#of neonates	# of survivors	Percent survival of CNN admissions, excluding DR deaths	# of neonates who received palliative care	Palliat ive care	Active care **	Total	# of neonates who received palliative care	# of neonates who received active care**	Percent survival of neonates who received active care	Percent survival of all neonates (CNN admissions + DR deaths)	
	а	Ь	b/ a	С	d	е	a+d+e	c+d	(a-c) +e	b/ (a-c)+e	b/(a+d+e)	
<500	43	20	47	0	54	3	100	54	46	43	20	
500-749	479	353	74	1	68	7	554	69	485	73	64	
750-999	673	608	90	0	9	4	686	9	677	90	89	
1000-1249	831	797	96	0	4	3	838	4	834	96	95	
1250-1499	933	913	98	0	9	0	942	9	933	98	97	
1500-2499	4 704	4 637	99	2	13	8	4 725	15	4 710	98	98	
2500-4499	6 781	6 693	99	2	6	9	6 796	8	6 788	99	98	
>4499	207	205	99	0	0	0	207	0	207	99	99	
Total neonates included	14 651	14 226	97	5	163	34	14 848	168	14 680	97	96	
Missing BW	0				3	1	4	3	1			
Total # of neonates	14 651				166	35	14 852	171	14 681			

*Please note that delivery room deaths are only included in Presentations #4, #6a and #6b in this report. **Active care refers to infants who received cardiopulmonary resuscitation at birth.

Note: The results should be used cautiously for antenatal counseling. The survival rates are based upon the final discharge from the participating neonatal site. Note that these rates include only neonates admitted to the sites or dying in the delivery rooms of participating sites and thus are not reflective of the entire Canadian population. Only one CNN site did not contribute delivery room death data.

Presentation #6b Survival to discharge by BW: BW <1000g including delivery room (DR) deaths



CNN Adm	issions, exc	luding deliv	ery room deaths	3	Deliver deaths*	y room *	Total CNN admissions + Delivery room deaths*					
BW (grams)	Number of neonates	Number of survivors	Percent survival of CNN admissions, excluding DR deaths	Number of neonates who received palliative care	Pallia tive care	Active care **	Total	Number of neonates who received palliative care	Number of neonates who received active care**	Percent survival of neonates who received active care	Percent survival of all neonates (CNN admissions + DR deaths)	
	а	b	b/ a	С	d	е	a+d+e	c+d	(a-c) +e	b/ (a-c)+e	b/(a+d+e)	
<400	6	2	33	0	14	1	21	14	7	29	10	
400-499	37	18	49	0	40	2	79	40	39	46	23	
500-599	131	87	66	1	40	3	174	41	133	65	50	
600-699	213	153	72	0	20	2	235	20	215	71	65	
700-799	262	221	84	0	12	3	277	12	265	83	80	
800-899	262	233	89	0	2	3	267	2	265	88	87	
900-999	284	267	94	0	3	0	287	3	284	94	93	
Total included	1 195	981	82	1	131	14	1 340	132	1 208	81	73	

*Please note that delivery room deaths are *only included in Presentations #4, #6a and #6b* in this report. **Active care refers to infants who received cardiopulmonary resuscitation at birth.

Note: The results should be used cautiously for antenatal counseling. The survival rates are based upon the final discharge from the participating neonatal site. <u>Note that these rates include only neonates admitted to the sites or died in delivery room of participating sites and thus are not reflective of the entire Canadian population.</u> Only one CNN site did not contribute delivery room death data.

Characteristi									
		Missing/ Unknown		<26	26-28	29-32	33 - 36	<u>></u> 37	Total
Total				599	1077	2793	4310	5872	14651
No prenatal c	are	301	Ν	10	23	45	79	74	231
1			%	1.7	2.2	1.6	1.9	1.3	1.6
Marijuana/car	Marijuana/cannabis		Ν	33	81	204	336	389	1043
			%	5.6	7.6	7.4	7.9	6.7	7.1
Smoking		67	Ν	58	127	339	548	590	1662
_			%	9.7	11.9	12.2	12.8	10.1	11.4
Maternal hype	ertension	790	Ν	53	234	678	981	738	2684
. –			%	9.2	22.2	25.3	23.6	13.7	19.4
Maternal diab	etes	900	Ν	59	159	555	901	1033	2707
			%	10.5	15.4	20.9	21.9	19.2	19.7
Assisted preg	nancy (ART)	2	Ν	75	111	278	359	254	1077
			%	12.5	10.3	10.0	8.3	4.3	7.4
Multiples		1	Ν	151	244	851	1131	164	2541
			%	25.2	22.7	30.5	26.2	2.8	17.3
MgSO ₄ for		984	Ν	477	859	1956	668	47	4007
neuroprotecti	on		%	82.0	82.3	73.8	16.3	0.9	29.3
Antenatal	None	343	Ν	53	104	275	2525	5700	8657
steroids	INOILE		%	9.0	9.8	10.2	60.3	98.9	60.5
	Partial		Ν	205	290	715	424	5	1639
	Fatual		%	34.8	27.4	26.4	10.1	0.1	11.5
	Complete		Ν	332	664	1716	1240	60	4012
	Complete		%	56.3	62.8	63.4	29.6	1.0	28.0
Mode of	Vaginal	24	Ν	249	337	915	1770	3206	6477
birth	vagillai		%	41.6	31.3	32.9	41.1	54.7	44.3
	C/S		Ν	349	740	1870	2532	2659	8150
	C/3		%	58.4	68.7	67.2	58.9	45.3	55.7
Presentation	Vertex	1275	Ν	287	583	1817	3176	4711	10574
	vertex		%	49.4	56.9	69.3	79.3	91.6	79.1
	Breech		Ν	251	367	700	724	336	2378
	Dieeen		%	43.2	35.8	26.7	18.1	6.5	17.8
	Other		Ν	43	74	106	107	94	424
	Other		%	7.4	7.2	4.0	2.7	1.8	3.2
Rupture of	<24 h	1375	Ν	403	729	1952	3404	4767	11255
membranes	<u>>∠</u> + II		%	71.0	72.3	76.1	85.2	92.7	84.8
	24h to		Ν	98	128	323	373	314	1236
	1wk		%	17.3	12.7	12.6	9.3	6.1	9.3
	>1 wk		Ν	67	152	289	217	60	785
	~1 WK		%	11.8	15.1	11.3	5.4	1.2	5.9

Presentation #7a Maternal and peripartum characteristics: All neonates

Character	ristics			GA at bi	irth (compl	leted weeks	5)		
		Missing/ Unknown		<26	26-28	29-32	33 - 36	<u>></u> 37	Total
Total				599	1077	2793	4310	5872	14651
Chorioam	nionitis*	1383	Ν	254	308	410	317	574	1863
			%	44.5	29.9	15.7	7.9	11.4	14.0
Deferred	<u><</u> 29 sec	2234	Ν	45	52	122	105	116	440
cord			%	8.0	5.1	4.7	2.8	2.6	3.5
clamping	30-59 sec		Ν	105	230	435	547	677	1994
			%	18.6	22.7	16.9	14.4	15.2	16.1
	<u>></u> 60 sec		Ν	151	367	1299	2040	2005	5862
			%	26.8	36.2	50.4	53.8	44.9	47.2
	Yes, but timing		Ν	4	7	59	101	199	370
	unknown		%	0.7	0.7	2.3	2.7	4.5	3.0
	No		Ν	259	359	663	1002	1468	3751
			%	45.9	35.4	25.7	26.4	32.9	30.2

Presentation #7a (continued) Maternal and peripartum characteristics: All neonates

*Chorioamnionitis is defined as documented histological chorioamnionitis on placenta pathology <u>or</u> "suspected or confirmed clinical chorioamnionitis" in chart <u>or</u> presence of maternal fever <u>and *either* leukocytosis *or* purulent discharge *or* fetal tachycardia.</u>

Presentation #7b Maternal and peripartum characteristics: Timing of single course of Antenatal Corticosteroids (ANCS): GA <33 weeks

			No ANCS	Complete course within last week prior to birth *	Complete course more than 1 week before birth **	Complete course but timing unknown ***	Partial course within last 24 hours ****
	Weeks						
	22-28	Ν	68	572	395	20	344
Inborn	22-28	%	4.7	39.8	27.5	1.4	23.9
Indom	29-32	Ν	160	842	756	43	536
	29-32	%	6.7	35.3	31.7	1.8	22.5
	22-28	Ν	89	1	8	0	112
Outborn	22-20	%	37.4	0.4	3.4	0.0	47.1
Outborn	29-32 N		115	52	21	2	138
	27-32	%	28.4	12.8	5.2	0.5	34.1

*Complete course within last week prior to birth – defined as receipt of at least two doses of corticosteroids 24 hours or more but within one week of birth.

******Complete course before 1 week of birth – defined as receipt of at least two doses of corticosteroids initiated more than one week prior to birth.

*******Complete course but timing unknown – defined as receipt of at least two doses of corticosteroids or if "complete course" was documented, but the dates of administration were not available.

********Partial course within last 24 hours – defined as any dose given less than 24 hours prior to birth.

Note: Data on "Partial course >24 hours ago" and "Partial course but timing unknown" are collected in the database but they are not reported in this table.

Presentation #7c Maternal and peripartum characteristics: Timing of deferred cord clamping: GA <33 weeks

						gleton				
				Defer		Turneralista				
			0-15 seconds	16-30 seconds	31-60 seconds	61-75 seconds	>75 seconds	Duration unknown	Immediate Cord clamping	Unknown timing
	Weeks									
	22-28	Ν	25	150	493	7	12	5	385	12
Inborn	22-20	%	2.3	13.8	45.3	0.6	1.1	0.5	35.4	1.1
moom	29-32	Ν	32	164	959	34	22	31	337	28
	29-32	%	2.0	10.2	59.7	2.1	1.4	1.9	21.0	1.7
	22-28	Ν	4	20	27	1	1	0	82	56
Outborn	22-20	%	2.1	10.5	14.1	0.5	0.5	0.0	42.9	29.3
Guiboin	29-32	Ν	7	23	60	3	7	7	91	137
	27-32	%	2.1	6.9	17.9	0.9	2.1	2.1	27.2	40.9

Singleton

	First twin													
				Defer	red Cord	clamping	timing		Immediate					
			0-15 seconds	16-30 seconds	31-60 seconds	61-75 seconds	>75 seconds	Duration unknown	Cord clamping	Unknown timing				
	Weeks													
	22-28	Ν	5	19	62	0	1	3	63	7				
Inborn		%	3.1	11.9	38.8	0.0	0.6	1.9	39.4	4.4				
mbom	29-32	Ν	6	32	171	7	4	6	106	11				
		%	1.8	9.3	49.9	2.0	1.2	1.8	30.9	3.2				
	22.29	Ν	0	2	5	0	0	0	9	7				
Outborn	22-28	%	0.0	8.7	21.7	0.0	0.0	0.0	39.1	30.4				
Outborn	29-32	Ν	0	2	9	0	0	0	11	11				
		%	0.0	6.1	27.3	0.0	0.0	0.0	33.3	33.3				

Second twin

				Defer	red Cord	clamping	timing		Immediate	
			0-15 seconds	16-30 seconds	31-60 seconds	61-75 seconds	>75 seconds	Duration unknown	Cord clamping	Unknown timing
	Weeks									
22-28		Ν	5	32	49	1	0	3	62	5
т 1	22-20	%	3.2	20.4	31.2	0.6	0.0	1.9	39.5	3.2
Inborn	29-32	Ν	7	41	171	9	4	11	84	10
		%	2.1	12.2	50.7	2.7	1.2	3.3	24.9	3.0
	22.28	Ν	0	3	3	0	0	0	9	9
On the ser	22-28	%	0.0	12.5	12.5	0.0	0.0	0.0	37.5	37.5
Outborn	20.22	Ν	0	5	6	0	0	0	10	13
	29-32	%	0.0	14.7	17.7	0.0	0.0	0.0	29.4	38.2

Action taken Total No resuscitation needed/provided CPAP PPV via mask PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2 41-70% O2	N % N	<u>≤23</u> 131 0	irth (com 24 214	25	26	27	28	20	20	
No resuscitation needed/provided CPAP PPV via mask PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2	% N	131 0				41	20	29	30	Total
needed/provided CPAP PPV via mask PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O ₂	% N	-		254	298	331	448	514	577	2767
CPAP PPV via mask PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2	Ν	0.0	0	0	1	0	9	6	22	38
PPV via mask PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O ₂		0.0	0.0	0.0	0.3	0.0	2.0	1.2	3.8	1.4
PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O ₂	%	16	93	119	197	247	356	426	479	1933
PPV via ETT Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2		12.2	43.5	47.0	66.1	74.9	79.5	82.9	83.0	69.9
Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O ₂	Ν	116	195	228	257	263	309	340	359	2067
Chest compression Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O ₂	%	88.6	91.1	90.1	86.2	79.7	69.0	66.2	62.2	74.8
Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2	Ν	116	140	142	119	95	108	86	83	889
Epinephrine Unknown Any resuscitation provided* Initial gas Air 22-40% O2	%	88.6	65.4	56.1	39.9	28.8	24.1	16.7	14.4	32.2
Unknown Any resuscitation provided* Initial gas Air 22-40% O2	Ν	7	15	17	17	8	10	7	12	93
Unknown Any resuscitation provided* Initial gas Air 22-40% O2	%	5.3	7.0	6.7	5.7	2.4	2.2	1.4	2.1	3.4
Any resuscitation provided* Initial gas Air 22-40% O ₂	Ν	6	6	5	5	7	5	4	6	44
Any resuscitation provided* Initial gas Air 22-40% O ₂	%	4.6	2.8	2.0	1.7	2.1	1.1	0.8	1.0	1.6
provided* Initial gas Air 22-40% O2	Ν	0	0	2	4	1	3	1	0	11
provided* Initial gas Air 22-40% O2	%	0.0	0.0	0.8	1.3	0.3	0.7	0.2	0.0	0.4
Initial gas Air 22-40% O ₂	Ν	130	213	251	293	328	433	503	542	2693
22-40% O ₂	%	99.2	99.5	99.2	98.3	99.4	96.7	97.9	93.9	97.4
	Ν	12	35	45	46	58	107	170	210	683
	%	9.2	16.4	17.7	15.4	17.5	23.9	33.1	36.4	24.7
41-70% O ₂	Ν	64	125	137	185	216	266	251	229	1473
41-70% O ₂	%	48.9	58.4	53.9	62.1	65.3	59.4	48.8	39.7	53.2
	Ν	7	12	14	12	10	11	20	38	124
	%	5.3	5.6	5.5	4.0	3.0	2.5	3.9	6.6	4.5
71-99% O ₂	Ν	2	4	1	4	4	4	2	4	25
	%	1.5	1.9	0.4	1.3	1.2	0.9	0.4	0.7	0.9
$100\% O_2$	Ν	36	25	34	28	19	23	28	21	214
	%	27.5	11.7	13.4	9.4	5.7	5.1	5.5	3.6	7.7
Unknown/	Ν	10	13	23	23	24	37	43	75	248
Missing	%	7.6	6.1	9.1	7.7	7.3	8.3	8.4	13.0	9.0
Maximum 21%	Ν	0	1	2	2	0	7	12	25	49
O_2 conc.	%	0.0	0.5	0.8	0.7	0.0	1.6	2.3	4.3	1.8
during 22-40%	Ν	3	13	22	52	86	126	154	188	644
resus.	%	2.3	6.1	8.7	17.5	26.0	28.1	30.0	32.6	23.3
41-70%	Ν	11	30	33	55	64	99	124	114	530
	%	8.4	14.0	13.0	18.5	19.3	22.1	24.1	19.8	19.2
>70%	Ν	110	162	186	177	169	185	196	186	1371
	%	84.0	75.7	73.2	59.4	51.1	41.3	38.1	32.2	49.6
Missing	Ν	7	8	11	12	12	31	28	64	173
* Number of neonat	%	5.3	3.7	4.3	4.0	3.6	6.9	5.5	11.1	6.3

Presentation #8a Resuscitation details: GA < 31 weeks

* Number of neonates who received any resuscitation includes those who received CPAP, PPV, chest compression or epinephrine


NOTE: Please use caution when interpreting these data. Resuscitation time was defined as the first 30 minutes after birth. Note that delivery room deaths are not included in the denominator.

Action take	n		esuscita GA at b	irth (com						
			31	32	33	34	35	36	>37	Total
Total			761	941	812	1119	1072	1307	5872	11884
No resuscitat	tion needed /	Ν	41	115	200	388	391	499	2107	3741
provided		%	5.4	12.2	24.6	34.7	36.5	38.2	35.9	31.5
CPAP		Ν	614	671	454	493	460	514	2358	5564
		%	80.8	71.3	55.9	44.1	42.9	39.3	40.2	46.8
PPV via mas	k	Ν	425	419	261	315	286	370	1827	3903
		%	55.9	44.5	32.1	28.2	26.7	28.3	31.1	32.9
PPV via ET	Г	Ν	74	54	31	51	41	68	414	733
	%	9.7	5.7	3.8	4.6	3.8	5.2	7.1	6.2	
Chest compr	Ν	9	10	11	13	8	21	139	211	
-	%	1.2	1.1	1.4	1.2	0.8	1.6	2.4	1.8	
Epinephrine	Ν	5	4	6	10	0	4	55	84	
		%	0.7	0.4	0.7	0.9	0.0	0.3	0.9	0.7
Unknown		Ν	4	11	10	1	3	7	45	81
			0.5	1.2	1.2	0.1	0.3	0.5	0.8	0.7
Any resuscitation		Ν	690	732	504	576	539	636	2935	6612
provided*		%	90.8	77.8	62.1	51.5	50.3	48.7	50.0	55.7
Initial gas	Air	Ν	280	420	265	354	368	393	1897	3977
		%	36.8	44.6	32.6	31.6	34.3	30.1	32.3	33.5
	22-40% O ₂	Ν	293	229	190	189	135	160	531	1727
		%	38.5	24.3	23.4	16.9	12.6	12.2	9.0	14.5
	41-70% O ₂	Ν	33	39	24	27	23	31	142	319
		%	4.3	4.1	3.0	2.4	2.2	2.4	2.4	2.7
	71-99% O ₂	Ν	4	5	2	3	7	5	29	55
		%	0.5	0.5	0.3	0.3	0.7	0.4	0.5	0.5
	100% O ₂	Ν	30	33	40	56	42	61	309	571
		%	3.9	3.5	4.9	5.0	3.9	4.7	5.3	4.8
	Unknown/	Ν	121	215	291	490	497	657	2964	5235
	Missing	%	15.9	22.9	35.8	43.8	46.4	50.3	50.5	44.1
Maximum	21%	Ν	36	87	81	119	113	113	583	1132
O_2 conc.		%	4.7	9.3	10.0	10.6	10.5	8.7	9.9	9.5
during	22-40%	Ν	280	267	188	208	198	217	770	2128
resus		%	36.8	28.4	23.2	18.6	18.5	16.6	13.1	17.9
	41-70%	Ν	164	193	111	130	109	103	448	1258
		%	21.6	20.5	13.7	11.6	10.2	7.9	7.6	10.6
	>70%	Ν	180	164	137	152	132	187	1004	1956
		%	23.7	17.4	16.9	13.6	12.3	14.3	17.1	16.5
	Missing	Ν	101	230	295	510	520	687	3067	5410
	wissing	ΤN	101	450	275	510	540	007	3007	5110

Presentation #8b Resuscitation details: $GA \ge 31$ weeks

* Number of neonates who received any resuscitation includes those who received CPAP, PPV, Chest compression or epinephrine

NOTE: Please use caution while interpreting these data. Resuscitation time was defined as the first 30 minutes after birth. Note that delivery room deaths are not included in the denominator.




Presentation #9 Early onset sepsis rates: All GA

CA at hirth (completed	Total number	No. of neonates	% of neonates	Total	Organism				
GA at birth (completed weeks)	of neonates	with infection	with infection	number of organisms	E. Coli	GBS	Others		
<25	345	17	4.9	17	7	4	6		
25-26	552	15	2.7	15	6	4	5		
27-28	779	13	1.7	15	9	1	5		
29-30	1091	15	1.4	16	6	3	7		
31-32	1702	11	0.7	11	6	2	3		
33-34	1931	6	0.3	6	3	1	2		
35-36	2379	7	0.3	7	2	1	4		
≥37	5872	26	0.4	26	3	9	14		
Total neonates included	14 651	110	0.8	113	42	25	46		
Missing	0								
Total # of neonates	14 651								

COMMENTS: Early onset sepsis is indicated by positive bacterial, viral or fungal culture in blood and/or cerebrospinal fluid, in the first two days after birth. In other category, top six organisms were: Bacillus (n=8), Streptococci (n=6), Viridans streptococci (n=5), Enterococci (n=5), Morganella (n=3), Staph aureus (n=3). In contrast to previous CNN reports, CONS was *not* included as an organism causing early onset sepsis in this report based on consultation with microbiologists.

Syphilis (n=21) was not counted as an early onset sepsis in this presentation.




Presentation #10 Late onset sepsis rates: All GA

GA at birth	Total	Number of d deaths in the	neonates	Number of neonates	Number of neonates	Among neonates who survived day 2,	Total	Organisms						
(completed weeks)	number		survived beyond day 2 after birth	with at least one infection	with more than one infection	percentage with at least one infection	age with st one organisms CONS E. Coli Staph aureus Fungal		Fungal	Virus	Other			
<25	345	20	325	122	30	38	179	77	17	27	7	8	43	
25-26	552	8	544	117	20	22	142	62	15	15	9	3	38	
27-28	779	11	768	89	9	12	104	46	8	13	4	8	25	
29-30	1 091	4	1 087	55	8	5	64	31	5	7	2	0	19	
31-32	1 702	1	1 701	35	3	2	39	14	10	4	1	3	7	
33-34	1 931	6	1 925	23	3	1	33	14	4	2	0	0	13	
35-36	2 379	6	2 373	24	5	1	33	12	6	5	0	2	8	
≥37	5 872	14	5 858	58	3	1	64	36	2	5	1	2	18	
Total included	14 651	70	14 581	523	81	4	658	292	67	78	24	26	171	
Missing	0													
Total # of	14 (51	1												

neonates 14 651

COMMENTS: Late onset sepsis is defined as any positive blood and/or cerebrospinal fluid culture for bacteria, viral or fungi after 2 days of age (analysis is neonate-based). The numbers are adjusted for readmission. Among other category, top 5 organisms were: Klebsiella (n=42), GBS (n=34), Enterococci (n=32), Bacillus (n=21) Enterobacter (n=12). Virus category includes Cytomegalovirus (n=20), Herpes simplex virus (n=5), Enterovirus (n=1).

Note: In 2020, the coding for CONS and Staph Aureus were revised which has led to a change in proportion of each.



Presentation #11 Late onset sepsis rates: All BW

		Number of	Number of	Number of neonatesNumber of neonatesNumber of neonatesneonates 		Among neonates who	Total			Orga	anisms		
BW (grams)	Total number	deaths in the first 2 days after birth	neonates survived beyond		survived day 2, percentage with at least one infection	number of organis ms	CON S	E. Coli	Staph aureu s	Fung al	Virus	Other	
<500	43	6	37	11	3	30	14	6	2	1	1	0	4
500-749	479	19	460	131	31	28	190	85	15	27	7	9	47
750-999	673	7	666	134	22	20	166	75	15	21	6	8	41
1000-1499	1 764	9	1 755	103	12	6	122	49	14	13	7	3	36
1500-1999	2 325	4	2 321	43	6	2	53	22	6	6	2	3	14
2000-2499	2 379	3	2 376	33	3	1	36	15	7	5	1	1	7
<u>></u> 2500	6 988	22	6 966	68	4	1	77	40	8	5	0	2	22
Total included	14 651	70	14 581	523	81	4	658	292	67	78	24	26	171
Missing (BW)	0												
T 14 C		1											

Total # of neonates 14 651

COMMENTS: Late onset sepsis is defined as any positive blood and/or cerebrospinal fluid culture for bacteria, viral or fungi after 2 days of age (analysis is neonate-based). The numbers are adjusted for readmission. Among other category, top 5 organisms were: Klebsiella (n=42), GBS (n=34), Enterococci (n=32), Bacillus (n=21) Enterobacter (n=12). Virus category includes Cytomegalovirus (n=20), Herpes simplex virus (n=5), Enterovirus (n=1).

Note: In 2020, the coding for CONS and Staph Aureus were revised which has led to a change in proportion of each.

Characteristics		Missing			GA at	birth (co	mpleted v	weeks)		
				<u><</u> 25	26 - 28	29 - 30	31 - 32	33 - 36	<u>></u> 37	Total
Total				599	1077	1091	1702	4310	5872	14651
Prophylactic	Indomethacin	2	Ν	79	73	3	0	0	2	157
			%	13.2	6.8	0.3	0.0	0.0	0.0	1.1
	Probiotics	2	Ν	400	764	740	910	545	101	3460
			%	66.8	70.9	67.8	53.5	12.7	1.7	23.6
RDS	Unknown	6	Ν	0	2	11	7	7	6	33
			%	0.0	0.2	1.0	0.4	0.2	0.1	0.2
	Uncertain		Ν	1	9	12	25	44	30	121
			%	0.2	0.8	1.1	1.5	1.0	0.5	0.8
	None		Ν	14	112	214	772	3591	5572	10275
			%	2.3	10.4	19.7	45.4	83.4	94.9	70.2
	Definite		Ν	584	954	852	898	665	263	4216
			%	97.5	88.6	78.2	52.8	15.4	4.5	28.8
Surfactant in first 30			Ν	119	86	34	14	15	0	268
min			%	19.9	8.0	3.1	0.8	0.4	0.0	1.8
Surfactant in first 60			Ν	283	227	99	47	31	1	688
min			%	47.3	21.1	9.1	2.8	0.7	0.0	4.7
Surfactant in first			Ν	393	372	198	110	62	9	1144
120 min			%	65.6	34.5	18.2	6.5	1.4	0.2	7.8
Surfactant after 120			Ν	160	338	266	262	275	184	1485
minutes			%	26.7	31.4	24.4	15.4	6.4	3.1	10.1
Surfactant at any			Ν	553	710	464	372	337	193	2629
time			%	92.3	65.9	42.5	21.9	7.8	3.3	17.9
Surfactant dose > 1	% out of surfactant		Ν	273	246	91	43	27	31	711
	at any time		%	49.4	34.7	19.6	11.6	8.0	16.1	27.0
Method of	Endotracheal		Ν	637	686	359	277	273	181	2413
surfactant			%	85.3	77.3	70.0	70.3	78.0	87.4	77.9
(first dose only	LISA/MIST		Ν	61	122	116	74	61	13	447
among the neonates			%	8.2	13.7	22.6	18.8	17.4	6.3	14.4
who received	Other*		Ν	49	80	38	43	16	13	239
surfactant)*			%	6.6	9.0	7.4	10.9	4.6	6.3	7.7
Pneumothorax		2	Ν	48	45	26	43	169	414	745
diagnosis			%	8.0	4.2	2.4	2.5	3.9	7.1	5.1
Pneumothorax	No intervention		Ν	6	8	8	16	93	294	425
treatment**			%	12.5	17.8	30.8	37.2	55.0	71.0	57.1
	Needle drainage		Ν	28	21	13	18	52	81	213
	~		%	58.3	46.7	50.0	41.9	30.8	19.6	28.6
	Chest tube		Ν	32	31	14	24	50	67	218
			%	66.7	68.9	53.9	55.8	29.6	16.2	29.3
Seizures	Definite	7	Ν	35	30	26	23	75	374	563
	/suspected		%	5.8	2.8	2.4	1.4	1.7	6.4	3.8

Presentation #12 Other diagnoses / interventions / procedures: All GA

* "Other" includes other method of surfactant, surfactant method unknown (i.e. "unknown" checked) and method missing (i.e. "method" left blank).

** One neonate can have multiple treatments. Denominators for treatment were based on the number of neonates who had pneumothorax.

Characteristics		Missing			GA at	birth (co	mpleted v	weeks)		
				<u><</u> 25	26 - 28	29 - 30	31 - 32	33 - 36	<u>></u> 37	Total
Total				599	1077	1091	1702	4310	5872	14651
Operations	Thoracotomy	2	Ν	5	6	8	6	18	30	73
			%	0.8	0.6	0.7	0.4	0.4	0.5	0.5
	Laparotomy	2	Ν	42	44	17	32	94	119	348
			%	7.0	4.1	1.6	1.9	2.2	2.0	2.4
	Ostomy		Ν	6	6	1	5	8	13	39
			%	1.0	0.6	0.1	0.3	0.2	0.2	0.3
	Reservoir/Drain	2	Ν	22	18	6	8	5	6	65
			%	3.7	1.7	0.6	0.5	0.1	0.1	0.4
	VP shunt	2	Ν	8	16	6	9	6	5	50
			%	1.3	1.5	0.6	0.5	0.1	0.1	0.3
Gastro-intestinal	Spontaneous	18	Ν	33	13	9	7	14	11	87
perforation			%	5.5	1.2	0.8	0.4	0.3	0.2	0.6
	NEC related		Ν	28	11	3	6	4	3	55
			%	4.7	1.0	0.3	0.4	0.1	0.1	0.4
Acquired		2	Ν	7	6	3	4	4	2	26
stricture			%	1.2	0.6	0.3	0.2	0.1	0.0	0.2
Exchange		2	Ν	2	1	1	1	8	12	25
transfusion			%	0.3	0.1	0.1	0.1	0.2	0.2	0.2
Congenital	None		Ν	382	761	884	1403	3532	4426	11388
anomaly*			%	63.8	70.7	81.0	82.4	82.0	75.4	77.7
	Minor		Ν	204	276	163	231	476	849	2199
			%	34.1	25.6	14.9	13.6	11.0	14.5	15.0
	Major		Ν	13	40	44	68	302	597	1064
			%	2.2	3.7	4.0	4.0	7.0	10.2	7.3

Presentation #12 (continued) Other diagnoses / interventions / procedures: All GA


*A list of major anomalies can be found in the 2013 annual report, pages 124-127. It is available via the following link:

http://www.canadianneonatalnetwork.org/Portal/LinkClick.aspx?fileticket=lreR0871sjA%3 d&tabid=39

Section D.3

Analyses based on number of eligible very preterm (GA <33 weeks) or very low birth weight (BW <1 500g) neonates

These included data from 4 469 eligible very preterm neonates and 2 959 eligible VLBW neonates.



Pres	entati	on #13			
Patent ductus arteriosus	(PDA)	treatments:	GA	<33	weeks

Birth GA			Missing							Treatme	ent†		
(complete d weeks)		Total	data on PDA	PDA unknown	No PDA		Conserva tive	Indo	Ibu	Acetamin ophen	> 1 medical*	Medical and ligation#	Ligation alone
<25	Ν	345	0	7	64	274	88	8	54	35	56	33	0
	%						32%	3%	20%	13%	20%	12%	0%
25-26	Ν	552	0	3	193	356	147	18	71	48	55	17	0
	%						41%	5%	20%	13%	15%	5%	0%
27-28	Ν	779	0	4	485	290	156	10	58	33	29	4	0
	%						54%	3%	20%	11%	10%	1%	0%
29-30	Ν	1091	2	1	899	189	139	1	19	17	9	3	1
	%						74%	1%	10%	9%	5%	2%	1%
31-32	Ν	1702	1	4	1555	142	129	0	4	5	2	2	0
51-52	%						91%	0%	3%	4%	1%	1%	0%
Total	Ν	4469	3	19	3196	1251	659	37	206	138	151	59	1
neonates included	%						53%	3%	16%	11%	12%	5%	0%


[†]The percentage of neonates receiving each PDA treatment was calculated using the total number of neonates diagnosed with PDA as the denominator.

*>1 medical = 2 or 3 of (Indomethacin or Ibuprofen or Acetaminophen)

#Medical and ligation = Ligation + at least one of the drugs (Indomethacin or Ibuprofen or Acetaminophen)

Out of 59 Medical and ligation = surgical (31), device close (25), unknown (3) Out of 1 Ligation alone = surgical (0), device closure (1)

COMMENTS: Specific reasons for treatment with indomethacin and frequency of repeat course of indomethacin were not recorded. Excludes indomethacin prophylaxis started on the first day of age. Neonates were identified as without PDA if there was no clinical suspicion of PDA.



Presentation #14 Patent ductus arteriosus (PDA) treatments: BW <1500g

			Missing	PDA			Treatme	ent†					
BW (grams)		Total	data on PDA	information unknown	No PDA	Neonates with PDA	Conser vative	Indo	Ibu	Acetamin ophen	> 1	Medical and ligation#	Ligation alone
<500	Ν	43	0	3	13	27	9	0	3	8	3	4	0
	%						33%	0%	11%	30%	11%	15%	0%
500-749	Ν	479	0	6	142	331	122	12	63	40	59	35	0
	%						37%	4%	19%	12%	18%	11%	0%
750-999	Ν	673	1	4	312	356	148	19	79	38	55	16	1
	%						42%	5%	22%	11%	15%	4%	0%
1000-1249	Ν	831	0	0	597	234	136	5	35	34	23	1	0
	%						58%	2%	15%	15%	10%	0%	0%
1250-1499	Ν	933	0	1	786	146	104	1	21	12	7	1	0
	%						71%	1%	14%	8%	5%	1%	0%
Total	Ν	2959	1	14	1850	1094	519	37	201	132	147	57	1
neonates included	%						47%	3%	18%	12%	13%	5%	0%


[†] The percentage of neonates receiving each PDA treatment was calculated using the total number of neonates diagnosed with PDA as the denominator.

*>1 medical = 2 or 3 of (Indomethacin or Ibuprofen or Acetaminophen)

[#]Medical and ligation = Ligation + at least one of the drugs (Indomethacin or Ibuprofen or Acetaminophen)

Out of 59 Medical and ligation = surgical (31), device close (25), unknown (3) Out of 1 Ligation alone = surgical (0), device closure (1)


COMMENTS: Specific reasons for treatment with indomethacin and frequency of a repeat course of indomethacin were not recorded. Data excludes indomethacin prophylaxis started on the first day of age. Neonates were identified as without PDA if there was no clinical suspicion of PDA.



Presentation #15 Neuroimaging findings: GA <33 weeks

100 90 Percentage with ventricular 80 70 enlargement Unknown 60 □None 50 □ Unmeasured 40 🖾 Mild 30 ■ Moderate 20 Severe 10 光環線 10 11 11 0 <25 25-26 27-28 29-30 31-32 Gestational age at birth (completed weeks)


Ventricular enlargement




											Neur	oimagin	g findi	ngs							
				GM 1	nemorrha	age		ventricu norrhage			Ventr	ricular en	largen	nent		1	oarenchy lesion	mal		ventricul komalaci	
GA at bin (complet weeks)	ed	Total	Neuro- imaging available	Present	None/suspected	Unknown	Present	None/suspected	Unknown	Mild	Moderate	Severe	Unmeasured	None	Unknown	Present	None/suspected	Unknown	Present	None/suspected	Unknown
<25	Ν	345	322	187	135	0	151	169	2	45	23	12	18	217	6	75	242	5	23	292	7
	%			58%	42%	0%	47%	52%	1%	14%	7%	4%	6%	68%	2%	23%	75%	2%	7%	91%	2%
25-26	Ν	552	542	223	318	1	159	382	1	48	24	20	9	438	2	72	467	3	36	500	6
	%			41%	59%	0%	29%	70%	0%	9%	4%	4%	2%	81%	0%	13%	86%	1%	7%	92%	1%
27-28	Ν	779	768	236	531	1	124	642	2	45	31	19	6	660	3	52	712	3	31	730	6
	%			31%	69%	0%	16%	84%	0%	6%	4%	2%	1%	86%	0%	7%	93%	0%	4%	95%	1%
29-30	Ν	1091	1045	235	809	1	82	961	2	37	25	18	3	961	1	27	1013	5	29	1008	8
	%			22%	77%	0%	8%	92%	0%	4%	2%	2%	0%	92%	0%	3%	97%	0%	3%	96%	1%
31-32	Ν	1702	1045	152	890	3	45	996	4	38	10	12	8	971	4	17	1022	6	20	1018	7
	%			15%	85%	0%	4%	95%	0%	4%	1%	1%	1%	93%	0%	2%	98%	1%	2%	97%	1%
Total number of	Ν	4469	3722	1033	2683	6	561	3150	11	213	113	81	44	3247	16	243	3456	22	139	3548	34
neonates	%			28%	72%	0%	15%	85%	0%	6%	3%	2%	1%	87%	0%	7%	93%	1%	4%	95%	1%

Presentation #15 (continued) Neuroimaging findings: GA <33 weeks

Note: Neuroimaging findings were not mutually exclusive, i.e. one neonate may have had more than one finding. See <u>page 137</u> for classifications of ventricular enlargement.



Presentation #16 Neuroimaging findings: BW <1500g




Ventricular enlargement

See page 137 for classifications of ventricular enlargement.

											Neuroi	maging	finding	gs							
			Net	GM	hemorrh	nage		aventric morrha			Ventri	cular en	largen	nent		-	oarenchy lesion	mal	-	ventricul comalaci	
BW (grams	5)	Total	Neuro-imaging available	Present	None/suspected	Unknown	Present	None/suspected	Unknown	Mild	Moderate	Severe	Unmeasured	None	Unknown	Present	None/suspected	Unknown	Present	None/suspected	Unknown
<500	Ν	43	35	17	17	1	10	25	0	5	4	0	0	25	0	5	30	0	3	32	0
~ 500	%			49%	49%	3%	29%	71%	0%	15%	12%	0%	0%	74%	0%	14%	86%	0%	9%	91%	0%
500-749	Ν	479	460	222	238	0	165	292	3	46	23	12	17	358	4	76	377	7	32	422	6
	%			48%	52%	0%	36%	63%	1%	10%	5%	3%	4%	78%	1%	17%	82%	2%	7%	92%	1%
750-999	Ν	673	659	219	440	0	139	519	1	54	22	22	8	548	4	68	589	1	31	619	8
	%			33%	67%	0%	21%	79%	0%	8%	3%	3%	1%	83%	1%	10%	90%	0%	5%	94%	1%
1000-1249	Ν	831	805	219	585	1	98	707	0	37	31	13	8	711	3	44	758	3	21	778	6
	%			27%	73%	0%	12%	88%	0%	5%	4%	2%	1%	89%	0%	5%	94%	0%	3%	97%	1%
1250-1499	Ν	933	802	180	620	2	87	712	3	32	17	15	6	728	1	30	768	4	26	770	6
	%			22%	77%	0%	11%	89%	0%	4%	2%	2%	1%	91%	0%	4%	96%	1%	3%	96%	1%
Total	Ν	2959	2761	857	1900	4	499	2255	7	174	97	62	39	2370	12	223	2522	15	113	2621	26
neonates	%			31%	69%	0%	18%	82%	0%	6%	4%	2%	1%	86%	0%	8%	91%	1%	4%	95%	1%

Presentation #16 (continued) Neuroimaging findings: BW <1500g

Note: Neuroimaging findings were not mutually exclusive, i.e. one neonate may have more than one finding. See <u>page 137</u> for classifications of ventricular enlargement.



Prese	entatio	n #17
Necrotizing enterocolitis ((NEC)	treatments: GA <33weeks

GA at birth		Total	Missing			Neo	nates with nec	rotizing entero	colitis**	Death
(completed weeks)		number of neonates	data on NEC	No NEC	NEC*	Medical treatment only	Medical + peritoneal drainage	Laparotomy	Peritoneal drainage + Laparotomy	among infants with NEC**
<25	Ν	345	0	289	56	28	5	21	2	17
	%			84%	16%	50%	9%	38%	4%	30%
25-26	Ν	552	0	501	51	25	4	19	3	19
	%			91%	9%	49%	8%	37%	6%	37%
27-28	Ν	779	2	756	21	11	0	8	2	6
	%			97%	3%	52%	0%	38%	10%	29%
29-30	Ν	1091	1	1069	21	17	1	2	1	5
	%			98%	2%	81%	5%	10%	5%	24%
31-32	Ν	1702	1	1683	18	9	2	6	1	6
	%			99%	1%	50%	11%	33%	6%	33%
Total	Ν	4469	4	4298	167	90	12	56	9	53
number of neonates	%			96%	4%	54%	7%	34%	5%	32%


*The percentage of neonates with NEC was calculated using the total number of neonates in the same GA category with data available on NEC as the denominator.

**The percentages were calculated using the total number of neonates in the same GA category that had NEC as the denominator.

COMMENTS: NEC is identified according to the following criteria: a) definite pneumatosis (air within the bowel wall) or portal/hepatic gas as diagnosed by x-ray or ultrasound, or b) if there is a surgical or autopsy diagnosis of NEC. Diagnoses of 'suspected NEC' or x-rays showing pneumoperitoneum without pneumatosis are not classified as NEC.

Number (%) of neonates with NEC and GA > 33 weeks: GA 33 - 36 weeks: 29 neonates (0.7%)

 $GA \ge 37$ weeks: 11 neonates (0.2%)



Presentation #18 Necrotizing enterocolitis (NEC) treatments: BW <1500 g

		Total	Missing			Neonates w	ith necrotizing	enterocolitis**		Death
Birth weigh (grams)	t	number of neonates	Missing data on NEC	No NEC	NEC*	Medical treatment only	Medical + peritoneal drainage	Laparotomy	Peritoneal drainage + laparatomy	among infants with NEC**
<500	Ν	43	0	36	7	0	1	5	1	3
	%			84%	16%	0%	14%	71%	14%	43%
500-749	Ν	479	0	412	67	39	5	19	4	21
	%			86%	14%	58%	7%	28%	6%	31%
750-999	Ν	673	3	624	46	27	3	14	2	14
	%			93%	7%	59%	7%	30%	4%	30%
1000-1249	Ν	831	0	817	14	4	0	10	0	5
	%			98%	2%	29%	0%	71%	0%	36%
1250-1499	Ν	933	0	920	13	8	1	3	1	3
	%			99%	1%	62%	8%	23%	8%	23%
Total	Ν	2959	3	2809	147	78	10	51	8	46
number of neonates	%			95%	5%	53%	7%	35%	5%	31%


*The percentage of neonates with NEC was calculated using the total number of neonates in the same GA category with data available on NEC as the denominator.

** The percentages were calculated using the total number of neonates in the same GA category that had NEC as the denominator.

COMMENTS: NEC is identified according to the following criteria: a) definite pneumatosis (air within the bowel wall) or portal/hepatic gas as diagnosed by x-ray or ultrasound, or b) if there is a surgical or autopsy diagnosis of NEC. Diagnoses of 'suspected NEC' or x-rays showing pneumoperitoneum without pneumatosis are not classified as NEC.

Number (%) of neonates with NEC and BW > 1500g: BW 1500 - 2499g: 46 neonates (1.0%) BW ≥ 2500g: 14 neonates (0.2%)

Presentation #19 Chronic lung disease (CLD) at 36 weeks post menstrual age (PMA) or discharge: GA <33 weeks




GA	Total number of neonates	Number of neonates who died before 36 weeks PMA	Number of surviving neonates whose respiratory support is unknown*	CLD from**	Number of neonates with known results	Number of neonates with severe CLD, N (%)	Number of neonates with moderate CLD, N (%)	Number of neonates with mild CLD, N (%)	Number of neonates with CLD but severity unknown, N (%)	Number of neonates without CLD, N (%)
<25	345	125	0	36w	191	58 (30)	81 (42)	12 (6)	15 (8)	25 (13)
~25	545	125	0	Disch	29	8 (28)	11 (38)	1 (3)	2 (7)	7 (24)
25-26	552	71	1	36w	357	34 (10)	156 (44)	42 (12)	19 (5)	106 (30)
23-20	552	/ 1	1	Disch	123	8 (7)	32 (26)	16 (13)	3 (2)	64 (52)
27-28	779	39	0	36w	440	36 (8)	158 (36)	42 (10)	8 (2)	196 (45)
27-20	117	37	0	Disch	300	9 (3)	62 (21)	14 (5)	9 (3)	206 (69)
29-30	1 091	17	2	36w	488	24 (5)	95 (19)	31 (6)	5 (1)	333 (68)
27-30	1 0 7 1	17	2	Disch	584	4 (1)	65 (11)	15 (3)	6 (1)	494 (85)
31-32	1 702	17	9	36w	610	27 (4)	68 (11)	29 (5)	17 (3)	469 (77)
51-52	1/02	1/	,	Disch	1066	4 (0)	49 (5)	12 (1)	4 (0)	997 (94)
Total	4 469	269	12	36w	2086	179 (9)	558 (27)	156 (7)	64 (3)	1129 (54)
TOTAL	+ +09	209	12	Disch	2102	33 (2)	219 (10)	58 (3)	24 (1)	1768 (84)

COMMENTS: See pages 137-138 for the definition of severity of CLD.

*unknown = first admission was after 36 weeks' PMA ** w = weeks' PMA, Disch = Status based on discharge status prior to 36 weeks' PMA

Note: Percentages of neonates with CLD were calculated based on the total number of neonates in the same GA category with known CLD results.

Presentation #20 Chronic lung disease (CLD) at 36 weeks post menstrual age (PMA) or discharge: BW < 1500g




BW	Total number of neonates	Number of neonates who died before 36 weeks' PMA	Number of surviving neonates whose respiratory support is unknown*	CLD from**	Number of neonates with known results	Number of neonates with severe CLD, N (%)	Number of neonates with moderate CLD, N (%)	Number of neonates with mild CLD, N (%)	Number of neonates with CLD but severity unknown, N (%)	Number of neonates without CLD, N (%)
<500	43	22	0	36w	19	8 (42)	4 (21)	1 (5)	4 (21)	2 (11)
\ 500	43	22	0	Disch	2	1 (50)	1 (5)	0	0	0
500-749	479	120	1	36w	289	73 (25)	140 (48)	19 (7)	15 (5)	42 (15)
500-749	479	120	1	Disch	69	14 (20)	17 (25)	8 (12)	3 (4)	27 (39)
750-999	673	67	0	36w	424	41 (10)	182 (43)	49 (12)	17 (4)	135 (32)
750-999	075	07	0	Disch	182	8 (4)	41 (23)	12 (7)	4 (2)	117 (64)
1000-1249	831	65	2	36w	415	17 (4)	113 (27)	31 (7)	4 (1)	250 (60)
1000-1247	0.51	05	2	Disch	349	1 (0)	64 (18)	15 (4)	9 (3)	260 (75)
1250-1499	933	130	2	36w	368	20 (5)	58 (16)	22 (6)	10 (3)	258 (70)
1250-1477	,55	150	2	Disch	433	4 (1)	41 (9)	8 (2)	3 (1)	377 (87)
Total	2 959	404	5 -	36w	1 515	159 (11)	497 (33)	122 (8)	50 (3)	687 (45)
I Jtal	2 737	-0 -		Disch	1 035	28 (3)	164 (16)	43 (4)	19 (2)	781 (75)

COMMENTS: See pages 137-138 for the definition of severity of CLD.

*unknown = first admission was after 36 weeks' PMA ** w = weeks' PMA, Disch = Discharge prior to 36 weeks' PMA

Note: Percentages of neonates with CLD were calculated based on the total number of neonates in the same GA category with known CLD results.



Retinopathy of prematurity (ROP) staging: GA <33 weeks


Presentation #21

		Total	Number of	Number of	Retinopathy	of prematu	rity*		
GA (completed weeks)	1	number of neonates	neonates alive at 6 weeks of age	neonates with known eye examination results	Immature	None	Stages 1 & 2	Stage 3	Stages 4 & 5
<25	Ν	345	230	215	4	18	118	74	1
	%				2%	8%	55%	34%	0%
25-26	Ν	552	485	470	55	127	250	37	1
	%				12%	27%	53%	8%	0%
27-28	Ν	779	742	635	108	315	202	10	0
	%				17%	50%	32%	2%	0%
29-30	Ν	1 091	1 074	616	105	404	100	6	1
	%				17%	66%	16%	1%	0%
31-32	Ν	1 702	1 683	180	32	135	12	1	0
	%				18%	75%	7%	1%	0%
Total	Ν	4 469	4 214	2 116	304	999	682	128	3
neonates included	%				14%	47%	32%	6%	0%

*The percentage of neonates diagnosed with each stage of ROP was calculated using the total number of neonates in the same GA category with known eye examination results as the denominator.

COMMENTS: ROP is defined according to the International Classification of Retinopathy of Prematurity (ICROP) and includes the highest level of ROP in either eye. More advanced stages may have been detected in neonates transferred from network sites to level II sites or units. **Caution should be used when interpreting these data**.

Presentation #22 Retinopathy of prematurity (ROP) staging: BW< 1500 g




		Total	Number of	Number of		Retinopat	hy of prema	aturity*	
BW (grams)		number of neonates	neonates alive at 6 weeks of age	neonates with known eye examination results	Immature	None	Stages 1 & 2	Stage 3	Stages 4 & 5
<500	Ν	43	22	21	1	2	14	4	0
	%				5%	10%	67%	19%	0%
500-749	Ν	479	369	344	19	69	180	75	1
	%				6%	20%	52%	22%	0%
750-999	Ν	673	613	554	67	192	257	37	1
	%				12%	35%	46%	7%	0%
1000-1249	Ν	831	802	580	116	317	139	8	0
	%				20%	55%	24%	1%	0%
1250-1499	Ν	933	921	404	71	261	68	4	0
1200-1499	%				18%	65%	17%	1%	0%
Total	Ν	2959	2727	1903	274	841	658	128	2
neonates included	%				14%	44%	35%	7%	0%

*The percentage of neonates diagnosed with each stage of ROP was calculated using the total number of neonates in the same GA category with known eye examination results as the denominator.

COMMENTS: ROP is defined according to the International Classification of Retinopathy of Prematurity (ICROP) and includes the highest level of ROP in either eye. More advanced stages may have been detected in neonates transferred from network sites to level II sites or units. **Caution should be used when interpreting these data**.

Presentation #23




Retinopathy of prematurity (ROP) treatments: GA <33 weeks

			Number of			Therapy fo	r ROP	
Birth GA (completed weeks)		Total number of neonates	neonates with known eye examination results	Therapy for retinopathy of prematurity (ROP)*	Laser	Anti-VEGF	Both Laser and Anti- VEGF	Other surgery**
<25	Ν	345	215	68	10	50	8	1
	%			33%				
25-26	Ν	552	470	33	5	27	0	0
	%			8%				
27-28	Ν	779	635	4	2	2	0	0
	%			1%				
29-30	Ν	1 091	616	3	2	1	0	0
	%			1%				
31-32	Ν	1 702	180	1	0	1	0	0
51-52	%			1%				
Total	Ν	4 469	2 116	109	19	81	8	1
neonates included	%			5%				

*The percentage of neonates who received ROP therapy was calculated using the total number of neonates in the same GA category with known eye examination results as the denominator.

**Infants who had other surgery may have one or both of Laser and Anti-VEGF treatments.

COMMENTS: ROP is defined according to the International Classification of Retinopathy of Prematurity (ICROP) and includes the highest level of ROP in either eye. More advanced stages may have been detected in neonates transferred from network sites to level II sites or units. **Caution should be used when interpreting these data as some neonates did not have eye examination data.**



Presentation #24 Retinopathy of prematurity (ROP) treatments: BW <1500 g

			Number of	Therapy for		Thera	py for ROP	
BW (grams	s)	Total number of neonates	neonates with known eye examination results	retinopathy of prematurity (ROP)*	Laser	Anti- VEGF	Both Laser and Anti- VEGF	Other surgery
<500 N		43	27	3	1	2	0	0
~500	%			11%				
500-749	Ν	436	322	68	11	53	4	0
500-749	%			21%				
750-999	Ν	668	614	33	3	25	4	1
750-999	%			5%				
1000-1249	Ν	731	703	3	2	1	0	0
1000-1249	%			0%				
1250-1499	Ν	878	864	2	2	0	0	0
1250-1499	%			0%				
Total	Ν	2756	2530	109	19	81	8	1
neonates included	%			4%				

*The percentage of neonates who received ROP therapy was calculated using the total number of neonates in the same GA category with known eye examination results as the denominator.

**Infants who had other surgery may have one or both of Laser and Anti-VEGF treatments.

COMMENTS: ROP is defined according to the International Classification of Retinopathy of Prematurity (ICROP) and includes the highest level of ROP in either eye. More advanced stages may have been detected in neonates transferred from network sites to level II sites or units. **Caution should be used when interpreting these data as some neonates did not have eye examination data.**

GA	Number of neonates	Number survived until discharge / transfer (%)	Major morbidityª (%)	CLD ^b (%)	Severe ROP ^c (%)	Severe neurological injury ^d (%)	NEC ^e (%)	Late onset sepsis ^f
<24	129	64 (50)	102 (79)	55 (84)	32 (52)	38 (33)	18 (14)	51 (40)
24	211	152 (72)	178 (84)	130 (86)	57 (39)	42 (21)	38 (18)	70 (33)
25	246	201 (82)	190 (77)	141 (71)	27 (15)	46 (19)	30 (12)	55 (22)
26	291	268 (92)	197 (68)	162 (60)	19 (9)	34 (12)	17 (6)	57 (20)
27	319	296 (93)	180 (56)	148 (50)	8 (4)	30 (10)	9 (3)	42 (13)
28	427	413 (97)	201 (47)	169 (41)	2 (1)	25 (6)	11 (3)	38 (9)
29	496	489 (99)	152 (31)	119 (24)	4 (2)	20 (4)	11 (2)	31 (6)
30	551	541 (98)	141 (26)	103 (19)	2 (1)	28 (5)	8 (1)	18 (3)
31	726	718 (99)	110 (15)	82 (11)	1 (1)	18 (3)	8 (1)	15 (2)
32	908	900 (99)	112 (12)	93 (10)	0	13 (3)	6 (1)	13(1)
Total neonates	4304	4042 (94)	1563 (36)	1202 (30)	152 (9)	294 (8)	156 (4)	390 (9)

Presentation #25 Select major morbidity: GA <33 weeks

Inclusion criteria for these analyses:

- 1. Neonate born at <33 weeks GA without major congenital anomaly
- 2. Denominators were based on the number of neonates with available data and those without major congenital anomaly (see below for details)

Definitions:

^a Major morbidity was counted as any one of the following

- 1. CLD (any grade)
- 2. Severe ROP
- 3. Severe neurological injury (IVH \geq grade 3 and/or PVL)
- 4. Stage 2 or 3 NEC
- 5. Late onset sepsis

^b Chronic lung disease was defined as per presentation #19 of any grade

^c Severe ROP was defined as ROP stage 3,4,5 and/or those with ROP treatment (laser or intraocular injection).

^d Severe neurological injury was defined as IVH \geq grade 3 and/or PVL

^eNEC defined as stage 2 or 3

^fLate onset sepsis was defined as any positive blood and/or cerebrospinal fluid culture after 2 days of age. Analysis was neonate-based.

Denominator used in percentage calculation for each morbidity

Survivor until discharge: All neonates Major morbidities: All neonates CLD: First admission before 36 week PMA and survived beyond 36 week PMA ROP: Eye exam done and results available NEC: All neonates Late onset sepsis: All neonates

E. Site Comparisons

E.1. Site Comparisons – Care Practices

Presentation #26 Prenatal and delivery room care practices: GA<29 weeks: Site specific crude rates* (inborn only)

Site	Number of neonates	Antenatal MgSO4		Antenatal steroids ^a	Timing of cord clamping			Admission temperature			Apgar <5 at 5 minutes	
	Ν	Yes	No	Missing	Completed	<u>></u> 30	< 30	Missing	<36.5	36.5-	>37.2	
					course within	sec	sec or			37.2		
					last week prior		none					
					to birth ^a							
xxxi		0.0	100.0	0.0	0.0	33.3	0.0	66.7	100.0	0.0	0.0	0.0
xxiv		93.8	6.3	0.0	37.5	43.8	56.3	0.0	26.7	66.7	6.7	6.3
xxxii		88.9	11.1	0.0	55.6	22.2	77.8	0.0	33.3	33.3	33.3	22.2
xvii	< 20	100.0	0.0	0.0	81.8	90.9	9.1	0.0	27.3	18.2	54.6	9.1
xxv	< 20	86.7	13.3	0.0	46.7	53.3	40.0	6.7	15.4	46.2	38.5	0.0
xi		87.5	12.5	0.0	50.0	68.8	31.3	0.0	31.3	62.5	6.3	0.0
ii		50.0	50.0	0.0	50.0	0.0	100.0	0.0	100.0	0.0	0.0	50.0
xx		82.4	17.7	0.0	64.7	47.1	52.9	0.0	0.0	93.8	6.3	5.9
iii		66.7	29.2	4.2	29.2	70.8	29.2	0.0	54.2	45.8	0.0	20.8
viii		87.2	12.8	0.0	23.1	61.5	38.5	0.0	26.3	63.2	10.5	2.6
xvi		92.0	8.0	0.0	28.0	88.0	12.0	0.0	20.8	58.3	20.8	8.0
xxx		82.8	17.2	0.0	34.5	55.2	41.4	3.5	10.3	58.6	31.0	10.3
xii	21-40	87.9	12.1	0.0	24.2	72.7	24.2	3.0	9.1	54.6	36.4	24.2
iv		90.9	9.1	0.0	42.4	48.5	51.5	0.0	12.1	54.6	33.3	27.3
i		80.0	20.0	0.0	25.7	60.0	40.0	0.0	20.6	61.8	17.7	25.7
xxiii		81.5	18.5	0.0	55.6	48.2	51.9	0.0	55.6	40.7	3.7	18.5
x		87.2	12.8	0.0	23.1	59.0	41.0	0.0	21.1	47.4	31.6	15.8
ix		80.5	19.5	0.0	46.3	22.0	78.1	0.0	65.7	22.9	11.4	14.6
vii		95.7	4.4	0.0	63.0	43.5	56.5	0.0	47.8	45.7	6.5	8.7
xxxiii		85.1	12.8	2.1	43.5	55.3	40.4	4.3	67.4	26.1	6.5	21.3
xxii	41-80	94.4	5.6	0.0	48.2	50.0	46.3	3.7	43.4	45.3	11.3	20.4
xxi	41-80	86.0	12.3	1.8	39.3	70.2	29.8	0.0	29.8	63.2	7.0	29.8
xxviii		81.8	13.6	4.6	41.9	68.2	27.3	4.6	9.3	67.4	23.3	14.3
v		85.5	14.5	0.0	40.6	44.9	39.1	15.9	49.3	46.4	4.4	27.5
xix		92.9	7.1	0.0	48.6	21.4	77.1	1.4	12.9	67.1	20.0	25.7
xxvi		80.9	12.8	6.4	45.7	63.8	35.1	1.1	36.9	46.4	16.7	16.0
xiii		59.2	40.8	0.0	34.0	63.1	36.9	0.0	21.6	54.9	23.5	9.7
vi	> 80	88.1	9.5	2.4	27.4	48.8	50.0	1.2	18.1	56.6	25.3	8.3
xxvii		90.7	9.3	0.0	40.0	64.3	35.7	0.0	39.9	44.2	15.9	8.6
xxix		92.8	7.2	0.0	43.1	60.5	39.5	0.0	18.0	59.9	22.2	16.2
Total CNN		85.4	13.7	0.9	40.4	56.0	42.2	1.8	29.8	52.4	17.9	15.6

*Denominators were based on **inborn** neonates <29 weeks' GA admitted without major congenital anomaly.

^a Completed course of antenatal steroids within the last week prior to birth = received at least two doses of corticosteroids for a period of 24 hours or more, but within one week of birth **These are unadjusted rates.**

Site	Number	No	Never	de rates* (if Fed at any	Never received	Exclusive	Exclusive
	of	mechanical	received	time in	antimicrobials ^b	mother's	formula
	neonates	ventilation	mechanical	first 2		own milk	feeding at
		at any time	ventilation ^a	days of		feeding at	dischargec
		in first 3		admission		discharge ^c	0
		days ^a				0	
	Ν	%	%	%	%	%	%
xxxi		33.3	33.3	100.0	33.3	0.0	100.0
xxxii		55.6	44.4	100.0	0.0	44.4	22.2
xvii		9.1	9.1	100.0	9.1	54.6	36.4
xxv	< 20	13.3	13.3	86.7	6.7	0.0	40.0
xi	< 20	31.3	31.3	93.8	0.0	31.3	25.0
ii		0.0	0.0	50.0	0.0	0.0	50.0
xxiv		37.5	37.5	93.8	56.3	31.3	12.5
xx		35.3	35.3	76.5	11.8	17.7	23.5
xvi		24.0	24.0	76.0	24.0	64.0	8.0
xxiii		18.5	18.5	70.4	0.0	0.0	44.4
viii		33.3	30.8	56.4	7.7	38.5	23.1
xxx		62.1	48.3	72.4	34.5	41.4	31.0
xii	21-40	42.4	36.4	72.7	0.0	51.5	12.1
iv		24.2	18.2	72.7	6.1	36.4	39.4
iii		29.2	16.7	95.8	8.3	20.8	33.3
i		31.4	25.7	97.1	2.9	22.9	34.3
x		28.2	25.6	84.6	18.0	53.9	10.3
ix		17.1	14.6	82.9	14.6	19.5	19.5
xxviii		20.5	15.9	93.2	11.4	59.1	13.6
vii		10.9	10.9	47.8	8.7	23.9	39.1
xxxiii	41-80	21.3	14.9	44.7	2.1	42.6	36.2
xxii	41-00	44.4	29.6	87.0	0.0	46.3	25.9
xxi		33.3	29.8	87.7	1.8	43.9	19.3
v		26.1	20.3	85.5	8.7	24.6	30.4
xix		24.3	22.9	88.6	8.6	55.7	14.3
xxvi		34.0	27.7	89.4	6.4	22.3	19.2
vi		8.3	6.0	94.1	3.6	51.2	16.7
xiii	> 80	24.3	21.4	77.7	1.0	62.1	4.9
xxvii		44.3	36.4	91.4	10.7	61.4	8.6
xxix		60.5	43.1	86.2	3.6	48.5	15.0
Total CNN		32.8	26.4	82.8	7.6	42.8	20.0

Presentation #27 Postnatal care practices: GA <29 weeks: Site specific crude rates* (inborn only)

*Denominators were based on **inborn** neonates <29 weeks' GA admitted without major congenital anomaly.

^a Neonates either received high frequency ventilation or intermittent positive pressure ventilation.

^b Neonates never received any antimicrobials. Prophylactic administration of trimethoprim or amoxicillin for the prevention of urinary tract infections with a suspected renal anomaly was not included as antimicrobials.

^c Information obtained from *Discharge* screen/table of CNN database, includes discharge and transfer. **These are unadjusted rates.**

Presentation #28

Proportion of babies on Invasive Mechanical Ventilation (IMV) among babies ALIVE at the specified post-natal ages (INBORN AND OUTBORN included)

- Invasive mechanical ventilation (IMV) includes any of conventional ventilation (IPPV), High Frequency Oscillatory Ventilation (HFOV) and High Frequency Jet Ventilation (HFJV)
- Denominator for each cell will be babies of the GA range who are still alive at the specified post-natal age
- Numerator for each cell will be babies from the GA range who are on IMV on that day regardless of previous respiratory status (i.e. this is not continuous days of IMV)

GA groups			22-25 we	eks' GA (N = 606)			26-28 wee	eks' GA (I	N = 1084)	
Postnatal age	Number of neonates based on GA 22-25	3 days	7 days	28 days	32 weeks CGA	36 weeks CGA	3 days	7 days	28 days	32 weeks CGA	36 weeks CGA
CNN overall	606	82.1	74.3	50.1	18.3	5.3	38.6	25.4	11.9	7.8	3.3
Sites											
 11		100.0	NA	NA	NA	NA	100.0	0.0	0.0	0.0	0.0
xxxii		0.0	0.0	NA	NA	NA	33.3	0.0	0.0	0.0	0.0
XXX		66.7	66.7	66.7	0.0	0.0	10.3	0.0	3.6	3.6	0.0
xxxi	< 6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
xviii		100.0	75.0	50.0	0.0	0.0	14.3	0.0	0.0	0.0	0.0
xvii		NA	NA	NA	NA	NA	45.5	27.3	10.0	10.0	0.0
XX		100.0	100.0	0.0	50.0	0.0	53.3	46.7	26.7	13.3	15.4
xi		83.3	50.0	40.0	40.0	0.0	50.0	20.0	0.0	0.0	0.0
xvi		50.0	25.0	25.0	0.0	0.0	29.2	25.0	14.3	9.5	0.0
xxiv	6-10	75.0	50.0	0.0	0.0	0.0	25.0	18.2	0.0	0.0	0.0
xii	0-10	100.0	85.7	57.1	14.3	0.0	32.1	25.0	10.7	7.1	0.0
XXV		100.0	62.5	71.4	16.7	0.0	42.9	57.1	0.0	0.0	0.0
 111		71.4	60.0	66.7	50.0	0.0	35.0	25.0	15.0	10.5	0.0
i		80.0	75.0	66.7	83.3	20.0	35.7	25.0	14.8	7.4	0.0
xxiii		100.0	100.0	100.0	100.0	0.0	60.0	50.0	10.5	5.3	0.0
iv		75.0	75.0	63.6	9.1	11.1	54.2	33.3	13.6	4.8	5.6
viii	11-20	81.3	75.0	27.3	30.0	0.0	48.5	36.4	9.7	3.2	0.0
xxxiii	11-20	100.0	100.0	75.0	18.8	0.0	50.0	42.9	25.7	11.4	0.0
xxviii		83.3	77.8	56.3	12.5	6.7	41.3	32.6	13.5	7.5	4.0
vii		94.4	81.3	55.6	28.6	0.0	48.6	41.2	9.7	9.7	0.0
Х		87.5	64.3	22.2	0.0	0.0	29.2	16.7	9.1	0.0	0.0
xxii		77.3	81.8	33.3	6.3	6.3	37.8	22.2	13.6	4.7	0.0
ix		88.0	76.0	28.0	8.3	0.0	42.9	28.6	9.5	0.0	0.0
xxi	20-35	92.0	76.0	52.2	19.0	0.0	50.0	32.5	11.4	11.8	4.3
xix		84.4	64.3	56.5	9.1	5.6	37.3	20.0	23.7	18.9	15.8
V		80.6	82.1	58.3	21.7	4.3	59.5	35.0	5.3	2.6	0.0
xxvi		93.5	93.3	70.8	26.1	15.0	41.7	30.1	17.7	14.6	5.1
XIII]	89.5	64.9	55.9	25.0	4.2	50.0	24.1	7.9	6.5	7.4
vi	> 35	100.0	86.8	66.7	30.3	17.9	57.9	35.7	28.9	20.0	6.3
xxvii		84.1	86.6	56.9	10.7	2.8	24.5	15.5	5.6	3.4	0.0
xxix		50.0	50.0	25.4	13.6	6.3	15.3	11.0	6.1	6.3	10.9

Sites ii, xxxii and xvii did not have any infants in some or all of these categories.

NA = No infants in the denominator

Note that grouping of sites per number of neonates was based on the number of neonates in GA 22-25 category; and the number of corresponding neonates was not the same for GA 26-28 group.

E.2. Site Comparisons – Survival / Mortality

Site	Percer	ntage surv	vival for e	ach GA (completed	d weeks)			
	<25	25-26	27-28	29-30	31-32	33-34	35-36	≥37	Overall survival rate for sites*
Α	100.0	85.7	77.8	100.0	100.0	100.0	100.0	100.0	99.2
\mathbf{B}^{ϕ}	61.5	90.9	100.0	95.3	95.8	0.0	100.0	95.3	93.0
C∲	57.9	92.0	92.3	94.6	100.0	NA	NA	NA	91.7
D	73.5	90.0	89.8	99.1	96.4	99.3	98.9	98.6	96.5
Е	NA	100.0	88.9	100.0	100.0	100.0	100.0	97.6	98.5
F	0.0	88.9	80.0	100.0	100.0	100.0	100.0	98.3	98.0
G	42.9	37.5	94.1	92.0	98.1	100.0	100.0	99.4	98.2
\mathbf{H}^{ϕ}	100.0	100.0	92.3	100.0	100.0	NA	NA	NA	98.4
Ι	100.0	66.7	100.0	100.0	97.6	100.0	94.3	96.4	96.5
J∳	71.4	96.3	86.4	95.2	100.0	98.1	100.0	NA	96.8
K	0.0	58.8	90.0	100.0	97.1	100.0	98.7	99.4	96.8
L	56.8	88.6	86.1	98.5	100.0	97.7	97.1	99.6	96.9
М	76.3	91.0	100.0	96.2	100.0	98.9	98.9	100.0	96.6
Ν	66.7	100.0	100.0	100.0	100.0	100.0	100.0	99.5	99.3
0	NA	100.0	100.0	100.0	100.0	100.0	100.0	97.5	99.0
Р	0.0	75.0	100.0	100.0	100.0	100.0	100.0	98.9	98.6
Q	33.3	80.0	94.1	92.3	97.6	100.0	100.0	100.0	97.9
R	42.9	89.3	96.9	93.3	100.0	97.2	98.1	98.8	97.4
S	NA	NA	NA	NA	100.0	91.7	95.0	94.7	94.7
Т	25.0	100.0	90.9	100.0	100.0	100.0	98.6	99.3	98.2
U	60.0	100.0	90.0	93.3	100.0	100.0	99.1	99.1	98.4
\mathbf{V}^{ϕ}	40.0	75.0	95.5	97.9	100.0	88.2	100.0	83.3	92.8
\mathbf{W}^{Φ}	60.0	88.9	87.5	95.5	100.0	97.1	0.0	100.0	94.3
Xφ	NA	NA	NA	100.0	100.0	87.5	100.0	95.5	93.8
Y	60.0	82.8	89.3	97.8	98.9	98.4	93.4	97.3	95.4
Z	72.0	97.4	98.3	100.0	100.0	98.9	100.0	98.7	98.5
AA	33.3	81.0	100.0	100.0	97.6	100.0	100.0	100.0	98.4
AB	88.9	81.0	97.1	100.0	95.7	92.0	100.0	98.3	97.0
AC	0.0	100.0	NA	100.0	100.0	100.0	100.0	100.0	99.3
AD	93.3	88.9	100.0	100.0	98.4	100.0	100.0	99.3	98.8
$\mathbf{AE}^{ar{\Phi}}$	54.5	84.6	100.0	100.0	100.0	NA	NA	NA	95.6
\mathbf{AF}^{Φ}	56.3	81.8	90.3	98.0	95.7	100.0	97.8	99.3	97.4
AG [≬]	45.5	69.2	94.4	NA	NA	NA	NA	NA	73.8
Overall survival rate for GA**	63.5	86.8	94.4	97.8	98.6	98.8	98.6	98.7	97.1

Presentation #29 Survival rates by site: All GA

These analyses included 14 651 neonates from 33 sites. **Twenty-three sites collected data on all** eligible admissions whereas ten sites (marked by⁴) collected data on selected eligible admissions only. ⁴ Please note the data collection criteria were not the same for these eight cites an

admissions only. • Please note the data collection criteria were not the same for these eight sites, and thus their rates may not be comparable with other sites.

 $Overall^* = (number of neonates who survived per site / total number of neonates for that site)*100$ $Overall^{**} = (number of neonates who survived for each GA category / total number of neonates in each GA category)*100$

NA = no data available, 0 = no neonates survived, Delivery room deaths were not included

Site Percentage survival for each BW (g) category										
	<500	500-749	750-999	1000-1249	1250-1499	1500-2499	≥2500	Overall survival rate for sites*		
Α	NA	100.0	85.7	80.0	100.0	100.0	100.0	99.2		
$\mathbf{B}^{ar{\Phi}}$	NA	75.7	83.3	98.2	100.0	95.3	92.0	93.0		
\mathbf{C}_{ϕ}	100.0	75.0	93.3	92.6	96.4	98.3	100.0	91.7		
D	54.5	80.3	93.7	97.0	94.4	98.3	99.0	96.5		
Е	NA	100.0	100.0	87.5	100.0	100.0	98.1	98.5		
F	NA	40.0	85.7	100.0	90.9	100.0	98.7	98.0		
G	0.0	50.0	53.8	96.0	100.0	98.3	99.7	98.2		
\mathbf{H}_{ϕ}	NA	100.0	100.0	96.6	95.7	100.0	100.0	98.4		
Ι	100.0	100.0	100.0	91.7	100.0	96.7	96.4	96.5		
\mathbf{J}^{ϕ}	NA	73.3	100.0	94.1	95.1	99.3	100.0	96.8		
K	NA	20.0	60.0	100.0	100.0	98.8	99.5	96.8		
L	25.0	62.5	89.6	93.2	98.0	98.9	99.1	96.9		
М	62.5	83.6	95.9	98.6	100.0	98.5	99.2	96.6		
Ν	NA	71.4	100.0	100.0	100.0	100.0	99.6	99.3		
0	NA	NA	100.0	100.0	100.0	100.0	98.1	99.0		
Р	NA	33.3	100.0	100.0	100.0	98.1	99.5	98.6		
Q	0.0	66.7	85.7	100.0	100.0	97.9	100.0	97.9		
R	0.0	76.9	90.3	96.4	93.5	98.9	98.5	97.4		
S	NA	NA	NA	NA	100.0	92.0	95.2	94.7		
Т	0.0	50.0	87.5	100.0	100.0	99.2	99.5	98.2		
U	NA	80.0	83.3	83.3	100.0	98.4	99.2	98.4		
\mathbf{V}^{ϕ}	0.0	71.4	78.6	95.7	95.1	98.8	87.8	92.8		
\mathbf{W}^{Φ}	0.0	63.6	94.1	94.1	100.0	97.3	100.0	94.3		
\mathbf{X}^{ϕ}	NA	NA	NA	100.0	100.0	96.6	90.9	93.8		
Y	100.0	62.5	85.3	93.5	96.4	98.1	96.4	95.4		
Ζ	100.0	81.1	97.8	98.5	100.0	99.0	99.4	98.5		
AA	0.0	66.7	88.2	90.3	100.0	100.0	100.0	98.4		
AB	NA	69.2	93.1	96.2	100.0	96.6	98.6	97.0		
AC	NA	0.0	100.0	100.0	100.0	100.0	100.0	99.3		
AD	NA	88.9	94.4	100.0	97.1	100.0	99.4	98.8		
$\mathbf{AE}^{ar{\mathbf{\Phi}}}$	50.0	80.0	88.9	100.0	100.0	100.0	100.0	95.6		
$\mathbf{AF}^{ar{\Phi}}$	66.7	63.6	86.4	97.1	95.3	97.7	99.6	97.4		
AG∳	NA	54.5	84.2	70.0	100.0	NA	NA	73.8		
Overall survival rate for BW**	46.5	73.7	90.3	95.9	97.9	98.6	98.7	97.1		

Presentation #30 Survival rates by site: All BW

These analyses included 14 651 neonates from 33 sites. Twenty-three sites collected data on all eligible admissions whereas ten sites (marked by $^{\phi}$) collected data on selected eligible admissions only. $^{\phi}$ Please note the data collection criteria were not the same for these eight sites, and thus their rates may not be comparable with other sites.


Overall* = (number of neonates who survived per site / total number of neonates for site)*100 Overall** = (number of neonates who survived for each BW category / total number of neonates in each BW category)*100

NA = no data available, 0 = no neonates survived, Delivery room deaths were not included

Mortality: GA<33 weeks: Adjusted standardized ratios by site										
Site	of	of	expected number	standardized		adjusted				
Site	neonates	deaths	of deaths	ratio		ized ratio				
1	116	8	6.8	1.2	0.5	2.3				
2	102	2	4.7	0.4	0.0	1.5				
3	78	10	3.7	2.7	1.3	4.9				
4	155	4	10.4	0.4	0.1	1.0				
6	176	14	10.5	1.3	0.7	2.2				
7	390	28	29.0	1.0	0.6	1.4				
8	108	6	5.5	1.1	0.4	2.4				
9	58	4	2.5	1.6	0.4	4.0				
10	166	7	7.7	0.9	0.4	1.9				
11	213	8	7.9	1.0	0.4	2.0				
13	103	11	5.5	2.0	1.0	3.6				
14	76	3	2.5	1.2	0.2	3.5				
15	150	10	9.9	1.0	0.5	1.9				
16	140	8	5.8	1.4	0.6	2.7				
17	14	0	0.3	0.0	•	11.5				
18	29	2	1.0	2.1	0.2	7.4				
19	293	24	23.6	1.0	0.7	1.5				
20	94	7	3.4	2.1	0.8	4.2				
21	148	7	9.3	0.8	0.3	1.6				
22	179	14	12.0	1.2	0.6	2.0				
23	41	11	6.3	1.7	0.9	3.1				
24	60	2	1.8	1.1	0.1	4.0				
25	321	8	18.5	0.4	0.2	0.9				
26	35	1	0.9	1.1	0.0	5.9				
27	61	4	2.6	1.5	0.4	3.9				
28	292	17	19.5	0.9	0.5	1.4				
29	48	4	2.3	1.8	0.5	4.5				
30	206	17	14.8	1.1	0.7	1.8				
31	121	2	3.4	0.6	0.1	2.1				
32	313	18	29.3	0.6	0.4	1.0				
33	12	1	0.4	2.4	0.0	13.4				

Presentation #31a Mortality: GA<33 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 31a-f and they may not correspond to other presentations in this report. Neonates with major congenital anomalies were excluded. [#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Sites 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.



Presentations #31b Mortality: GA<33 weeks: Adjusted standardized ratios by site

Explanation for Presentation 31a

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<33 weeks GA and no major anomaly) Column 3: Number of neonates with the outcome of interest among those eligible neonates Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed deaths/expected deaths Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 31b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.


Mortality: GA<29 weeks: Adjusted standardized ratios by site										
Site	of	of	expected number	standardized		adjusted				
	neonates	deaths	of deaths	ratio		ized ratio				
1	49	7	5.8	1.2	0.5	2.5				
2	36	2	3.9	0.5	0.1	1.9				
3	28	9	3.1	2.9	1.3	5.5				
4	47	3	9.1	0.3	0.1	1.0				
6	66	12	9.6	1.2	0.6	2.2				
7	179	25	26.9	0.9	0.6	1.4				
8	39	6	4.6	1.3	0.5	2.8				
9	16	4	2.2	1.8	0.5	4.7				
10	55	6	6.3	0.9	0.3	2.1				
11	60	5	6.2	0.8	0.3	1.9				
13	30	9	4.4	2.1	0.9	3.9				
14	18	3	1.9	1.6	0.3	4.6				
15	65	8	8.3	1.0	0.4	1.9				
16	39	7	4.3	1.6	0.7	3.4				
18	9	2	1.0	2.1	0.2	7.5				
19	106	23	21.3	1.1	0.7	1.6				
20	29	5	2.6	1.9	0.6	4.4				
21	51	7	8.3	0.8	0.3	1.7				
22	81	12	11.2	1.1	0.6	1.9				
23	41	11	6.2	1.8	0.9	3.2				
24	12	1	1.5	0.7	0.0	3.8				
25	120	8	15.7	0.5	0.2	1.0				
26	11	1	0.6	1.7	0.0	9.2				
27	20	4	2.3	1.7	0.5	4.4				
28	108	12	16.8	0.7	0.4	1.2				
29	17	3	2.3	1.3	0.3	3.8				
30	76	16	12.7	1.3	0.7	2.0				
31	33	2	2.0	1.0	0.1	3.6				
32	177	15	27.2	0.6	0.3	0.9				

Presentation #31c Mortality: GA<29 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 31a-f and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies were excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Presentations #31d Mortality: GA<29 weeks: Adjusted standardized ratios by site

Explanation for Presentation 31c

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of neonates with the outcome of interest among those eligible neonates Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed deaths/expected deaths Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 31d

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.


Site	Number of	Number of	Adjusted# expected number	Adjusted [#] standardized	95% confide (CI) for	ence interval adjusted
1	neonates 540	deaths 8	of deaths 10.4	ratio 0.8	0.3	ized ratio 1.5
2	450	3	7.5	0.4	0.1	1.2
3	400	11	6.9	1.6	0.8	2.9
4	427	5	13.3	0.4	0.1	0.9
5	111	6	1.0	5.8	2.1	12.6
6	871	18	15.7	1.1	0.7	1.8
7	995	34	32.2	1.1	0.7	1.5
8	154	8	6.7	1.2	0.5	2.4
9	333	6	6.2	1.0	0.4	2.1
10	273	8	10.2	0.8	0.3	1.5
11	526	14	12.2	1.1	0.6	1.9
12	56	3	0.8	3.9	0.8	11.5
13	823	13	12.1	1.1	0.6	1.8
14	361	3	5.3	0.6	0.1	1.7
15	664	17	15.8	1.1	0.6	1.7
16	169	10	7.9	1.3	0.6	2.3
17	96	1	0.9	1.1	0.0	6.2
18	274	2	2.3	0.9	0.1	3.2
19	1106	29	30.8	0.9	0.6	1.4
20	367	7	5.9	1.2	0.5	2.4
21	148	7	9.8	0.7	0.3	1.5
22	179	14	11.0	1.3	0.7	2.1
23	41	11	5.9	1.9	0.9	3.3
24	514	18	4.7	3.8	2.3	6.1
25	927	10	25.0	0.4	0.2	0.7
26	128	2	2.3	0.9	0.1	3.2
27	325	6	5.0	1.2	0.4	2.6
28	343	21	22.7	0.9	0.6	1.4
29	419	6	4.3	1.4	0.5	3.0
30	721	28	21.0	1.3	0.9	1.9
31	121	2	4.1	0.5	0.1	1.8
32	587	20	31.1	0.6	0.4	1.0
33	138	1	1.3	0.8	0.0	4.4

Presentation #31e Mortality: All neonates: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 31a-f and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies were excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.



Presentations #31f Mortality: All neonates: Adjusted standardized ratios by site

Explanation for Presentation 31e

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (no major anomaly)

Column 3: Number of neonates with outcome of interest among those eligible neonates Column 4: Expected number of neonates with the outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed deaths/expected deaths Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 31f

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

E.3. Site Comparisons –

Mortality / Morbidities

Site	Number	Mortality	Severe	Severe	CLD at	NEC	Late	Mortality
	of		neurological	ROP	36 weeks	stage	onset	or severe
	neonates		injury		PMA or	2 or 3	sepsis	morbidity
			, <u> </u>		discharge*		-	
	Ν	%	%	%	%	%	%	%
Р		6.5	3.6	10.0	17.2	3.2	12.9	32.3
S		0.0	40.0		60.0	0.0	0.0	60.0
AC	< 40	8.3	8.3	14.3	0.0	8.3	16.7	25.0
0		0.0	28.6	50.0	14.3	7.1	0.0	21.4
Х		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Е		2.9	3.2	0.0	14.7	0.0	5.7	22.9
AG		26.2	19.5	16.7	74.2	7.1	23.8	83.3
U		8.3	10.5	0.0	22.7	0.0	2.1	29.2
F		8.5	14.9	0.0	22.2	3.4	13.6	30.5
Т	41-80	6.4	9.1	3.1	15.3	1.6	3.2	23.8
Ι		2.9	7.3	0.0	48.3	8.7	10.1	58.0
А		3.9	4.8	4.9	22.7	2.6	3.9	28.2
Κ		13.8	19.3	2.9	14.5	6.3	6.3	33.8
Q		8.3	6.0	3.6	10.1	2.1	7.2	19.6
Ν		1.9	2.9	8.6	23.3	1.0	10.6	29.8
G]	11.9	11.0	9.8	21.9	0.9	3.7	35.8
W	81-150	6.3	10.1	14.3	19.1	2.7	4.5	27.9
AA		7.6	4.9	23.5	23.6	2.5	16.0	32.8
Н		1.6	4.6	1.6	28.3	2.5	8.2	34.4
V		5.6	5.9	9.2	22.1	3.5	9.0	29.9
R		6.5	15.3	5.1	25.0	4.6	13.1	36.0
AD]	2.6	9.9	7.5	19.5	1.9	7.0	31.9
AE		4.4	5.9	10.5	77.0	8.2	8.2	79.3
J	151-300	4.6	5.0	11.3	43.0	1.7	9.8	49.1
С	131-300	8.3	14.4	12.5	27.0	4.4	11.6	38.1
AF		9.6	10.6	6.7	25.7	3.2	9.1	39.0
Y	-	8.3	8.6	18.5	39.1	5.1	15.3	51.4
AB		4.5	6.0	20.8	25.5	1.8	7.1	30.8
L		8.6	6.9	15.0	36.6	3.7	14.3	43.9
Μ		5.7	7.4	7.2	19.9	4.4	9.2	31.1
В	> 300	6.8	16.4	12.1	25.0	2.5	6.8	35.1
Ζ		2.7	7.7	9.4	40.1	3.4	4.3	44.5
D		7.8	7.5	4.9	42.9	6.9	12.0	50.5
Total CNN		6.5	8.8	8.6	30.8	3.7	9.4	39.7
L	I	I	1	l	1	I	i	1

Presentation #32 Mortality/morbidities: GA<33 weeks: Site specific crude rates

Mortality or severe morbidity = Mortality prior to discharge or any of the five morbidities *PMA: Post-menstrual age

NA = no data available

These are unadjusted rates.

Site	Number	Mortality	Severe	Severe	CLD at	NEC	Late	Mortality
	of		neurological	ROP	36 weeks	stage	onset	or severe
	neonates		injury		PMA or	2 or 3	sepsis	morbidity
					discharge*			
	Ν	%	%	%	%	%	%	%
Е		9.1	9.1	0.0	30.0	0.0	9.1	45.5
AC		50.0	50.0	100.0	0.0	50.0	50.0	100.0
Ο	< 15	0.0	33.3	100.0	33.3	33.3	0.0	33.3
Р		18.2	10.0	11.1	44.4	9.1	18.2	72.7
Ι		8.3	33.3	0.0	90.9	0.0	8.3	100.0
F		29.4	31.3	0.0	75.0	11.8	41.2	82.4
U		17.7	21.4	0.0	50.0	0.0	5.9	58.8
А	15-30	16.7	6.3	13.3	80.0	11.1	11.1	83.3
Т	15-50	19.1	10.5	5.9	35.3	4.8	9.5	47.6
Κ		34.5	29.6	5.0	47.4	13.8	13.8	75.9
Q		16.7	13.3	8.0	28.0	6.7	13.3	43.3
G		31.3	16.7	19.1	54.6	3.1	12.5	75.0
Н		6.1	3.1	3.3	61.3	3.0	21.2	69.7
Ν		5.6	2.9	12.1	51.4	2.8	27.8	61.1
V	31-50	18.0	10.3	18.2	43.8	7.7	20.5	56.4
W	31-30	15.4	15.4	23.1	51.5	7.7	10.3	66.7
AG		26.2	19.5	16.7	74.2	7.1	23.8	83.3
AD		6.3	14.6	15.6	46.7	6.3	16.7	66.7
AA		16.0	8.0	33.3	50.0	4.0	28.0	62.0
AE		13.0	7.7	14.3	97.9	16.7	18.5	98.2
J		10.7	9.1	30.4	78.0	3.6	21.4	85.7
AB		9.4	10.9	25.0	62.1	0.0	23.4	68.8
R	51-100	11.9	22.4	7.1	47.5	7.7	20.9	62.7
AF		20.3	14.7	12.3	58.9	7.3	21.7	75.4
Y		20.8	14.7	29.0	70.5	11.7	36.4	87.0
С		15.7	19.5	15.0	54.3	8.4	20.5	67.5
L		23.2	10.9	18.7	79.1	8.3	30.6	86.1
В		10.9	27.0	15.9	44.3	3.4	14.3	60.5
Ζ	> 100	7.3	13.2	11.0	75.4	8.9	7.3	80.5
М		8.4	10.3	8.0	31.1	7.3	14.5	46.9
D		14.4	12.4	6.0	66.7	12.3	22.5	74.3
Total		1 4 5	142	10.0	F0 4		10.4	70.2
CNN		14.5	14.3	12.8	58.1	7.7	19.6	70.2
			– Mortolity pr	. 1.	1		~	

Presentation #33 Mortality/morbidities: GA<29 weeks: Site specific crude rates

Mortality or severe morbidity = Mortality prior to discharge or any of the five morbidities *PMA: Post-menstrual age

Note: Sites S and X had no neonates with GA<29.

These are unadjusted rates.

E.3.1. Site Comparisons – Late Onset Sepsis and Antimicrobial Use

In presentations #34 and #35, late onset sepsis was attributed to the hospital where the first episode of sepsis was acquired. Each neonate was counted only once even if there were multiple episodes of infections.


In presentations #36 and #37, assignment of infection was based on location where the infection happened and not assigned to the hospital where the first episode of sepsis was acquired. Each episode of infection was counted (the total number of episodes exceeds the total number of neonates).

In all other presentations of this report, all morbidities including late onset sepsis were attributed to the hospital where the neonate was first admitted.

Presentation #34

Late onset sepsis: GA<33 weeks: Site specific crude rates

(n=4 425 neonates, 44 excluded due to death before 3 days of age)



COMMENTS: Late onset sepsis is defined as any positive blood and/or cerebrospinal fluid culture after 2 days of age (analysis is neonate-based and deaths before 3 days of age are excluded).

*Site X's rate goes over the range of Y-axis in the plot. Refer to the table for the actual rate for site X.

<u>In presentations #34 and #35</u>, late onset sepsis was attributed to the hospital where the first episode of sepsis was acquired. Each neonate was counted only once even if there were multiple episodes of infections.


Late onset sepsis: GA<33 weeks: Adjusted standardized ratios by site											
Site	Number of neonates	Number of NI	Adjusted [#] expected number of NI	Adjusted [#] standardized ratio	(CI) for	ence interval adjusted ized ratio					
1	117	18	11.2	1.6	1.0	2.5					
2	102	10	7.8	1.3	0.6	2.4					
3	79	5	6.8	0.7	0.2	1.7					
4	157	11	15.2	0.7	0.4	1.3					
6	184	18	17.3	1.0	0.6	1.6					
7	394	38	44.9	0.8	0.6	1.2					
8	109	6	9.2	0.7	0.2	1.4					
9	58	8	4.9 1.6 0.7		3.2						
10	168	16	13.6	13.6 1.2 0.7		1.9					
11	226	18	17.0	1.1	0.6	1.7					
13	106	5	7.9	0.6	0.2	1.5					
14	75	2	4.8	0.4	0.0	1.5					
15	155	22	15.9	1.4	0.9	2.1					
16	143	13	10.1	1.3	0.7	2.2					
17	14	0	0.8	0.0	•	4.3					
18	29	3	1.9	1.5	0.3	4.5					
19	295	42	30.2	1.4	1.0	1.9					
20	97	7	7.1	1.0	0.4	2.0					
21	159	13	14.5	0.9	0.5	1.5					
22	175	15	19.4	0.8	0.4	1.3					
23	40	10	8.1	1.2	0.6	2.3					
24	87	25	8.6	2.9	1.9	4.3					
25	324	12	28.9	0.4	0.2	0.7					
26	35	2	2.3	0.9	0.1	3.2					
27	62	2	4.8	0.4	0.0	1.5					
28	318	22	29.3	0.8	0.5	1.1					
29	48	1	4.5	0.2	0.0	1.2					
30	216	35	21.4	1.6	1.1	2.3					
31	119	8	6.4	1.3	0.5	2.5					
32	307	22	41.6	0.5	0.3	0.8					
33	12	2	0.9	2.3	0.3	8.2					

Presentation #35a Late onset sepsis: GA<33 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 35a-d and they may not correspond to other presentations in this report. *Late onset sepsis was attributed to the hospital where the first episode of sepsis was acquired. *Neonates who died before 3 days of age were excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.



Presentation # 35b Late onset sepsis: GA<33 weeks: Adjusted standardized ratios by site

Explanation for Presentation 35a

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<33 weeks GA)

Column 3: Number of neonates with outcome of interest among those eligible neonates

Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed late onset sepsis/expected late onset sepsis

Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 35b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation)

Dark points with numerical notation: Site and its location matching x and y axis values

Red funnel shaped lines: 95% confidence limits based on entire network information.

Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Site	Number of neonates	Number of NI	A<29 weeks: Ad Adjusted [#] expected number of NI	Adjusted# standardized ratio	95% confide (CI) for	ence interval adjusted ized ratio
1	50	15	9.1	1.7	0.9	2.7
2	34	9	5.8	1.6	0.7	3.0
3	28	4	5.5	0.7	0.2	1.9
4	48	8	11.2	0.7	0.3	1.4
6	66	15	13.7	1.1	0.6	1.8
7	175	33	36.9	0.9	0.6	1.3
8	37	5	7.2	0.7	0.2	1.6
9	16	7	3.6	1.9	0.8	4.0
10	53	11	10.3	1.1	0.5	1.9
11	64	15	11.7	1.3	0.7	2.1
13	30	5	5.6	0.9	0.3	2.1
14	15	1	2.9	0.3	0.0	1.9
15	69	16	13.0	1.2	0.7	2.0
16	38	8	6.6	1.2	0.5	2.4
18	9	1	1.4	0.7	0.0	4.1
19	103	33	23.6	1.4	1.0	2.0
20	30	4	5.1	0.8	0.2	2.0
21	54	10	10.9	0.9	0.4	1.7
22	80	14	16.6	0.8	0.5	1.4
23	40	10	8.3	1.2	0.6	2.2
24	28	17	7.0	2.4	1.4	3.9
25	121	9	22.6	0.4	0.2	0.8
26	11	1	1.6	0.6	0.0	3.4
27	20	2	3.7	0.5	0.1	1.9
28	115	17	22.4	0.8	0.4	1.2
29	17	1	3.3	0.3	0.0	1.7
30	77	30	16.7	1.8	1.2	2.6
31	30	5	4.0	1.2	0.4	2.9
32	172	19	36.3	0.5	0.3	0.8

Presentation #35c Late onset sepsis: GA<29 weeks: Adjusted standardized ratios by site


Numeric site codes were used in Presentations 35a-d and they may not correspond to other presentations in this report.

*Late onset sepsis was attributed to the hospital where the first episode of sepsis was acquired.

*Neonates who died before 3 days of age are excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Presentation # 35d Late onset sepsis: GA<29 weeks: Adjusted standardized ratios by site

Explanation for Presentation 35c

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<29 weeks GA)

Column 3: Number of neonates with outcome of interest among those eligible neonates

Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed late onset sepsis/expected late onset sepsis

Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 35d


X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation)

Dark points with numerical notation: Site and its location matching x and y axis values

Red funnel shaped lines: 95% confidence limits based on entire network information.

Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Presentation #36 Late onset sepsis per 1000 patient days: GA<33 weeks: Site specific crude rates




Site	Infections per 1000 patient days	Site	Infections per 1000 patient days	Site	Infections per 1000 patient days
Α	0.8	L	5.0	W	2.4
В	2.5	Μ	3.0	Х	4.6
С	4.3	Ν	2.0	Y	3.6
D	4.2	0	0.0	Z	1.7
Е	1.4	Р	2.6	AA	3.0
F	3.4	Q	2.0	AB	2.8
G	1.5	R	2.7	AC	6.3
Н	2.1	S	1.3	AD	2.4
Ι	5.5	Т	0.6	AE	2.1
J	1.9	U	0.4	AF	4.0
K	1.2	V	2.9	AG	3.7
				CNN	2.9

Total number of neonates = 4469

COMMENTS: Late onset sepsis is defined as positive blood and/or cerebrospinal fluid culture after 2 days of age (includes all admissions). Considerable variation exists when late onset sepsis is analyzed as infections per 1000 patient days. Note that it is possible that certain sites with high retro transfer rates may report a high incidence per 1000 patient days since neonates who are transferred out are those with lower acuity. If a neonate had >1 distinct episodes of infection, each episode will be counted as separate infections in the numerator.

<u>In presentations #36 and #37</u>, the infection was assigned to the hospital where the infection happened and not assigned to the hospital where the first episode of sepsis happened.

Presentation #37a Central Line-Associated Bloodstream Infections per 1000 central line* days: GA < 33 weeks: Site specific crude rates




	CLABSI**		Central	CLABSI per 1000 central line days			CLABSI**		Central	CLABSI per 1000 central line days	
Site	CONS	Non- CONS	line days	CONS	Non- CONS	Site -	CONS	Non- CONS	line days	CONS	Non- CONS
Α	0	1	577	0.0	1.7	R	8	15	2611	3.1	5.7
В	6	17	5277	1.1	3.2	S	0	1	863	0.0	1.2
С	5	11	1777	2.8	6.2	Т	1	0	488	2.0	0.0
D	9	14	3476	2.6	4.0	U	0	1	344	0.0	2.9
Ε	1	1	182	5.5	5.5	V	8	9	1460	5.5	6.2
F	3	2	437	6.9	4.6	W	2	5	1521	1.3	3.3
G	2	1	1130	1.8	0.9	Χ	2	5	761	2.6	6.6
Η	3	6	862	3.5	7.0	Y	16	19	2962	5.4	6.4
Ι	7	8	4625	1.5	1.7	Z	2	6	2992	0.7	2.0
J	6	10	2647	2.3	3.8	AA	8	1	728	11.0	1.4
K	3	1	405	7.4	2.5	AB	8	6	2938	2.7	2.0
L	13	14	3250	4.0	4.3	AC	0	2	84	0.0	23.8
Μ	6	8	2593	2.3	3.1	AD	9	2	1645	5.5	1.2
Ν	3	0	409	7.3	0.0	AE	4	7	1250	3.2	5.6
0	0	0	50	0.0	0.0	AF	9	6	2117	4.3	2.8
Р	1	0	124	8.1	0.0	AG	0	7	642	0.0	10.9
Q	1	3	612	1.6	4.9	CNN	146	189	51839	2.8	3.6

*Central line = Any of UV, surgical CVL, or PICC

** CLABSI was defined as a primary bloodstream infection in a neonate who developed infection while a central line was in situ or within 2 days of removal of the central line.


Presentation #37b Central Line-Associated Bloodstream Infections per 1000 central line* days: All neonates: Site specific crude rates



	CLABSI**		Central		CLABSI per 1000 central line days			CLABSI**		Central	CLABSI per 1000 central line days	
Site	CONS	Non- CONS	line days	CONS	Non- CONS		Site -	CONS	Non- CONS	line days	CONS	Non- CONS
Α	1	1	993	1.0	1.0		R	14	19	4382	3.2	4.3
В	6	17	5624	1.1	3.0		S	2	2	2057	1.0	1.0
С	5	11	1777	2.8	6.2		Т	1	0	758	1.3	0.0
D	9	16	3869	2.3	4.1		U	0	1	584	0.0	1.7
Ε	1	1	237	4.2	4.2		V	10	12	2244	4.5	5.3
F	3	2	679	4.4	2.9		W	2	6	1843	1.1	3.3
G	4	2	2898	1.4	0.7		Χ	4	7	1316	3.0	5.3
Η	3	6	862	3.5	7.0		Y	24	27	5979	4.0	4.5
Ι	7	10	8202	0.9	1.2		Z	2	7	3523	0.6	2.0
J	6	10	2775	2.2	3.6		AA	10	1	1046	9.6	1.0
K	3	1	590	5.1	1.7		AB	14	9	5067	2.8	1.8
L	17	22	5248	3.2	4.2		AC	0	2	145	0.0	13.8
Μ	6	9	2949	2.0	3.1		AD	9	4	1886	4.8	2.1
Ν	3	0	499	6.0	0.0		AE	4	7	1250	3.2	5.6
0	0	0	122	0.0	0.0		AF	11	8	3137	3.5	2.6
Р	1	0	178	5.6	0.0		AG	0	7	642	0.0	10.9
Q	1	4	766	1.3	5.2		CNN	183	231	74127	2.5	3.1

*Central line = Any of UV, surgical CVL, or PICC

** CLABSI was defined as a primary bloodstream infection in a neonate who developed infection while a central line was in situ or within 2 days of removal of the central line.




Presentation #38 Days of antimicrobial use per 1000 patient days among neonates who did not develop NEC, early-onset sepsis or late onset sepsis: <u>GA <33 weeks</u>*

Site	Days of antimicrobial use per 1000 patient days	Site	Days of antimicrobial use per 1000 patient days	Site	Days of antimicrobial use per 1000 patient days
Α	101.8	L	144.4	W	82.9
В	127.3	Μ	97.4	Х	129.0
С	114.7	Ν	90.4	Y	55.5
D	126.1	0	26.5	Ζ	166.1
Ε	80.2	Р	163.8	AA	110.2
F	54.5	Q	48.3	AB	122.8
G	162.6	R	105.2	AC	54.7
Η	47.1	S	108.1	AD	82.8
Ι	293.5	Т	68.6	AE	112.4
J	80.1	U	52.4	AF	149.2
Κ	64.0	V	70.6	AG	122.1
				CNN	105.3

*Denominators were based on neonates born < 33 weeks' GA without major congenital anomaly who did not develop early-onset sepsis, late-onset sepsis or necrotising enterocolitis.

Note: Prophylactic administration of trimethoprim or amoxicillin for the prevention of urinary tract infections with a suspected renal anomaly was not included.



Presentation #39 Days of antimicrobial use per 1000 patient days among neonates who did not develop NEC, early-onset sepsis or late onset sepsis: <u>GA <29 weeks</u>*


Site	Days of antimicrobial use per 1000 patient days	Site	Days of antimicrobial use per 1000 patient days	Site	Days of antimicrobial use per 1000 patient days
Α	163.4	L	146.8	W	118.7
В	145.4	Μ	87.9	Y	82.0
С	98.9	Ν	102.0	Z	150.5
D	128.3	0	12.4	AA	113.2
Ε	101.1	Р	169.8	AB	135.9
F	72.5	Q	59.6	AC	118.2
G	181.4	R	112.1	AD	85.0
Η	59.9	S	95.5	AE	157.1
Ι	0.0	Т	68.6	AF	167.2
J	97.5	U	79.0	AG	122.1
K	66.4	V	146.8	CNN	115.7

*Denominators were based on neonates born < 29 weeks' GA without major congenital anomaly who did not develop early-onset sepsis, late-onset sepsis or necrotising enterocolitis.

Note: Sites S and X do not have any neonates with GA < 29.

Note: Prophylactic administration of trimethoprim or amoxicillin for the prevention of urinary tract infections with a suspected renal anomaly was not included.

Presentation #40 Rate of treatment[#] for patent ductus arteriosus (PDA): GA<33 weeks who had PDA*: Site specific crude rates




Site	Treatment [#] for PDA among neonates who had PDA (%)	Site	Treatment [#] for PDA among neonates who had PDA (%)
Α	22.7	R	0.0
В	39.8	S	100.0
С	52.5	Т	33.3
D	56.8	U	40.0
Ε	71.4	V	48.3
F	64.7	W	40.6
G	75.0	Χ	0.0
Η	44.8	Y	43.5
Ι	62.5	Ζ	58.3
J	78.6	AA	46.4
K	81.3	AB	54.7
L	64.2	AC	0.0
Μ	59.2	AD	0.0
Ν	30.0	AE	25.5
0	100.0	AF	41.4
Р	33.3	AG	43.5
Q	40.6	CNN	47.4

Total number of neonates who had PDA = 1251

*PDA diagnosis is based on clinical suspicion and/or echocardiography findings.

"Treatment of PDA includes any of indomethacin, ibuprofen, acetaminophen, or ligation. The percentage of neonates with treated PDA was attributed to the site where the neonate was first admitted.

Presentation #41 Surgical patent ductus arteriosus (PDA) closure rate: GA<33 weeks who had PDA: Site specific crude rates




Site	Surgical ligation for PDA among neonates who had PDA (%)	Site	Surgical ligation for PDA among neonates who had PDA (%)
Α	9.1	R	0.0
В	2.7	S	0.0
С	4.9	Т	0.0
D	9.3	\mathbf{U}	0.0
Ε	0.0	V	0.0
F	5.9	W	9.4
G	12.5	Χ	0.0
Η	0.0	Y	1.2
Ι	25.0	Z	8.3
J	10.7	AA	3.6
K	0.0	AB	3.8
L	1.2	AC	0.0
Μ	15.5	AD	0.0
Ν	0.0	AE	0.0
0	0.0	AF	1.7
Р	0.0	AG	0.0
Q	3.1	 CNN	4.8

Total number of neonates who had PDA = 1251

The percentage of neonates with treated PDA was attributed to the site where the neonate was first admitted.

Presentation #42 Severe brain injury rates: GA<33 weeks: Site specific crude rates



IVH grade 1 or 2 = Germinal matrix hemorrhage or intraventricular hemorrhage **without** ventricular enlargement

IVH grade 3 or 4 or PVL (severe brain injury) = Intraventricular hemorrhage **with** ventricular enlargement or persistent parenchymal echogenicity or periventricular leukomalacia

Site	<25	25-26	27-28	29-30	31-32	Overall rate* per site %
Α	0.0	0.0	14.3	8.0	0.0	4.8
В	52.2	28.1	16.7	5.5	8.0	16.4
С	36.8	16.0	13.2	7.4	4.4	14.4
D	20.8	6.1	11.4	2.8	2.5	7.5
Е	NA	0.0	11.1	0.0	0.0	3.2
F	33.3	37.5	20.0	14.3	0.0	14.9
G	33.3	28.6	5.9	8.3	8.1	11.0
Н	0.0	0.0	4.0	10.3	2.1	4.6
Ι	0.0	100.0	16.7	0.0	0.0	7.3
J	0.0	14.8	4.8	4.9	1.6	5.0
К	0.0	46.7	10.0	12.5	7.1	19.3
L	13.3	14.3	5.6	4.8	1.9	6.9
Μ	18.9	7.7	8.2	2.7	4.3	7.4
Ν	20.0	0.0	0.0	4.2	2.3	2.9
0	NA	50.0	0.0	0.0	100.0	28.6
Р	NA	25.0	0.0	0.0	0.0	3.6
Q	66.7	20.0	0.0	3.9	0.0	6.0
R	28.6	32.1	12.5	10.3	3.6	15.3
S	NA	NA	NA	NA	40.0	40.0
Т	66.7	0.0	0.0	15.4	4.4	9.1
U	100.0	0.0	10.0	6.7	0.0	10.5
V	20.0	8.3	9.1	2.1	6.1	5.9
W	20.0	16.7	12.5	4.6	5.6	10.1
Х	NA	NA	NA	0.0	0.0	0.0
Y	20.0	14.8	10.7	4.4	5.2	8.6
Ζ	30.4	7.9	10.0	4.3	2.4	7.7
AA	0.0	19.1	0.0	3.7	0.0	4.9
AB	22.2	14.3	5.9	4.8	1.7	6.0
AC	0.0	100.0	NA	0.0	0.0	8.3
AD	13.3	11.1	20.0	6.8	7.5	9.9
AE	18.2	7.7	3.6	5.7	3.1	5.9
AF	33.3	18.2	3.2	10.2	2.9	10.6
AG	50.0	23.1	0.0	NA	NA	19.5
Overall rate** per GA group %	25.2	16.1	8.6	5.4	3.5	8.8

Presentation #42 (continued) Severe brain injury rate: GA<33 weeks: Site specific crude rates

Total number of neonates = 3724

Severe brain injury includes Grade 3 or 4 IVH or PVL


Note that the proportion of neonates with neuroimaging data available varies by GA.

745 neonates were excluded due to neuroimaging data not available.

*Overall % = (number of neonates with cranial ultrasound abnormalities for site / total number of neonates for site with neuroimaging data available) *100

**Overall % = (number of neonates with cranial ultrasound abnormalities for GA category / total number of neonates in GA category with neuroimaging data available) *100 NA = no data available

Presentation #43 Periventricular leukomalacia (PVL) rates: GA<33 weeks: Site specific crude rates



Site	<25	25-26	27-28	29-30	31-32	Overall rate* per site %
Α	0.0	0.0	14.3	8.0	0.0	4.8
В	4.4	18.8	10.0	0.0	6.0	6.7
С	15.8	8.0	7.9	0.0	4.4	6.8
D	10.4	2.0	3.4	0.0	1.3	2.7
Е	NA	0.0	0.0	0.0	0.0	0.0
F	0.0	12.5	0.0	7.1	0.0	4.3
G	0.0	0.0	5.9	4.2	2.7	3.3
Н	0.0	0.0	0.0	6.9	0.0	1.9
Ι	0.0	33.3	0.0	0.0	0.0	1.8
J	0.0	3.7	4.8	4.9	1.6	3.1
К	0.0	20.0	10.0	6.3	7.1	10.5
L	0.0	5.7	2.8	1.6	0.0	1.8
М	2.7	0.0	2.7	2.7	0.0	1.7
Ν	20.0	0.0	0.0	4.2	2.3	2.9
0	NA	0.0	0.0	0.0	100.0	14.3
Р	NA	25.0	0.0	0.0	0.0	3.6
Q	0.0	10.0	0.0	3.9	0.0	2.4
R	14.3	17.9	10.0	10.3	3.6	10.7
S	NA	NA	NA	NA	20.0	20.0
Т	33.3	0.0	0.0	15.4	4.4	7.3
U	0.0	0.0	0.0	0.0	0.0	0.0
V	0.0	8.3	0.0	2.1	3.0	2.5
W	0.0	5.6	6.3	0.0	0.0	2.5
Х	NA	NA	NA	0.0	0.0	0.0
Y	0.0	3.7	7.1	0.0	1.3	2.0
Z	21.7	0.0	3.3	2.9	0.0	3.3
AA	0.0	14.3	0.0	3.7	0.0	3.9
AB	11.1	14.3	6.1	3.2	1.7	4.9
AC	0.0	100.0	NA	0.0	0.0	8.3
AD	6.7	5.6	6.7	0.0	5.0	3.8
AE	0.0	0.0	3.6	0.0	3.1	1.7
AF	13.3	0.0	0.0	8.2	2.9	4.6
AG	10.0	7.7	0.0	NA	NA	4.9
Overall rate** per GA group %	7.1	6.6	4.0	2.8	1.9	3.7

Presentation #43 (continued) Periventricular leukomalacia (PVL) rate: GA<33 weeks: Site specific crude rates

Total number of neonates = 3724

Note that the proportion of neonates with neuroimaging data available varies by GA. 745 neonates were excluded due to neuroimaging data not available.

*Overall % = (number of neonates with PVL for site / total number of neonates for site) *100


**Overall % = (number of neonates with PVL for GA category / total number of neonates in GA category) *100

NA = no data available

Site	Total number of neonates	Number of neonates with available data	Number of neonates with IVH G3/4 or PVL	Adjusted [#] expected number of neonates with IVH G3/4 or PVL	Adjusted# standardized ratio	95% conf interval for standardiz	idence adjusted
1	116	100	4	8.4	0.5	0.1	1.2
2	102	100	3	6.3	0.5	0.1	1.4
3	78	56	11	4.5	2.4	1.2	4.3
4	155	130	13	11.3	1.2	0.6	2.0
6	176	141	15	11.7	1.3	0.7	2.1
7	390	355	26	30.7	0.8	0.6	1.2
8	108	77	8	6.5	1.2	0.5	2.4
9	58	46	6	3.4	1.7	0.6	3.8
10	166	153	7	10.4	0.7	0.3	1.4
11	213	174	10	11.2	0.9	0.4	1.6
13	103	86	9	6.4	1.4	0.6	2.7
14	76	60	3	3.6	0.8	0.2	2.4
15	150	121	19	11.5	1.7	1.0	2.6
16	140	116	7	8.0	0.9	0.3	1.8
17	14	7	2	0.5	4.3	0.5	15.6
18	29	26	0	1.3	0.0		2.8
19	293	210	15	21.8	0.7	0.4	1.1
20	94	81	3	5.0	0.6	0.1	1.7
21	148	113	6	9.7	0.6	0.2	1.4
22	179	130	18	12.4	1.5	0.9	2.3
23	41	40	8	6.0	1.3	0.6	2.6
24	60	47	4	2.4	1.7	0.5	4.3
25	321	268	18	21.0	0.9	0.5	1.4
26	35	31	1	1.8	0.6	0.0	3.1
27	61	53	5	3.4	1.5	0.5	3.4
28	292	208	26	19.8	1.3	0.9	1.9
29	48	38	4	2.4	1.7	0.5	4.3
30	206	188	16	16.5	1.0	0.6	1.6
31	121	107	5	5.6	0.9	0.3	2.1
32	313	295	20	29.8	0.7	0.4	1.0
33	12	12	1	0.6	1.7	0.0	9.3

Presentation #44a IVH grade 3 or 4 or PVL: GA<33 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 44a-d and they may not correspond to other presentations in this report. Neonates with major congenital anomalies are excluded. [#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Sites 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.



Presentation #44b IVH grade 3 or 4 or PVL: GA<33 weeks: Adjusted standardized ratios by site

Explanation for Presentation 44a

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<33 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<33 weeks GA and no major anomaly) who were actually used to fit the model

Column 4: Number of neonates with outcome of interest among those eligible neonates Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA,

```
sex, and SNAPII > 20
```

Column 6: Adjusted standardized ratio calculated based on observed IVH or PVL/expected IVH or PVL Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 44b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Site	Total number of neonates	Number of neonates with available data	Number of neonates with IVH G3/4 or PVL	Adjusted st Adjusted# expected number of neonates with IVH G3/4 or PVL	Adjusted# standardized ratio	95% confidence interval for adjusted standardized ratio	
1	49	49	4	6.1	0.7	0.2	1.7
2	36	35	1	3.9	0.3	0.0	1.4
3	28	26	8	3.3	2.4	1.0	4.8
4	47	47	7	7.9	0.9	0.4	1.8
6	66	65	10	8.9	1.1	0.5	2.1
7	179	177	21	23.9	0.9	0.5	1.3
8	39	39	6	5.0	1.2	0.4	2.6
9	16	15	4	2.0	2.0	0.5	5.0
10	55	54	5	6.9	0.7	0.2	1.7
11	60	60	6	6.8	0.9	0.3	1.9
13	30	28	4	3.9	1.0	0.3	2.6
14	18	16	1	1.9	0.5	0.0	2.9
15	65	65	15	8.8	1.7	0.9	2.8
16	39	39	4	4.8	0.8	0.2	2.1
18	9	8	0	0.7	0.0	•	5.0
19	106	99	11	17.0	0.6	0.3	1.2
20	29	29	3	3.1	1.0	0.2	2.9
21	51	50	4	7.0	0.6	0.2	1.5
22	81	80	15	10.7	1.4	0.8	2.3
23	41	40	8	5.9	1.3	0.6	2.7
24	12	12	4	1.3	3.0	0.8	7.8
25	120	118	15	15.2	1.0	0.6	1.6
26	11	11	1	1.0	1.0	0.0	5.6
27	20	18	2	2.2	0.9	0.1	3.4
28	108	104	23	15.0	1.5	1.0	2.3
29	17	14	3	1.4	2.1	0.4	6.2
30	76	74	11	12.0	0.9	0.5	1.6
31	33	32	1	2.8	0.4	0.0	2.0
32	177	173	16	24.7	0.6	0.4	1.1


Presentation# 44c IVH grade 3 or 4 or PVL: GA<29 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 44a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies are excluded.

^{##}The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Presentation #44d IVH grade 3 or 4 or PVL: GA<29 weeks: Adjusted standardized ratios by site

Explanation for Presentation 44c

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) who were actually used to fit the model

Column 4: Number of neonates with outcome of interest among those eligible neonates


Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 6: Adjusted standardized ratio calculated based on observed IVH or PVL/expected IVH or PVL Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 44d

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Presentation #45 Necrotizing enterocolitis (NEC) treatment rates: GA<33 weeks: Site specific crude rates



	Treatment (%)			
Site	Medical treatment only	Medical + peritoneal drainage	Laparotomy only	Peritoneal drainage + Laparotomy	Any
Α	2.6	0.0	0.0	0.0	2.6
В	2.2	0.0	0.3	0.0	2.5
С	2.8	0.6	0.6	0.6	4.4
D	3.2	0.0	3.2	0.5	6.9
Е	0.0	0.0	0.0	0.0	0.0
F	3.4	0.0	0.0	0.0	3.4
G	0.9	0.0	0.0	0.0	0.9
Н	0.0	0.0	2.5	0.0	2.5
Ι	7.3	0.0	1.5	0.0	8.7
J	0.6	0.0	1.2	0.0	1.7
K	2.5	3.8	0.0	0.0	6.3
L	1.7	0.0	2.0	0.0	3.7
Μ	2.9	0.0	1.6	0.0	4.5
Ν	0.0	1.0	0.0	0.0	1.0
0	7.1	0.0	0.0	0.0	7.1
Р	3.2	0.0	0.0	0.0	3.2
Q	0.0	1.0	0.0	1.0	2.1
R	2.0	0.0	2.0	0.7	4.6
S	0.0	0.0	0.0	0.0	0.0
Т	1.6	0.0	0.0	0.0	1.6
U	0.0	0.0	0.0	0.0	0.0
V	0.0	0.7	0.7	2.1	3.5
W	0.9	0.9	0.9	0.0	2.7
Χ	0.0	0.0	0.0	0.0	0.0
Y	2.8	0.0	2.3	0.0	5.1
Ζ	1.2	0.3	1.5	0.3	3.3
AA	0.8	0.0	1.7	0.0	2.5
AB	0.0	0.5	1.4	0.0	1.8
AC	8.3	0.0	0.0	0.0	8.3
AD	1.3	0.0	0.6	0.0	1.9
AE	6.9	0.0	1.3	0.0	8.2
AF	1.6	1.1	0.5	0.0	3.2
AG	7.1	0.0	0.0	0.0	7.1
Total	2.0	0.3	1.3	0.2	3.7

Presentation #45 (continued) Necrotizing enterocolitis (NEC) treatment rates: GA<33 weeks: Site specific crude rates


COMMENTS: These analyses include 4 465 neonates from 33 sites.

Site	Number of neonates	Number of neonates with NEC	Adjusted [#] expected number of neonates with NEC	Adjusted [#] standardized ratio	95% confide for adjusted s rat	standardized
1	116	2	4.1	0.5	0.1	1.7
2	102	1	3.1	0.3	0.0	1.8
3	78	4	2.4	1.7	0.5	4.3
4	155	3	5.5	0.5	0.1	1.6
6	176	6	6.7	0.9	0.3	1.9
7	390	27	18.8	1.4	0.9	2.1
8	108	3	3.6	0.8	0.2	2.5
9	58	2	1.9	1.1	0.1	3.9
10	166	3	5.1	0.6	0.1	1.7
11	211	3	5.8	0.5	0.1	1.5
13	103	1	2.6	0.4	0.0	2.1
14	76	2	1.9	1.0	0.1	3.8
15	149	7	5.4	1.3	0.5	2.7
16	140	5	3.6	1.4	0.4	3.2
17	14	1	0.3	3.3	0.0	18.3
18	29	1	0.9	1.1	0.0	6.3
19	293	10	12.0	0.8	0.4	1.5
20	94	2	2.5	0.8	0.1	2.9
21	148	12	5.2	2.3	1.2	4.0
22	179	8	7.8	1.0	0.4	2.0
23	41	3	3.2	0.9	0.2	2.8
24	60	5	1.4	3.6	1.2	8.5
25	321	11	10.7	1.0	0.5	1.8
26	35	0	0.8	0.0		4.6
27	61	1	1.8	0.5	0.0	3.1
28	292	6	10.1	0.6	0.2	1.3
29	48	0	1.9	0.0		2.0
30	206	10	7.4	1.3	0.6	2.5
31	121	3	2.5	1.2	0.2	3.5
32	313	13	16.6	0.8	0.4	1.3
33	12	1	0.4	2.8	0.0	15.4

Presentation #46a

Numeric site codes were used in Presentations 46a-d and they may not correspond to other presentations in this report. Neonates with major congenital anomalies are excluded. [#] Variables adjusted for in the prediction model: GA, SGA, sex, and SNAPII > 20 Note: Sites 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.

Presentation #46b Necrotizing enterocolitis (NEC): GA<33 weeks: Adjusted standardized ratios by site



Explanation for Presentation 46a

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<33 weeks GA and no major anomaly) Column 3: Number of neonates with outcome of interest among those eligible neonates Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed NEC/expected NEC Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 46b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Site	Number of neonates	Number of neonates with NEC	Adjusted standar expected number of neonates with NEC	Adjusted# standardized ratio	95% confiden	ce interval for dardized ratio
1	49	1	3.3	0.3	0.0	1.7
2	36	1	2.3	0.4	0.0	2.5
3	28	3	1.8	1.7	0.3	4.8
4	47	3	4.3	0.7	0.1	2.0
6	66	5	5.4	0.9	0.3	2.2
7	179	22	15.6	1.4	0.9	2.1
8	39	3	2.7	1.1	0.2	3.2
9	16	2	1.4	1.4	0.2	5.2
10	55	2	3.7	0.5	0.1	1.9
11	60	0	3.8	0.0		1.0
13	30	1	1.8	0.6	0.0	3.1
14	18	2	1.3	1.6	0.2	5.8
15	64	5	4.4	1.1	0.4	2.7
16	39	3	2.3	1.3	0.3	3.7
18	9	1	0.6	1.8	0.0	9.9
19	106	8	10.0	0.8	0.3	1.6
20	29	2	1.7	1.2	0.1	4.2
21	51	9	4.2	2.1	1.0	4.1
22	81	7	6.5	1.1	0.4	2.2
23	41	3	3.1	1.0	0.2	2.8
24	12	0	0.9	0.0	•	4.2
25	120	11	8.2	1.3	0.7	2.4
26	11	0	0.5	0.0	•	7.4
27	20	1	1.4	0.7	0.0	3.9
28	108	4	8.0	0.5	0.1	1.3
29	17	0	1.4	0.0		2.6
30	76	9	5.9	1.5	0.7	2.9
31	33	1	1.5	0.7	0.0	3.7
32	177	12	14.6	0.8	0.4	1.4


Presentation #46c NEC: GA<29 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 46a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies are excluded.

^{##}The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Presentation #46d NEC: GA<29 weeks: Adjusted standardized ratios by site

Explanation for Presentation 46c

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of neonates with outcome of interest among those eligible neonates Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed NEC/expected NEC Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 46d

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

_	·	· /	GA at bi		-	
Site	<25	25-26	27-28	29-30	31-32	Overall CLD rate for sites
Α	100.0	83.3	71.4	8.0	8.6	22.7
В	81.3	50.0	31.7	22.2	8.9	25.0
С	90.9	65.2	36.1	16.7	1.6	27.0
D	86.1	73.3	54.3	29.4	21.1	42.9
Е	NA	50.0	25.0	10.0	7.1	14.7
F	NA	100.0	25.0	21.4	0.0	22.2
G	100.0	100.0	37.5	21.7	7.8	21.9
Н	100.0	40.0	62.5	13.8	18.3	28.3
Ι	100.0	100.0	83.3	60.0	29.4	48.3
J	100.0	84.6	63.2	40.0	21.3	43.0
К	NA	60.0	33.3	6.3	0.0	14.5
L	100.0	81.3	63.6	28.8	11.8	36.6
М	55.2	31.2	21.6	9.3	1.7	19.9
Ν	100.0	83.3	33.3	12.5	6.8	23.3
0	NA	50.0	0.0	33.3	0.0	14.3
Р	NA	66.7	33.3	11.1	0.0	17.2
Q	100.0	37.5	18.8	8.3	0.0	10.1
R	100.0	52.0	38.7	13.8	7.1	25.0
S	NA	NA	NA	NA	60.0	60.0
Т	100.0	33.3	30.0	7.7	6.9	15.3
U	100.0	100.0	22.2	14.3	6.3	22.7
V	50.0	55.6	38.1	19.6	12.1	22.1
W	100.0	50.0	42.9	13.6	0.0	19.1
X	NA	NA	NA	0.0	0.0	0.0
Y	100.0	70.8	56.0	35.6	19.8	39.1
Ζ	100.0	94.6	55.9	36.5	11.5	40.1
AA	100.0	76.5	26.1	7.4	7.3	23.6
AB	100.0	50.0	58.8	14.9	9.9	25.5
AC	NA	0.0	NA	0.0	0.0	0.0
AD	64.3	43.8	33.3	8.9	7.8	19.5
AE	100.0	100.0	96.7	73.7	64.2	77.0
AF	55.6	68.4	53.6	18.4	3.0	25.7
AG	100.0	88.9	58.8	NA	NA	74.2
Overall CLD rate for GA group	85.5	64.6	45.7	22.9	12.5	30.8

Presentation #47 Chronic lung disease (CLD): GA<33 weeks: Site specific crude rates


Total number of neonates = 4.188

281 neonates were excluded due to death prior to week 36 or first admission after week 36 NA = Data not available

Site	Total number of neonates	Number of neonates with available data	Number of neonates with CLD at 36w or discharge	Adjusted# expected number of CLD at 36w or discharge	Adjusted# standardized ratio	95% confidence interv for adjusted standardized ratio	
1	116	108	25	31.8	0.8	0.5	1.2
2	102	101	24	28.4	0.8	0.5	1.3
3	78	68	10	16.5	0.6	0.3	1.1
4	155	152	30	45.3	0.7	0.4	0.9
6	176	164	42	47.2	0.9	0.6	1.2
7	390	365	151	132.9	1.1	1.0	1.3
8	108	102	19	28.7	0.7	0.4	1.0
9	58	54	12	14.0	0.9	0.4	1.5
10	166	159	67	43.8	1.5	1.2	1.9
11	213	207	47	53.0	0.9	0.7	1.2
13	103	92	19	20.5	0.9	0.6	1.4
14	76	73	17	17.3	1.0	0.6	1.6
15	150	141	33	45.1	0.7	0.5	1.0
16	140	132	26	32.3	0.8	0.5	1.2
17	14	14	2	2.9	0.7	0.1	2.5
18	29	27	5	6.6	0.8	0.2	1.8
19	293	271	96	80.8	1.2	1.0	1.5
20	94	87	8	21.3	0.4	0.2	0.7
21	148	141	106	38.9	2.7	2.2	3.3
22	179	166	44	53.0	0.8	0.6	1.1
23	41	30	22	16.5	1.3	0.8	2.0
24	60	51	26	11.2	2.3	1.5	3.4
25	321	313	125	93.4	1.3	1.1	1.6
26	35	34	5	8.7	0.6	0.2	1.3
27	61	57	7	13.1	0.5	0.2	1.1
28	292	273	58	80.2	0.7	0.5	0.9
29	48	44	10	12.6	0.8	0.4	1.5
30	206	188	72	56.9	1.3	1.0	1.6
31	121	119	34	26.7	1.3	0.9	1.8
32	313	295	58	119.9	0.5	0.4	0.6
33	12	11	0	2.1	0.0		1.8

Presentation #48a Chronic lung disease (CLD): GA <33 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 48a-d and they may not correspond to other presentations in this report. Neonates with major congenital anomalies and death before 36 weeks were excluded. [#]The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Site 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.



Presentation #48b Chronic lung disease (CLD): GA <33 weeks: Adjusted standardized ratios by site

Explanation for Presentation 48a

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<33 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<33 weeks GA and no major anomaly) who were actually used to fit the model

Column 4: Number of neonates with outcome of interest among those eligible neonates Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 6: Adjusted standardized ratio calculated based on observed CLD/expected CLD Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 48b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Note: Deaths before 36 weeks were excluded in the denominator.

Site	Total number of neonates	Number of neonates with available data	Number of neonates with CLD at 36w or discharge	Adjusted [#] expected number of neonates with CLD at 36w or discharge	Adjusted# standardized ratio	95% confiden for adjusted st rati	ce interval andardized
1	49	42	21	22.3	0.9	0.6	1.4
2	36	35	18	18.5	1.0	0.6	1.5
3	28	19	9	10.2	0.9	0.4	1.7
4	47	44	21	29.1	0.7	0.4	1.1
6	66	55	32	31.9	1.0	0.7	1.4
7	179	156	103	94.9	1.1	0.9	1.3
8	39	33	17	19.1	0.9	0.5	1.4
9	16	12	9	6.8	1.3	0.6	2.5
10	55	49	39	28.5	1.4	1.0	1.9
11	60	55	33	30.1	1.1	0.8	1.5
13	30	21	12	10.1	1.2	0.6	2.1
14	18	15	12	8.9	1.3	0.7	2.4
15	65	57	26	31.9	0.8	0.5	1.2
16	39	32	14	16.7	0.8	0.5	1.4
18	9	7	4	3.4	1.2	0.3	3.0
19	106	84	66	52.5	1.3	1.0	1.6
20	29	24	6	12.7	0.5	0.2	1.0
21	51	44	43	25.5	1.7	1.2	2.3
22	81	69	37	39.5	0.9	0.7	1.3
23	41	30	22	16.8	1.3	0.8	2.0
24	12	11	10	5.8	1.7	0.8	3.2
25	120	112	85	64.7	1.3	1.0	1.6
26	11	10	3	5.2	0.6	0.1	1.7
27	20	16	5	7.9	0.6	0.2	1.5
28	108	96	39	53.7	0.7	0.5	1.0
29	17	14	7	7.6	0.9	0.4	1.9
30	76	60	42	37.1	1.1	0.8	1.5
31	33	31	19	14.7	1.3	0.8	2.0
32	177	162	50	96.4	0.5	0.4	0.7


Presentation #48c Chronic lung disease (CLD): GA <29 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 48a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies and death before 36 weeks were excluded.

[#]The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Presentation #48d Chronic lung disease (CLD): GA <29 weeks: Adjusted standardized ratios by site

Explanation for Presentation 48c

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) who were actually used to fit the model


Column 4: Number of neonates with outcome of interest among those eligible neonates Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 6: Adjusted standardized ratio calculated based on observed CLD/expected CLD Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 48d

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Note: Deaths before 36 weeks were excluded in the denominator.



Presentation #49a Postnatal use of steroids for treatment of CLD: GA<29 weeks: Site specific crude rates[†]

Total number of neonates = 1.676

0.0

0.0

0.0

0.0

0

Р

[†]Percentage of neonates treated for CLD at each network site; results were attributed to the site of first admission; Sites S and X did not have any neonates with GA<29.

AG

Total

19.1

13.1

0.0

7.2


0.0

11.6

COMMENTS: Specific criteria for these treatments at each site were not documented here.

0.0

0.0



Presentation #49b Systemic steroids for hypotension: GA<33 weeks: Site specific crude rates[†]

Total number of neonates = 4469

[†]Percentage of neonates treated with systemic steroids for hypotension at each network site; results were attributed to the site of first admission.

COMMENTS: Specific criteria for these treatments at each site were not documented here.

Site	Total number of neonates	Number of neonates with available data	Number of neonates with ROP ≥ Stage 3	Adjusted stand Adjusted# expected number of neonates with $ROP \geq Stage 3$	Adjusted# standardized ratio	95% confide for adj standardi	usted
1	116	17	4	1.7	2.3	0.6	5.9
2	102	57	5	3.3	1.5	0.5	3.6
3	78	35	1	1.4	0.7	0.0	4.1
4	155	93	6	8.6	0.7	0.3	1.5
6	176	99	7	6.7	1.0	0.4	2.1
7	390	195	10	20.9	0.5	0.2	0.9
8	108	40	6	3.2	1.9	0.7	4.0
9	58	29	0	1.3	0.0		2.8
10	166	61	7	3.7	1.9	0.8	3.9
11	213	20	4	3.8	1.0	0.3	2.7
13	103	37	4	1.7	2.4	0.7	6.2
14	76	39	2	1.8	1.1	0.1	4.0
15	150	78	4	5.4	0.7	0.2	1.9
16	140	83	7	2.8	2.5	1.0	5.1
18	29	18	2	0.4	5.4	0.6	19.6
19	293	97	15	12.9	1.2	0.7	1.9
20	94	54	2	1.8	1.1	0.1	4.1
21	148	37	4	3.1	1.3	0.3	3.3
22	179	47	6	6.4	0.9	0.3	2.1
23	41	23	4	3.1	1.3	0.3	3.3
24	60	8	0	1.0	0.0		3.6
25	321	103	10	11.5	0.9	0.4	1.6
26	35	17	0	0.4	0.0		8.7
27	61	30	1	1.1	0.9	0.0	5.0
28	292	110	15	11.5	1.3	0.7	2.1
29	48	32	0	0.6	0.0		6.4
30	206	63	12	7.3	1.7	0.9	2.9
31	121	62	1	2.3	0.4	0.0	2.5
32	313	151	11	22.2	0.5	0.2	0.9
33	12	7	1	0.1	9.3	0.1	51.6


Presentation #50a ROP > Stage 3: GA<33 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 50a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies are excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17 were not included in this analysis due to small number of eligible neonates in this category.



Explanation for Presentation 50a

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<33 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<33 weeks GA and no major anomaly) who were actually used to fit the model

Column 4: Number of neonates with outcome of interest among those eligible neonates Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 6: Adjusted standardized ratio calculated based on observed ROP/expected ROP Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 50b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

	ROP <u>></u> Stage 3: GA<29 weeks: Adjusted standardized ratios by site										
Site	Total number of neonates	Number of neonates with available data	Number of neonates with ROP <u>></u> Stage 3	Adjusted [#] expected number of neonates with ROP <u>></u> Stage 3	Adjusted# standardized ratio	95% confi interval for a standardize	adjusted				
1	49	12	4	1.6	2.5	0.7	6.3				
2	36	33	4	3.0	1.3	0.4	3.4				
3	28	20	1	1.1	0.9	0.0	4.9				
4	47	44	6	8.3	0.7	0.3	1.6				
6	66	56	7	6.3	1.1	0.4	2.3				
7	179	145	9	20.0	0.4	0.2	0.9				
8	39	26	6	3.1	1.9	0.7	4.2				
9	16	12	0	1.2	0.0	•	3.2				
10	55	23	7	3.5	2.0	0.8	4.1				
11	60	18	4	3.9	1.0	0.3	2.7				
13	30	20	4	1.5	2.6	0.7	6.7				
14	18	15	2	1.6	1.3	0.1	4.6				
15	65	55	4	4.9	0.8	0.2	2.1				
16	39	33	6	2.4	2.5	0.9	5.4				
18	9	7	1	0.3	3.8	0.0	21.0				
19	106	73	14	12.7	1.1	0.6	1.8				
20	29	24	2	1.5	1.4	0.2	4.9				
21	51	27	4	2.8	1.4	0.4	3.7				
22	81	39	6	6.2	1.0	0.4	2.1				
23	41	23	4	3.0	1.3	0.4	3.4				
24	12	5	0	1.0	0.0		3.8				
25	120	90	10	11.1	0.9	0.4	1.7				
26	11	9	0	0.3	0.0		11.9				
27	20	16	1	1.0	1.0	0.0	5.6				
28	108	79	14	11.2	1.2	0.7	2.1				
29	17	11	0	0.4	0.0		9.2				
30	76	37	11	7.1	1.5	0.8	2.8				
31	33	30	1	1.9	0.5	0.0	2.9				
32	177	135	11	21.9	0.5	0.3	0.9				


Presentation #50cROP \geq Stage 3: GA<29 weeks: Adjusted standardized ratios by site

Numeric site codes were used in Presentations 50a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies are excluded.

[#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20.

Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.



Explanation for Presentation 50c

Column 1: Numeric site codes

Column 2: Total number of neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) who were actually used to fit the model

Column 4: Number of neonates with outcome of interest among those eligible neonates Column 5: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 6: Adjusted standardized ratio calculated based on observed ROP/expected ROP Columns 7 and 8: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 50d


X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation) Dark points with numerical notation: Site and its location matching x and y axis values Red funnel shaped lines: 95% confidence limits based on entire network information. Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Site	Number of neonates	Number of neonates with mortality or major morbidities	Adjusted [#] expected number of neonates with mortality or major morbidities	Adjusted [#] standardized ratio	95% confiden for adju standardiz	isted
1	116	37	45.6	0.8	0.6	1.1
2	102	30	35.6	0.8	0.6	1.2
3	78	26	28.0	0.9	0.6	1.4
4	155	49	56.5	0.9	0.6	1.1
6	176	66	66.6	1.0	0.8	1.3
7	390	191	177.5	1.1	0.9	1.2
8	108	30	39.8	0.8	0.5	1.1
9	58	17	20.8	0.8	0.5	1.3
10	166	79	58.4	1.4	1.1	1.7
11	213	59	69.0	0.9	0.7	1.1
13	103	35	33.9	1.0	0.7	1.4
14	76	22	23.2	0.9	0.6	1.4
15	150	52	62.1	0.8	0.6	1.1
16	140	39	46.3	0.8	0.6	1.2
17	14	3	3.6	0.8	0.2	2.5
18	29	9	9.8	0.9	0.4	1.7
19	293	126	115.8	1.1	0.9	1.3
20	94	17	30.5	0.6	0.3	0.9
21	148	115	53.4	2.2	1.8	2.6
22	179	67	74.0	0.9	0.7	1.2
23	41	34	29.1	1.2	0.8	1.6
24	60	37	15.5	2.4	1.7	3.3
25	321	140	119.4	1.2	1.0	1.4
26	35	8	11.5	0.7	0.3	1.4
27	61	13	19.5	0.7	0.4	1.1
28	292	89	110.1	0.8	0.6	1.0
29	48	14	18.0	0.8	0.4	1.3
30	206	104	81.8	1.3	1.0	1.5
31	121	42	34.3	1.2	0.9	1.7
32	313	96	157.1	0.6	0.5	0.7
33	12	3	3.4	0.9	0.2	2.6

Presentation #51a Mortality or major morbidity: GA < 33 weeks: Adjusted standardized ratios by site

Major morbidity = IVH 3 or 4 or PVL or BPD or ROP >stage 2 or NEC or nosocomial sepsis Numeric site codes were used in Presentations 51a-d and they may not correspond to other presentations in this report. Neonates with major congenital anomalies were excluded. [#] The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Sites 5 and 12 were not included in this analysis due to small number of eligible neonates in this category.

Presentation #51b Mortality or major morbidity: GA < 33 weeks: Adjusted standardized ratios by site



Explanation for Presentation 51a

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<33 weeks GA and no major anomaly)

Column 3: Number of neonates with outcome of interest among those eligible neonates

Column 4: Expected number of neonates with outcome of interest after adjustment for GA, small for gestational age, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed death or morbidities/expected deaths or morbidities

Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 51b

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation)

Dark points with numerical notation: Site and its location matching x and y axis values

Red funnel shaped lines: 95% confidence limits based on entire network information.

Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

Site	Number of neonates	Number of neonates with mortality or major morbidities	Adjusted [#] expected number of neonates with mortality or major morbidities	Adjusted# standardized ratio	95% confidence interval for adjusted standardized ratio		
1	49	30	32.5	0.9	0.6	1.3	
2	36	22	22.5	1.0	0.6	1.5	
3	28	21	19.5	1.1	0.7	1.6	
4	47	31	35.7	0.9	0.6	1.2	
6	66	49	46.8	1.0	0.8	1.4	
7	179	132	128.3	1.0	0.9	1.2	
8	39	26	27.6	0.9	0.6	1.4	
9	16	13	11.8	1.1	0.6	1.9	
10	55	48	38.2	1.3	0.9	1.7	
11	60	40	39.2	1.0	0.7	1.4	
13	30	23	19.5	1.2	0.7	1.8	
14	18	15	12.2	1.2	0.7	2.	
15	65	40	44.3	0.9	0.6	1.	
16	39	22	25.7	0.9	0.5	1.	
18	9	7	5.8	1.2	0.5	2.	
19	106	91	80.0	1.1	0.9	1.	
20	29	12	18.9	0.6	0.3	1.	
21	51	50	35.9	1.4	1.0	1.	
22	81	54	56.1	1.0	0.7	1.	
23	41	34	29.2	1.2	0.8	1.	
24	12	12	7.6	1.6	0.8	2.	
25	120	96	82.1	1.2	0.9	1.	
26	11	5	6.9	0.7	0.2	1.	
27	20	9	12.7	0.7	0.3	1.	
28	108	61	73.2	0.8	0.6	1.	
29	17	10	11.3	0.9	0.4	1.	
30	76	66	56.4	1.2	0.9	1.	
31	33	23	18.4	1.2	0.8	1.	
32	177	82	124.8	0.7	0.5	0.	

Presentation #51c Mortality or major morbidity: GA < 29 weeks: Adjusted standardized ratios by site


Major morbidity = IVH 3 or 4 or PVL or BPD or ROP > stage 2 or NEC or nosocomial sepsis

Numeric site codes were used in Presentations 51a-d and they may not correspond to other presentations in this report.

Neonates with major congenital anomalies were excluded.

[#]The prediction model was adjusted for GA, SGA, sex, and SNAPII > 20. Note: Sites 5, 12, 17, 33 were excluded from the analysis due to the small number of eligible neonates.

Presentation #51d Mortality or major morbidity: GA < 29 weeks: Adjusted standardized ratios by site



Explanation for Presentation 51c

Column 1: Numeric site codes

Column 2: Number of eligible neonates at each site (<29 weeks GA and no major anomaly) Column 3: Number of neonates with outcome of interest among those eligible neonates Column 4: Expected number of neonates with outcome of interest after adjustment for GA, SGA, sex, and SNAPII > 20

Column 5: Adjusted standardized ratio calculated based on observed death or morbidities/expected deaths or morbidities

Columns 6 and 7: 95% CI around the adjusted standardized ratio for the outcome

Explanation for Presentation 51d

X-axis: Expected number of neonates with outcome (value from Column 4 of previous presentation) Y-axis: Adjusted standardized ratio (value from Column 5 of previous presentation)

Dark points with numerical notation: Site and its location matching x and y axis values

Red funnel shaped lines: 95% confidence limits based on entire network information.

Sites outside of red lines represent higher or lower (depending upon position in graph) adjusted standardized ratio. However, for determining whether site is statistically different from others, one should also assess 95% CI and check whether both upper and lower boundaries are also outside of the funnel area or not.

F. Discharge Disposition and Status


F. Discharge Disposition and Status


Presentation #52a

Final discharge destination: All GA: Crude rates

		GA (co	mpleted	weeks)						
		< 25	25-26	27-28	29-30	31-32	33-34	35-36	<u>></u> 37	Total
Home	Ν	102	222	320	429	660	928	1237	3452	7350
Home	%	29.6	40.2	41.1	39.3	38.8	48.1	52.0	58.8	
Community hospital	Ν	62	180	351	569	893	707	505	559	3826
Community nospital	%	18.0	32.6	45.1	52.2	52.5	36.6	21.3	9.5	
Tertiary hospital	Ν	15	17	11	14	13	30	43	200	343
rentary noopnar	%	4.4	3.1	1.4	1.3	0.8	1.6	1.8	3.4	
Died	Ν	126	73	44	24	23	24	33	78	425
	%	36.5	13.2	5.7	2.2	1.4	1.2	1.4	1.3	
Palliative care	Ν	0	0	1	1	1	0	5	14	22
(home/other institute)	%	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.2	
Another inpatient area in	Ν	38	59	52	54	112	242	554	1568	2679
site	%	11.0	10.7	6.7	5.0	6.6	12.5	23.3	26.7	
Out of country discharge	Ν	2	1	0	0	0	0	0	0	3
Out of country discharge	%	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	
Total neonates included	Ν	345	552	779	1091	1702	1931	2377	5871	14648
Total ficonates included	%	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Discharge destination	Ν									3
missing										5
GA missing	Ν									0
Total number of	Ν									14651
neonates	ΤN									11001

Presentation #52b





Presentation #52b (continued)

Final discharge destination by site: GA<33

	Discharge desti	nation		
Site	Death + Palliative care	Home	Community hospital + inpatient area	Tertiary hospital + Out of country
Α	3.9	83.3	10.3	2.6
В	6.8	49.4	40.4	3.4
С	8.8	9.9	79.6	1.7
D	7.8	7.1	82.1	2.9
Ε	2.9	62.9	34.3	0.0
F	8.5	62.7	27.1	1.7
G	11.9	78.0	10.1	0.0
Н	1.6	46.7	48.4	3.3
Ι	2.9	7.3	87.0	2.9
J	4.6	39.9	55.5	0.0
K	13.8	81.3	5.0	0.0
L	8.6	4.0	86.4	1.0
Μ	5.7	8.9	83.8	1.6
Ν	1.9	35.6	60.6	1.9
0	0.0	100.0	0.0	0.0
Р	6.5	93.6	0.0	0.0
Q	8.3	63.9	26.8	1.0
R	6.5	32.7	60.1	0.7
S	0.0	0.0	80.0	20.0
Т	6.4	90.5	3.2	0.0
U	8.3	85.4	0.0	6.3
V	5.6	77.8	16.0	0.7
W	6.3	80.2	13.5	0.0
Χ	0.0	0.0	100.0	0.0
Υ	8.3	67.1	24.5	0.0
Ζ	2.7	4.0	89.6	3.7
AA	8.4	58.0	32.8	0.8
AB	4.5	24.1	69.2	2.2
AC	8.3	83.3	8.3	0.0
AD	2.6	53.5	43.3	0.6
AE	5.0	80.5	14.5	0.0
AF	9.6	38.0	51.3	1.1
AG	26.2	40.5	33.3	0.0
Total %	6.6	38.8	53.0	1.6
Total N	293	1733	2370	73

Presentation #53

		GA (co	mpleted	l weeks)						
		< 25	25-26	27-28	29-30	31-32	33-34	35-36	<u>></u> 37	Total
Total available	Ν	345	552	779	1091	1702	1931	2379	5872	14651
Number of neonates										
who survived and										
were discharged	Ν	102	222	320	429	660	928	1237	3452	7350
home directly from										
the NICU										
Oxygen	Ν	32	43	28	29	26	3	4	32	197
onygen	%	31.4	19.4	8.8	6.8	3.9	0.3	0.3	0.9	2.7
Monitor	Ν	17	16	20	25	16	6	22	113	235
	%	16.7	7.2	6.3	5.8	2.4	0.7	1.8	3.3	3.2
Enterostomy	Ν	0	3	2	0	1	2	1	10	19
Lincrostoniy	%	0.0	1.4	0.6	0.0	0.2	0.2	0.1	0.3	0.3
Gavage	Ν	16	19	23	19	19	4	13	49	162
Gavage	%	15.7	8.6	7.2	4.4	2.9	0.4	1.1	1.4	2.2
Tracheostomy	Ν	1	0	0	0	0	2	1	2	6
	%	1.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.1
Gastrostomy	Ν	7	2	7	4	7	4	1	12	44
Gastrostomy	%	6.9	0.9	2.2	0.9	1.1	0.4	0.1	0.4	0.6
Ventilation	Ν	2	0	0	0	0	0	1	2	5
Ventilation	%	2.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1
СРАР	Ν	0	4	2	0	0	0	2	5	13
CIM	%	0.0	1.8	0.6	0.0	0.0	0.0	0.2	0.1	0.2
Feeding status at dis	char	ge dire	ctly hor	ne						
Mother's own milk	Ν	30	83	108	148	244	318	362	1088	2381
only	%	29.4	37.4	33.8	34.5	37.0	34.3	29.3	31.5	32.4
Economic contra	Ν	36	74	122	139	219	232	334	753	1909
Formula only	%	35.3	33.3	38.1	32.4	33.2	25.0	27.0	21.8	26.0
Mother's own milk	Ν	36	64	85	135	189	375	537	1600	3021
and formula	%	35.3	28.8	26.6	31.5	28.6	40.4	43.4	46.4	41.1

Support at discharge: Neonates who were discharged directly home: Crude rates

Note: In this presentation, denominators were based on the number of neonates who survived and were discharged directly home.

G. Hypoxic Ischemic Encephalopathy

Presentation #54

Hypoxic Ischemic Encephalopathy

		Sarnat's	Sarnat's staging of HIE on admission								
		Stage	Stage	Stage	Unknown	Total					
		1	2	3	stage	Iotui					
Hypothermia	Yes	78	320	86	36	520					
treatment	No	72	27	21	33	153					
treatment	Unknown	1	7	1	0	9					
	Total	151	354	108	69	682					

A. Sarnat staging at the time of admission and receipt of hypothermia

B. Reason for not receiving hypothermia treatment*

Reason	Number
Chromosomal anomalies	1
Major congenital anomalies	1
Weight < 2000 g or GA < 35 weeks	29
Extreme condition	14
Head trauma or intracranial hemorrhage	5
Mild HIE	70
Unit policy	14
Health care team preference	5
Delayed transfer	18
Parental request	1
Unknown	21

*One neonate can have more than one reasons.

C. Time of admission

Time	Number
<6 hours from birth	450
6 – 12 hours from birth	173
>12 hours from birth	58
Total**	681

**1 neonate was missing either time of birth or time of admission.

Presentation #54 (continued)

Characteristics	Ν		Results
Method	514	Selective head	3 (1%)
		Whole body cooling	511 (100%)
Target temperature	520	< 33°C	3 (1%)
		33-34°C	329 (63%)
		33.5-34.5°C	84 (16%)
		34-35°C	2 (0%)
		34.5-35.5°C	1 (0%)
		Unknown	101 (19%)
Seizures at initiation	520		107 (21%)
Seizures at completion	520		0 (0%)
GA < 33 weeks	520		0 (0%)
Birthweight < 2000g	520		4 (1%)
During hypothermia	504	Hypotension	150 (30%)
	501	Thrombocytopenia	69 (14%)
	503	Coagulopathy	133 (26%)
	497	Persistent metabolic acidosis	61 (12%)
Death	520		38 (7%)
Discharge on palliation	520		8 (2%)

Hypoxic Ischemic Encephalopathy D. Characteristics of neonates who received hypothermia (N=520)

E. Encephalopathy stage in relation to hypothermia treatment

Encephalopathy stage*		At the en					
	Stage 1	Stage 2	Stage 3	Unknown	Normal	Total	
At the start of	Stage 1	23	5	1	9	44	82
hypothermia	Stage 2	73	106	10	37	93	319
	Stage 3	3	6	55	8	9	81
	Unknown	1	4	0	16	17	38
	Total	100	121	66	70	163	520

*The numbers may be different from table A because table E presents encephalopathy staging at the start and end of hypothermia, whereas table A presents encephalopathy staging at the first assessment.

Presentation #54 (continued) **Hypoxic Ischemic Encephalopathy** For neonates* who received hypothermia (N=520)

Characteristics		Ν	Mean (h)	SD (h)	Min (h)	1 st Q (h)	Median (h)	3 rd Q (h)	Max (h)	Outside of recommendation	Time taken to achieve target
Timing** of hypothermia (in hours)	Initiation	512	5.0	4.0	0.0	2.5	4.9	6.1	38.0	After 6 hours 138 (27%)	
	Age at re- warming	516	72.7	17.2	3.0	74.6	76.9	78.3	117.8	After 78 hours 151(29%)	Re-warming started >72 hours after initiation 212 (41%)
Temperature during hypothermia	Lowest temp during hypothermia	414	32.8	0.9	25.0	32.6	33.0	33.2	36.3	Lowest temp < 32.5C 186 (45%)	
	Highest temp during hypothermia	413	34.2	0.8	31.9	33.7	33.9	34.3	37.7	Highest temp > 35.5C 29 (7%)	

*Neonates with time of initiation > 72 hours were excluded.

**All timings were calculated from time of birth in hours of age.

H. Trend Analyses over last 12 years

This section includes trend analyses of specific outcomes from the last 12 years (2010-21) for neonates <33 weeks' GA in CNN sites. The following table describes the number of neonates in the respective GA categories that were included in these trend analyses. Delivery room deaths were excluded.

							GA						
Year	Number of Sites	<23	23	24	25	26	27	28	29	30	31	32	Total
2010	27	9	73	172	270	333	388	371	480	611	678	788	4173
2011	30	15	86	166	242	318	332	391	467	553	643	828	4041
2012	30	28	85	184	285	294	348	416	510	610	738	872	4370
2013	29	16	76	197	247	267	357	434	479	620	733	836	4262
2014	31	8	81	226	250	332	362	412	517	585	743	871	4387
2015	30	14	99	177	248	289	317	425	470	536	662	793	4030
2016	30	16	79	214	275	272	380	431	437	551	722	861	4238
2017	31	16	133	215	257	294	325	434	467	606	743	868	4358
2018	32	25	132	215	271	334	380	424	518	576	744	863	4482
2019	32	25	118	217	279	297	342	440	470	613	740	905	4446
2020	33	15	127	201	236	265	310	402	491	593	634	834	4108
2021	33	32	99	214	254	298	331	448	514	577	761	941	4469

Number of neonates by admission year and GA


Number of neonates by admission year and birth weight

				Birth weight			
Year	Number of Sites	< 500	500 - 749	750 - 999	1000 - 1249	1250 - 1499	Total
2010	27	32	436	792	819	879	2958
2011	30	31	383	660	680	794	2548
2012	30	48	441	696	815	922	2922
2013	29	36	428	651	842	919	2876
2014	31	36	458	760	804	922	2980
2015	30	40	406	680	792	864	2782
2016	30	40	472	710	744	901	2867
2017	31	38	478	678	806	920	2920
2018	32	55	508	739	807	977	3086
2019	32	50	482	685	802	937	2956
2020	33	43	436	668	731	878	2756
2021	33	43	479	673	831	933	2959


			All neonates		Infan	ts with GA<33	weeks
Year	Number of Sites	Total Number of Neonates*	Inborn (%)	Outborn (%)	Number of Neonates* with GA<33	Inborn (%)	Outborn (%)
2010	27	13 147	10 662	2 485	3 383	2 824	559
			(81.1%)	(18.9%)		(83.5%)	(16.5%)
2011	30	13 548	10 972 (81.0%)	2 576 (19.0%)	4 040	3 460 (85.6%)	580 (14.4%)
			11 475	2 747		3 663	707
2012	30	14 222	(80.7%)	(19.3%)	4 370	(83.8%)	(16.2%)
			11 487	3 002		3 624	638
2013	29	14 489	(79.2%)	(20.7%)	4 262	(85.0%)	(15.0%)
2014	21	14.029	11 473	3 565	4 292	3658	725
2014	31	14 038	(76.3%)	(23.7%)	4 383	(83.5%)	(16.5%)
2015	30	14 814	11 583	3 231	4 030	3 459	571
2015	- 30	14 814	(78.2%)	(21.8%)	4 0 5 0	(85.8%)	(14.2%)
2016	30	14 905	11 388	3 517	4 238	3 585	653
2010	- 50	14 905	(76.4%)	(23.6%)	4 236	(84.6%)	(15.4%)
2017	31	14 773	11 320	3 453	4 358	3 685	673
2017	51	14 //3	(76.6%)	(23.4%)	4 556	(84.6%)	(15.4%)
2018	018 32	15 479	12 134	3 345	4 481	3 836	645
2010	52	15 475	(78.4%)	(21.6%)	+ +01	(85.6%)	(14.4%)
2019	32	14 868	11 750	3 118	4 446	3 856	590
2017	52	14 000	(79.0%)	(21.0%)	- + ++0	(86.7%)	(13.3%)
2020	33	14 271	11 091	3 180	4 108	3 564	544
2020		1,2/1	(77.7%)	(22.3%)	1100	(86.8%)	(13.2%)
2021	33	14 651	11 419	3 232	4 469	3 826	643
		11001	(77.9%)	(22.1%)		(85.6%)	(14.4%)

1. Neonates in the participating sites: Admission status:


*total number of neonates excluding those who are missing admission status



2. Multiple births



		2013	2014	2015	2016	2017	2018	2019	2020	2021
GA < 29	Total	1594	1671	1569	1667	1674	1780	1717	1556	1675
weeks	Multiple	460	441	366	374	422	504	446	349	395
	Multiple	(29%)	(26%)	(23%)	(22%)	(25%)	(28%)	(26%)	(22%)	(24%)
	Twin	398	415	321	345	375	466	415	316	364
	Higher- Order	62	26	45	29	47	38	31	33	31
GA < 33	Total	4262	4387	4030	4238	4358	4481	4445	4108	4468
weeks		1380	1356	1122	1213	1269	1337	1308	1097	1246
	Multiple	(32%)	(31%)	(28%)	(29%)	(29%)	(30%)	(29%)	(27%)	(28%)
	Twin	1193	1229	996	1094	1156	1202	1191	1000	1112
	Higher-	187	127	126	119	113	135	117	97	134
	Order									
BW <	Total	1115	1254	1126	1222	1194	1301	1217	1147	1194
1000g	Multiple	306	329	264	277	303	368	320	244	275
	1	(27%)	(26%)	(23%)	(23%)	(25%)	(28%)	(26%)	(21%)	(23%)
	Twin	259	306	236	260	269	338	295	218	249
	Higher-	47	23	28	17	34	30	25	26	26
	Order									
BW <	Total	2876	2980	2782	2867	2920	3085	2955	2756	2958
1500g	Multiple	905	900	731	782	831	907	831	726	789
	1	(31%)	(30%)	(26%)	(27%)	(28%)	(29%)	(28%)	(26%)	(27%)
	Twin	769	802	634	703	747	812	757	656	706
	Higher-	136	98	97	79	84	95	74	70	83
	Order									



3. Proportion of neonates who received active care out of all (including delivery room (DR) deaths)


		2013	2014	2015	2016	2017	2018	2019	2020	2021
<23 weeks	Number of neonates who received active care $(a-c) + e$	23	14	22	16	26	35	35	18	37
	Total number of neonates including DR deaths $a+d+e$	63	58	68	67	65	95	88	64	91
	Percentage of neonates who received active care	37%	24%	32%	24%	40%	37%	40%	28%	41%
23 weeks	Number of neonates who received active care $(a-c) + e$	85	92	106	82	136	133	127	131	101
	Total number of neonates including DR deaths $a+d+e$	113	131	142	121	171	185	178	162	155
	Percentage of neonates who received active care	75%	70%	75%	68%	80%	72%	71%	81%	65%
24 weeks	Number of neonates who received active care $(a-c) + e$	200	233	178	217	221	224	224	199	216
	Total number of neonates including DR deaths $a+d+e$	207	245	190	227	231	235	240	218	226
	Percentage of neonates who received active care	97%	95%	94%	96%	96%	95%	93%	91%	96%

Note: Refer to presentation #4 for detailed breakdown of neonates by GA in 2021. The alphabet notations used in the table above are carried from presentation #4.


Information should be interpreted with caution as not all sites provided data on delivery room deaths. Active care refers to infants who received cardiopulmonary resuscitation at birth.

4. Survival rate among those who were admitted to NICU:


a. 22-26 weeks' GA:



b. 27-32 weeks' GA:




5. Late onset sepsis (with at least one infection) among neonates who survived beyond 2 days post birth




a. 23-26 weeks' GA:


b. 27-32 weeks' GA:




6. Surgical ligation or device closure of PDA among all neonates



b. 27-32 weeks' GA:




7. Ventricular enlargement (VE): (moderate and severe VE only; among neonates who received ultrasound exams)




a. 23-26 weeks' GA:


b. 27-32 weeks' GA:




8. Parenchymal echogenicity (among neonates who received ultrasound exams)




b. 27-32 weeks GA:





9. NEC:




b. 27-32 weeks' GA:












b. 27-32 weeks' GA:




11. Therapy for ROP (among neonates who received eye exams)







b. 27-32 weeks' GA:




12a. Oxygen use at 36 weeks or at discharge:



b. 27-32 weeks' GA:




12b. Any respiratory support at 36 weeks or at discharge:





a. 23-26 weeks' GA:


b. 27-32 weeks' GA:





13a. Oxygen use at 36 weeks/discharge or death:














b. 27-32 weeks' GA:




14. Postnatal systemic steroids use for chronic lung disease (CLD)






b. 27-32 weeks' GA:




15. Mortality or major morbidity including CLD

Major morbidity was counted as any one of the following:

- 1. CLD (any grade)
- 2. Severe ROP (stage 3,4,5 and/or those with ROP treatment)
- 3. Severe neurological injury (IVH grade 3 or grade 4 or PVL)
- 4. NEC (stage 2 or 3)
- 5. Late onset sepsis (any positive blood and/or cerebrospinal fluid culture after 2 days of age)






b. 27-32 weeks' GA:


16. Mortality or major morbidity excluding CLD

Major morbidity was counted as any one of the following:

- 1. Severe ROP (stage 3,4,5 and/or those with ROP treatment)
- 2. Severe neurological injury (IVH grade 3 or grade 4 or PVL)
- 3. NEC (stage 2 or 3)
- 4. Late onset sepsis (any positive blood and/or cerebrospinal fluid culture after 2 days of age)



b. 27-32 weeks' GA:



I. 2021 CNN publications

Peer reviewed publications

- Rios JD, Shah PS, Beltempo M, Louis D, Mukerji A, Premji S, Shah V, Lee SK, Pechlivanoglou P; Canadian Preterm Birth Network Investigators; Canadian Neonatal Network Investigators. Costs of Neonatal Intensive Care for Canadian Infants with Preterm Birth. J Pediatr. 2021 Feb;229:161-167.e12.
- 2) Melamed N, Murphy K, Barrett J, Asztalos E, McDonald SD, Yoon EW, Shah PS; on behalf of the Canadian Neonatal Network and Canadian Preterm Birth Network Investigators. Benefit of Antenatal Corticosteroids by Year of Birth Among Preterm Infants in Canada During 2003-2017: A Population-Based Cohort Study. BJOG. 2021 Feb;128(3):521-531.
- Coshal H, Mukerji A, Lemyre B, Ng EH, Alvaro R, Ethier G, Yoon EW, Beltempo M, Shah PS. Characteristics and outcomes of preterm neonates according to number of doses of surfactant received. J Perinatol. 2021 Jan;41(1):39-46.
- 4) Zozaya C, Shah J, Pierro A, Zani A, Synnes A, Lee S, Shah PS on behalf of the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental and growth outcomes of extremely preterm infants with necrotizing enterocolitis or spontaneous intestinal perforation. J Pediatr Surg. 2021 Feb;56(2):309-316.
- 5) Gagliardi L, Rusconi F, Reichman B, Adams M, Modi N, Lehtonen L, Kusuda S, Vento M, Darlow BA, Bassler D, Isayama T, Norman M, Håkansson S, Lee SK, Lui K, Yang J, Shah PS on behalf of the International Network for Evaluating Outcomes of Neonates (iNeo) Investigators. Neonatal outcomes of extremely preterm twins by sex pairing: an international cohort study. Arch Dis Child Fetal Neonatal Ed. 2021 Jan;106(1):17-24.
- 6) Rizzolo A, Shah P, Bertelle V, Makary H, Ye X, Abenhain H, Piedboeuf B, and Beltempo M on behalf of Canadian Neonatal Network(CNN) and Canadian Preterm Birth Network (CPTBN) Investigators. Association of Timing of Birth with Mortality Among Preterm Infants Born in Canada. Journal of Perinatology. 2021 May; 41:2597-2606.
- 7) Roychoudhury S, Lodha A, Synnes A, Abou Mehrem A, Canning R, Banihani R, Beltempo M, Theriault K, Yang J, Shah PS, Soraisham A on behalf of the Canadian Neonatal Network, Canadian Preterm Birth Network and Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental Outcomes of Preterm Infants Conceived by Assisted Reproductive Technology. American Journal of Obstetrics & Gynecology. 2021 Sep;225(3):276.e1-276.e9.
- 8) Doucette S, Kelly E, Church P, Lee S, Shah V on behalf of Canadian Neonatal Network investigators and CNFUN Investigators and Steering Committee. Association of Inotrope Use with Neurodevelopmental Outcomes in Infants <29 Weeks Gestation: A Retrospective Cohort Study. J Matern Fetal Neonatal Med. 2021 Apr;1-9. [Epub ahead of print].
- 9) Puthattayil ZB, Luu TM, Beltempo M, Cross S, Pillay T, Ballantyne M, Synnes A, Shah PS, Daboval T, Canadian Neonatal Follow-Up Network. Risk factors for re-hospitalization following neonatal discharge of extremely preterm infants in Canada. Paediatr Child Health. April –May 2021;26(2):e96-e104.
- 10) Kandraju H. Kanungo J, Lee KS, Sibasis D, Adie M, Dorling J, Ye XY, Lee SK, Shah PS, Canadian Neonatal Network, Canadian Preterm Birth Network Investigators. Association of

Co-exposure of Antenatal Steroid and Prophylactic Indomethacin with Spontaneous Intestinal Perforation. J Pediatr. 2021 Aug;235:34-41.e1.

- 11) Mohammad K, Scott JM, Leijser L, Zein H, Afifi J, Piedboeuf B, Vries LS, Wezel-Meijler GV, Lee SK, Shah PS on behalf of the Canadian Neonatal Network and Canadian Preterm Birth Network Group on Neonatal Neurological Outcomes Improvement Investigators Consensus Approach for Standardizing the Screening and Classification of Preterm Brain Injury Diagnosed With Cranial Ultrasound: A Canadian Perspective. Front Pediatr. 2021 Mar;9:618236.
- 12) Seaton SE, Draper ES, Adams M, Kusuda S, Håkansson S, Helenius K, Reichman B, Lehtonen L, Bassler D, Lee S, Vento M, Darlow BA, Rusconi F, Beltempo M, Isayama T, Norman M, Yang J, Shah P, Modi N. Variations in Neonatal Length of Stay of Extremely Preterm Babies: An International Comparison Between iNeo Networks. Journal of Pediatrics. 2021 Jun;233:26-32.e6.
- 13) Qureshi M, Shah PS, Abdelgadir D, Ye XY, Afifi J, Yuen R. Crossman SC, Taylor B, Mohammad K, Piedboeuf B, Aziz K, Canadian Neonatal Network Investigators. Gestational Age-Dependent Variations in Effects of Prophylactic Indomethacin on Brain Injury and Intestinal Injury. Journal of Pediatrics. 2021 Aug;235:26-33.e2.
- 14) Weisz DE, Yoon E, Dunn M, Emberley J, Mukerji A, Read B, Shah PS and the Canadian Neonatal Network Investigators. Duration of and Trends in Respiratory Support among Extremely Preterm Infants. Arch Dis Child Fetal Neonatal Ed. 2021 May;106(3):286-291.
- 15) Hiersch L, Shah PS, Khurshid F, Masse E, Murphy K, McDonald SD, Carson G, Barrett J, Melamed N on behalf of the Canadian Neonatal Network Investigators and the Canadian Preterm Birth Network Investigators. Mode of Delivery and Neonatal Outcomes in Extremely Preterm Vertex/Non-Vertex Twins of <28 weeks' Gestation: A Cohort Study. Am J Obstet Gynecol.2021 Jun;224(6):613.e1-613.e10.
- 16) Dharel D, Singhal N, Wood C, Cieslak Z, Bacchini F, Shah PS, Xiang YE, Alshaikh B, Canadian Neonatal Network and Canadian Preterm Birth Network Investigators. Rate and determinants of Mother's own milk feeding in infants born very preterm. The Journal of Pediatrics. 2021 Sep;236:21-27.e4.
- 17) Ting J, Robert A, Abou Mehrem A, Khurshid F, Drolet C, Monterrosa L, Yoon EW, Shah PS. Variability in Antimicrobial Use Among Infants Born at <33 Weeks' Gestational Age. Infect Control Hosp Epidemiol. 2021 Sep17:1-5. [Epub ahead of print].
- 18) Khurshid F. Coo H. Khalil A. Messiha J. Ting JY, Wong J, Shah PS. Comparison of multivariable logistic regression and machine learning models for predicting bronchopulmonary dysplasia or death in very preterm infants. Frontiers in Pediatrics 2021 Dec 7;9:759776.

Abstracts

- Roychoudhury S, Lodha A, Synnes A, Ting J, Augustine S, Afifi J, Bizgu V, Shah PS, Soraisham A. Neurodevelopmental Outcomes of Extremely Preterm Infants with Late Onset Bacterial Sepsis According to Type of Bacteria. E-PAS 2021: EP-184.1530.
- Hamid F. Beltempo M, Alshaikh B, Hasan SU, Rustogi D, Abou Mehrem A, Ng E, Kanungo J, Shah PS, Yusuf K. Effect of blood transfusion on outcomes of singleton preterm infants <29 weeks gestation born small for gestation and appropriate for gestational age. E-PAS 2021: EP-194.1692.

- Styranko D. Shah PS, Xiang YY, Da Silva O, Piedboeuf B, Afifi J, El-Naggar W. Use of high initial Oxygen concentration for Delivery Room resuscitation is associated with increased mortality in extremely preterm infants. E-PAS 2021: EP-204.1835.
- 4) Debay A, Shah PS, Lodha A, Shivananda S, Redpath S, Seshi M, Dorling J, Lapointe A, Canning R, Strueby L, Beltempo M. Association of 24-hour In-house Neonatalogist Coverage with Outcomes of Extremely Preterm Infants. E-PAS 2021: EP-207.1873.
- Yeung T. Rios JD, Khurshid F, Toye J, Ojah C, Beltempo M, Pechlivanoglou P, Shah PS. Trends in Costs for Extreme Preterm Care in Canada between Years 2010 to 2019. E-PAS 2021: 2910-HP-QA.220.
- Beltempo M, Xiang YY, Synnes A, Piedboeuf B, Bacchini F, Shah PS. Regional variations in length of stay and readmission of preterm infants in Canada. E-PAS 2021: 2910-HP-QA.221.
- Armour E, Synnes A, Alshaikh B, Hasan SU, Fajardo C, Lodha A, Masse E, Shah PS, Yusuf K. Neurodevelopmental outcomes of preterm infants <29 weeks gestation with pneumothorax. E-PAS 2021: 3907-HP-QA.326.
- Ricci MF. Shah PS, Moddemann D, Alvaro R, Ng E, Lee SK, Synnes A. Long-term survival and neurodevelopmental outcomes of very-preterm infants born in Canada between 2009 and 2016. E-PAS 2021: 3907-HP-QA.328.
- 9) Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, Louis D, Monterossa L, Mukerji A, Schmolzer G, Singh B, Wong J, Xiang YY, Offringa M. Poractant alfa versus bovine lipid extract surfactant for respiratory distress syndrome in preterm infants: a prospective comparative effectiveness cohort study. E-PAS 2021: 3909-HP-QA.346.
- 10) Ting JY. Reduction of antimicrobial usage in very-low-birth-weight infants receiving prophylactic probiotic administration. E-PAS 2021: Platform presentation 4730-PL-L.2.
- Styranko D. Shah PS, Xiang YY, Emberley J, Ethier G, Afifi J, El-Naggar W. Escalation of oxygen concentration during Delivery Room resuscitation of extremely preterm infants. E-PAS 2021: 4910-HP-QA.487.
- 12) Shah PS. Association of Umbilical artery and vein gas values and mortality in extremely preterm neonates. E-PAS 2021: 2911-HP-QA.235.
- 13) Patel S. Piedboeuf B. Drolet C. Lapointe A. Bizgu V. Masse E. Beltempo M. Regional neonatal intensive care unit occupancy rate and access to appropriate level of care for very preterm infants in a regionalized healthcare system. E-PAS 2021: EP-179.1470.
- 14) Attari Z. Patel S. Saeed S. Drolet C. Bizgu V. Charbonneau L. Lapointe A. Massé E. Bertelle V. Platt R. Piedboeuf B. Beltempo M. The Association of Neonatal Intensive Care Unit Design Change and Move with Neonatal Outcomes - A Multicentre Study. E-PAS 2021: 4905-HP-QA.435.
- 15) Beltempo M, Platt R, Julien AS, Blais R, Bertelle V, Lapointe A, Lacroix G, Gravel S, Cabot M, Piedboeuf B. Association of unit occupancy and nurse staffing with mortality and morbidity among very preterm infants: a multricentric study. E-PAS 2021: 4905-HP-QA.436.

J. Appendices

Outcomes Definitions

Mortality: Death prior to discharge from the NICU.

Severe neurological injury: Intraventricular hemorrhage (IVH), ventricular enlargement or parenchymal echogenicity or periventricular leukomalacia (PVL): Defined as grade 3 IVH (intraventricular hemorrhage with ventricular enlargement) or grade 4 IVH (intraventricular hemorrhage and persistent parenchymal echogenicity) or persistent parenchymal echogenicity.

Ventricular enlargement

- *None:* Measurement of ventricles was <7 mm at any level section of lateral ventricle.
- *Mild:* Measurement was 7 to 10 mm at any level of the larger lateral ventricle. Classify as "mild" if there was no mention of "ventricular enlargement", "ventriculomegaly" or "hydrocephalus", or if the most severe report was of "mild ventriculomegaly" or "mild ventricular enlargement", or if described as "suspected"
- *Moderate:* Measurement was 11 to 15 mm at any level of the larger lateral ventricle on sagittal scan. Classify as "moderate" if the terms "grade III IVH", "ventricular enlargement", "ventriculomegaly" or "hydrocephalus" were used with "moderate", or without descriptors.
- Severe: Measurement was >15 mm at any level of the larger lateral ventricle on a sagittal scan, or ventricular drainage/shunting was required. If no measurement was made, classify as "severe" if the terms "severe" or "significant" were used to describe "grade III IVH", "ventricular enlargement", "ventriculomegaly" or "hydrocephalus".
- Not measured
- Unknown

Severe retinopathy of prematurity (ROP): Stage 3, 4 or 5 ROP as defined by the International Classification of Retinopathy of Prematurity¹ and/or those infants requiring treatment (laser or intraocular injection). ROP was scored as the highest stage in either eye identified at any time.

Necrotizing enterocolitis (NEC): Stage 2 or 3 NEC according to Bell's classification², diagnosed by clinical and imaging findings.

Sepsis: Isolation of bacterial, fungal or viral organism from blood or cerebrospinal fluid in a symptomatic infant.

Chronic lung disease (CLD): Defined as respiratory support given at 36 weeks' post menstrual age or at discharge (if earlier than 36 weeks' PMA) to level 2 centers and was classified in different degrees of severity described as follows (Note that some sites collect CLD status at 36 weeks' PMA for infants transferred to level 2 centers):

¹ An International Committee for the Classification of Retinopathy of Prematurity. **The International Classification of Retinopathy of Prematurity Revisited.** Arch Ophthalmol 2005;123:991-999

² Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1–7

Severity	Respiratory support at time of classification	Oxygen	Flow rate
	(at 36 weeks' PMA or at discharge if baby		
	was discharged prior to 36 weeks' PMA)		
No CLD	None	21%	None
Mild CLD	Headbox or incubator	>21%	Any amount
	Nasal cannula	100%	<0.1L/min
	Nasal cannula blended air/oxygen	21-99%	<1.5L/min
Moderate CLD	Nasal cannula	100%	<u>></u> 0.1L/min
	Nasal cannula blended air/oxygen	21-29%	<u>></u> 1.5L/min
	CPAP, SIPAP, NIPPV, NIHFV	21-29%	
Severe CLD	Nasal cannula blended oxygen	<u>></u> 30%	<u>></u> 1.5L/min
	CPAP, SIPAP, NIPPV, NIHFV	<u>></u> 30%	
	Mechanical ventilation (intubated)	21-100%	

Chronic lung disease (CLD) continued:

Survival without major morbidities: Defined as survival at discharge from the NICU without having any of CLD, NEC stage 2 or 3, IVH grade 3 or 4 or PVL, sepsis, or ROP stage 3, 4, 5, or ROP treatment.

Variables Definitions

Major Anomalies

A list of major anomalies can be found in the 2013 annual report, pages 124-127. It is available via the following link: <u>http://www.canadianneonatalnetwork.org/Portal/LinkClick.aspx?fileticket=lreR0871sjA%3d&tabid=39</u>

Abbreviations

ANCS	Antenatal Corticosteroids
BW	Birth Weight
BPD	Bronchopulmonary dysplasia
CONS	Coagulase-Negative Staphylococcus
CPAP	Continuous Positive Airway Pressure
CLABSI	Central Line-Associated Bloodstream Infection
CLD	Chronic Lung Disease
CVL	Central Venous Line
DR	Delivery Room
EPIQ	Evidence-based Practice for Improving Quality
ETT	Endotracheal Tube
GA	Gestational Age
GBS	Group B Streptococcus
GM	Germinal Matrix
HFV	High Frequency Ventilation
HIE	Hypoxic Ischemic Encephalopathy
ICROP	International Classification of Retinopathy of Prematurity
IPPV	Intermittent Positive Pressure Ventilation
IVH	Intra-Ventricular Hemorrhage
NEC	Necrotizing Enterocolitis
NI	Nosocomial Infection
NICE	Neonatal-Perinatal Interdisciplinary Capacity Enhancement
NICU	Neonatal Intensive Care Units
NTISS	Neonatal Therapeutic Intervention Scoring System
PDA	Patent Ductus Arteriosus
PEC	Parenchymal Echogenicity
PICC	Peripherally Inserted Central Catheters
PIV	Peripheral Intravenous
PMA	Postmenstrual Age
PPV	Positive Pressure Ventilation

PVL	Periventricular Leukomalacia
RDS	Respiratory Distress Syndrome
ROP	Retinopathy of Prematurity
SD	Standard Deviation
SEM	Standard Error of Mean
SGA	Small for Gestational Age
SNAP	Score for Acute Neonatal Physiology
SNAP-IIPE	Score for Acute Neonatal Physiology Version II, Perinatal Extension
SR	Standardized Ratio
SR TPN	Standardized Ratio Total Parenteral Nutrition
TPN	Total Parenteral Nutrition
TPN TRIPS	Total Parenteral Nutrition Transport Risk Index of Physiologic Stability
TPN TRIPS UV	Total Parenteral Nutrition Transport Risk Index of Physiologic Stability Umbilical Vein
TPN TRIPS UV VE	Total Parenteral Nutrition Transport Risk Index of Physiologic Stability Umbilical Vein Ventricular Enlargement

© Canadian Neonatal NetworkTM 2022

All rights reserved. No part of this publication may be reused, republished, stored in a retrieval system or transmitted in any form or by any means-electronic, mechanical, photocopying, recordings or otherwise-without prior consent of the publisher.

Canadian Neonatal Network[™], Maternal-Infant Care Research Centre 700 University Avenue, Suite 8-500, Toronto ON M5G 1X6